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ABSTRACT 
Expression of the nefgene from HIV-1 subtype C in Nicotiana benthamiana was carried out 
using a TMV -based vector with the aim of developing a plant-based candidate vaccine for 
HIV-1. The nef gene of the DU151 isolate of mV-l subtype C taken from a recently 
seroconverted individual was amplified by PCR with a deletion of 59 amino acids from the 
cytotoxic N-terminal. The amplified gene was inserted into a bacterial expression vector 
pProEXHTb for rapid expression of Nef protein, which was used as a diagnostic tool in the 
development of an indirect ELISA assay for detection of Nef in Nicotiana benthamiana. An 
indirect ELISA assay was developed using a commercially available polyclonal anti Nef 
antiserum raised in sheep. 
The role of codon optimization in expression of Nef in benthamiana was investigated. A 
synthetic nef gene was constructed based on the codon usage of benthamiana. The plant 
codon optimized gene and the wild type nef genes were inserted into the TMV -based vector 
pBSG1057. RNA transcripts from both constructs were used to infect young benthamiana 
plants. Expression of nefmRNA was confirmed by RT -PCR analysis of total RNA extracted 
from plants inoculated with respective constructs. The Nef protein was expressed at low 
levels which were detectable by ELISA. Nef was detectable by Western blot after 
concentration of plant extract using a membrane filter device. Quantitative analysis of Nef 
expression in plants was done by western blot on concentrated plant extract from three 
separate infections. Codon optimization of the nef gene improved the expression of Nef by a 
factor of about two. 
Expression of immunodominant CTL epitopes from the core region of Nef as TMV-CP 
translational fusions was attempted. Oligonucleotides encoding the peptides 
YKAAFDLSHFLKEKG (NP31) and EEPEVGFPV (EP1) were synthesized and cloned into 
the vector pBSG1057 in frame with the coat protein gene using an intermediate vector to be 
expressed as N- and C-terminal fusion products. No infectious rTMVs were generated by 
plants inoculated with RNA transcripts of these constructs and infections remained 
localised. RT -PCR of total RNA extracted from inoculated plants revealed the presence of 
mRNA encoding rTMV-CP. Western analysis of plant extracts showed no accumulation of 
TMV-CP in plants infected with NP31 constructs and poor accumulation of TMV-CP in 
plants infected with EP1 constructs. Both peptides interfered with expression and assembly 
of TMV particles. 
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Chapter 1: Introduction and Literature Review 
1.1 HIV/AIDS 
1.1.1 Epidemiology 
Since AIDS was recognized as a new disease in the beginning of the 1980s and HIV was 
isolated and identified as a transmissible pathogen causing this disease, HIV has spread 
all over the world and has already claimed more than 25 million lives. The number of 
persons currently living with HIV infection worldwide is estimated by the Joint United 
Nations Program on HIV/AIDS (UNAIDS) at more than 40 million. About 5 million new 
infections with HIV occurred in the year 2001 and about 3 million people died from 
HIV/AIDS, making HIV infection the single most important cause of death from 
infectious disease in that year (www.unaids.org). More than 95% of the approximately 
15000 new infections per day are transmitted in developing countries. The most severely 
affected part of the world is sub-Saharan Africa, with more than two thirds of all infected 
persons living in this region and 3.4 million new infections occurring in 2001. More 
Africans die from HIV/AIDS than from famine and wars and there are now 16 countries 
where more than 10% of those aged 15-49 years are infected. In South Africa's K wazulu-
Natal province, prevalence rates among women attending antenatal clinics have reached 
catastrophic proportions with the figure standing at 36% (Department of Health, Republic 
of South Africa 2000). 
The principal mode of transmission of HIV in Africa is unprotected heterosexual 
intercourse which is responsible for more than 85% of new infections. About 10% of new 
infections are due to mother-to-child transmission. Intravenous drug use has not played a 
large role in dissemination of HIV in Africa but recent studies show that use of non-
sterile surgical equipment in medical and cultural practices may play a significant role 
(UNAIDS). 
1.1.2 Molecular Biology of mv 
HIV belongs to the subfamily Lentivirinae (slow viruses) in the family Retroviridae. In 
general, retroviruses either cause proliferation (transforming) or destruction (cytopathic) 
of the cells they infect. Human T-cell leukaemia viruses HTLV-l and HTLV-2 are 
examples of transforming viruses. HIV is a cytopathic virus. There are two HIV s: HIV-l 
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and HIV-2. They share about 30% to 40% RNA sequence homology overall, with as high 
as 60% homology in some regions. HIV -1 is by far the most common cause of AIDS. 
HIV-2 produces a disease similar to HIV-l and is present in high incident in West Africa 
but is being found increasingly outside Africa. HIV-2 is very closely related to simian 
immunodeficiency viruses (SIV), which cause a form of AIDS with encephalitis in 
monkeys (macaques) that is very similar to AIDS in humans (SIVmac) (Fultz et al., 
1989). 
The life cycle of HIV can be briefly summarised as follows. The mature virion forms a 
sphere with 72 spikes that contain the Env (gp120 and gp41) glycoproteins. A region of 
the viral envelope gp 120 binds to a domain on the CD4 protein on the lymphocyte 
surface. This interaction causes a conformational change in the gp 120, resulting in co 
receptor binding. Although several chemokine receptors such as CCR1, CCR2b and 
CCR3 can function as coreceptors for cell entry, CCR5 and CXCR4 are the most relevant 
(Rucker et al., 1997). The viral envelope complex that interacts with the CD4 and 
chemokine cell membrane receptors is composed of six glycoprotein subunits: three 
gp120s and three gp41s (Trkola et ai., 1996). Binding of the HIV gp120 to CD4 leads to 
a conformational change in the envelope that creates a high affinity binding site for the 
chemokine receptor (Trkola et ai., 1996). Interaction of the gp 120, CD4 and the 
chemokine receptor causes structural changes that allow the external portion of gp41 (the 
fusion domain) to mediate the fusion of the viral and cell membranes. The fusion of the 
viral and cell membranes creates a pore which permits the HIV capsid to pass into the 
CD4 cell, releasing the viral RNA into the cell cytoplasm (Lapham et al., 1996). Once the 
virion is uncoated in the cytoplasm, virion-associated reverse transcriptase produces 
hybrid RNAIDNA molecules. These are converted to double stranded cDNA molecules. 
The linear HIV cDNA is translocated to the nucleus of the infected cell where it is 
integrated into the host DNA by the viral integrase enzyme (Burger and Poles, 2003). 
In the integrated proviral form HIV may remain latent in infected cells for months or 
years. The HIV genome consists of nine viral genes that are flanked by long terminal 
repeats (LTRs). These genes include the major gag gene, which encodes the viral capsid 
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structural protein; pol, which encodes enzymes required forintegration and replication as 
well as the viral protease protein; and env, which encodes the envelope glycoproteins. 
Low level transcription of the viral genome results in the production of multiply spliced 
RNA transcripts and the translation of the tat and rev early genes products. Tat functions 
as a transactivator, amplifying transcription of additional viral RNA transcripts, and Rev 
enhances export of viral RNA to the cytoplasm from the nucleus, where they are 
translated into proteins. On translation of the late Gag, Pol and Env viral proteins, virion 
assembly occurs at the cellular plasma membrane with two copies of single stranded 
genomic HIV RNA in each progeny virion. During budding from the cell, surface 
proteins such as MHC molecules are also incorporated into the viral coat. The final 
maturation steps, such as cleavage of the Gag and Pol precursor proteins and other post-
translational modifications of viral proteins, occur during and after the budding process. 
Acquisition of host proteins in the viral coat proteins produces ''pseudotypes'' of HIV 
with different host-derived surface proteins (Burger and Poles, 2003). 
1.1.3 Treatment 
To date, about 15 different antiretroviral drugs have been approved for use with HIV 
infections and are in regular use. Current antiretroviral therapy nearly always involves a 
combination of three or more drugs, which need to be given at regular intervals. A typical 
triple combination therapy (HAART) regimen includes either two inhibitors of the HIV 
protein reverse transcriptase (RT) (nucleoside RT inhibitors as well as non-nucleoside RT 
inhibitors) plus one inhibitor of the viral protease or a combination of three different RT 
inhibitors (usually 2 nucleoside RT inhibitors and 1 non-nucleoside RT inhibitor) 
(Marcus et al., 2002). Under HAART, significant suppression of virus load, usually to 
undetectable levels, can be achieved in most patients. Patient care has been transformed 
with the ability to withdraw prophylactic or suppressive chemotherapy for pneumocystis, 
taxoplasmosis, cytomegalovirus, Mycobacterium avium complex, leishmaniasis, 
cyptococcosis and candidal thrush, which previously had been lifelong afflictions 
(Kovacs and Masur, 2000). However, significant side effects, including anaemia, 
neutrophia, allergic reactions and lipodystrophy are just some of the challenges facing 
successful implementation of HAART. Because of problems with adherence, 
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phannacology and toxicity, only 50-90% of study subjects achieve the desired 
suppression with current regimens (Richman, 2000). More significant is the alanning 
emergence of drug resistance. There are increasing reports in the literature of 
transmission of resistant virus. Such documentation has expanded from anecdotes of 
transmission of AZT -resistant virus to the identification of large cohorts with 10% or 
more of new infections due to drug resistant virus, half of which exhibit resistance to 
multiple classes of drug (Little, 2000). This problem is anticipated to cause a significant 
loss of the therapeutic arsenal in the near future (Marcus et al. 2000). 
The benefits of improved treatment so far have been restricted to only a minority of 
patients, mainly from the developed countries. Even though these therapies are cost 
effective by western standards at US$1O,000-15,000 per year of life saved, most 
developing countries cannot afford the drugs as wen as the necessary monitoring and 
support (Forsythe, 1998). In South Africa widespread provision of antiretroviral therapy 
is yet to be achieved and has become a major political issue. 
The ultimate shortcoming of current therapies is that even in the healthiest and longest 
surviving HIV infected individuals, examination of tissues and blood for viral RNA and 
for short half-lifed closed circular reverse transcripts, as well as documentation of 
nucleotide sequence evolution, all indicate that most effectively treated patients are not 
completely suppressing virus replication but instead are experiencing intennittent or 
smouldering virus replication that is difficult to discern (Fischer et al., 2000). This 
incomplete suppression of viral replication, which is usually on a scale sufficient to exert 
selective pressure, drives the evolution and fixation of drug resistant virus at an 
unprecedented rate contributing to the worldwide incidence of drug resistance (Richman, 
2001) 
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1.2 VACCINE-BASED STRATEGIES FOR HIV PREVENTION 
1.2.1 Subunit vaccines 
Vaccination is one of the most cost effective and important methods of preventing 
infectious diseases. Owing to the worldwide vaccination programs, the incidence of many 
fatal diseases has drastically decreased. Most of the vaccines used routinely today as part 
of childhood immunization programs are whole organism vaccines, consisting of live 
attenuated or killed whole bacteria or viruses (Plotkin, 1993). However, there exists the 
risk of reversion to virulent wild-type strains that can lead to disease when using 
attenuated bacteria or virus, especially in immunocompromised hosts. In 1986, the first 
recombinant subunit vaccine, the hepatitis B surface antigen vaccine produced in 
Saccharomyces cerevisiae (S. cerevisiae) (Valenzuela et al., 1982), was licensed. The 
basic principle for subunit vaccines is that the gene encoding the subunit vaccine is 
isolated transferred to a second, normally non-pathogenic organism. The recombinant 
subunit vaccine is then produced by the heterologous host, and could be designated to be 
delivered either as a purified immunogen, or by using the production host as live vector. 
The advantages of subunit vaccines are numerous. Firstly, the pathogen can be entirely 
excluded from the production of the vaccine, which eliminates risks associated with 
production, as well as risks of contamination with toxic compounds, risks of reversion to 
virulent genotypes or incomplete inactivation of whole-cell vaccines. By optimizing the 
delivery system, the immune responses can be tailored for specific pathogen against 
which the vaccination is aimed, and many recombinant subunit vaccines are investigated 
for mucosal delivery, using appropriate vectors. 
Two immunological approaches have evolved for the development of anti-HIV vaccines: 
prophylactic and therapeutic vaccines. The prophylactic vaccines would elicit a humoral 
immune response since they induce the production of antibodies that are capable of 
neutralizing the viral antigen before it enters the cell and hence the target of choice would 
be the envelope proteins. Therapeutic vaccines are intended to induce cellular 
components of the immune system to recognize and attack HIV infected cells and hence 
viral accessory genes are considered the appropriate therapeutic agents since they are 
expressed through the various stages of HIV infection. 
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1.2.2 Prophylactic vaccines 
A prophylactic vaccine would aim to induce a response that causes neutralization of the 
free virus particles by antibodies. This activity is considered the most important for 
antibody-mediated protection. It is defined as "the loss of infectivity which ensues when 
antibody molecules bind to a virus particle, and usually occurs without the involvement 
of any other agency. As such it is an unusual activity of antibody paralleled only by the 
inhibition of toxins and enzymes". In order to achieve protection through these means, a 
vaccine should aim to elicit antibodies of the highest affinity for virion surface antigen 
(Burton, 2002). For this reason, early vaccine candidates concentrated on eliciting 
responses to Env. However, with these early vaccine candidates several important factors 
became apparent. Because genetic variability is one of the hallmarks of HI V, neutralizing 
antibodies, which are predominantly directed against the V3 loop of the envelope protein 
(gp120), react only with a small number of virus isolates. Other antibodies, especially 
those directed against conformational epitopes of the CD4 ligand of gp120 or 
transmembrane protein gp41, can neutralize a wider range of HIV -1 isolates. However, 
these antibodies are rarely, if ever, induced by experimental vaccination. Another 
extremely important consideration was that because the usual route of transmission of 
HIV-l is through mucosal surfaces, mucosal immunity may be required in order to 
prevent sexual transmission of the virus. Two studies have investigated the ability of 
antibodies to protect against infection from intravenous challenge (Mascola et al., 1999) 
and through mucosal surfaces, with encouraging results. Using chimaeric SIVIHIV 
viruses (SHIVs) in non-human primates, Mascola and colleagues infused neutralizing 
antibodies into rhesus macaques to protect against vaginally transmitted infection 
(Mascola et al., 2000), while Baba and co-workers tested the effects of such antibodies in 
an oral mucosal exposure after birth (Baba et al., 2000). Passive transfer of antibodies 
conferred protection against disease in both studies. Although relatively high 
concentrations of antibody (>100ug mrl) were used-levels much higher than would 
ordinarily be achieved by vaccination-these studies showed that an appropriate serum 
antibody response might reduce infection at mucosal surfaces. It is unlikely that 
vaccination could achieve such a robust antibody response, although vaccines could also 
generate cellular immunity that might reduce the requisite neutralizing antibody 
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concentration to protect against infection. It is also hoped that synergy between 
antibodies directed against different neutralizing determinants might reduce the 
concentration required for effective neutralization (Nabel, 2001). 
Thus far, attempts to design vaccines that stimulate neutralizing antibodies have been 
disappointing. No vaccine tested to date in monkeys with SN or SHN models has 
induced a sterilizing immunity, and all animals subsequently challenged became infected 
(Marcus et ai., 2002). Results from the long-awaited phase 3 trials of gp120 (AIDSV AX) 
reported in February 2003, have also been very disappointing, with these having been 
shown to be completely ineffective (VaxGen Inc Press release 24 February 2003). 
1.2.3 Therapeutic vaccination 
Therapeutic vaccination is an alternative approach to HN treatment that has been 
investigated by a number of groups in the last decade. The main objective has been to 
augment virus-specific host immune responses, both humoral and cellular, believed to be 
critical in achieving control of viral replication (Lisziewicz et ai., 2003). Three main 
types of therapeutic vaccines have been clinically tested to date. Firstly, subunit vaccines 
containing recombinant env proteins (rgpI60/rgpI20) have advanced in clinical trials 
(reviewed in Lisziewicz et ai., 2003), reflecting the preventive vaccine effort based on the 
fact that neutralising antibodies are directed primarily against these proteins. Subunit 
vaccines of HN-l immunogen (whole inactivated HN, depleted of gp160 and gp120 
proteins) and other viral proteins have also been developed (reviewed in Lisziewicz et ai., 
2003). Secondly, recombinant viral vectors encoding viral proteins are able to carry large 
sequences of DNA, and by mimicking microbial infection, induce both humoral and 
cellular responses to these antigens in vivo (Jin et ai., 2002). DNA vaccines have been 
tested with the first clinical trial in HN infected individuals reported in 1998 
(MacGregor et ai., 1998). 
Clinical trials of antiretroviral drugs have employed viral load as the surrogate marker to 
detect clinical efficacy. For the testing of therapeutic vaccines no immunological end-
point has been identified which correlates to survival in a similar manner. All of the 
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experimental therapeutic vaccines investigated have been safe and wen tolerated. Many 
have demonstrated immunogenicity, as measured with a variety of immunological 
parameters, but none have yet demonstrated clinical benefit (Lisziewicz et al., 2003) 
1.3 EXPRESSION SYSTEMS FOR VACCINES 
1.3.1 Recombinant subunit vaccine production hosts 
A large number of different hosts are being investigated for recombinant antigen 
production. Commonly used systems for recombinant protein production and their 
characteristics are listed in table 1.1. Each host offers its own advantage, but there are 
also limitations, which have to be considered when choosing the host. 
TABLE 1.1: Comparison of various systems for expression of foreign proteins 
Level of Sensitivity Growth Equipment protein Purification to growth Posttranslational Codon 
media costs conditions Processing * usageN production . 
Bacteria Moderate Moderate High to Moderate Poor Poor 
moderate 
Insect Moderate Moderate Moderate to Easy to Moderate Moderate Good 
cells to high high moderate 
Animal High High Low Moderate to High Excellent Excellent 
cells difficult 
Yeast Moderate Moderate High Easy to Moderate Moderate to Poor 
cells Moderate excellent 
Plants Low Low Low Moderate to Low Moderate Moderate difficult 
·Shear forces, pH, temperature, oxygen; #expression of mammalian proteins (Awram et al., 2002) 
1.3.1.1 Expression in E. coli 
The advantage of using E. coli for heterologous protein production is its ability to be 
grown rapidly at high density on inexpensive substrates, its well characterized genetics 
and the availability of a large number of cloning vectors (Baneyx, 1999). The main 
concern with using E. coli is that overproduction of heterologous proteins in the 
cytoplasm of E. coli is often accompanied by their misfolding and segregation into 
insoluble aggregates known as inclusion bodies. Although inclusion body formation can 
greatly simplify purification, there is no guarantee that the in vitro refolding will yield 
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large amounts of biologically active products. The arginine codons AGA and AGG are 
rarely found in E. coli genes; the presence of such codons in cloned genes affects protein 
accumulation levels and mRNA and plasmid stability, in extreme cases it inhibits cell 
growth and hence protein synthesis (Zahn, 1996). 
1.3.1.2 Recombinant baculovirus as expression vectors for insect cells 
Baculovirus expression vectors continue to be used extensively for the expression of a 
variety of recombinant proteins in insect cells. These include cytosolic, nuclear, 
mitochondrial, membrane-bound and secreted proteins (Kost and Condreay, 1999). 
Recombinant baculovirus (rBV) systems are being increasingly used for the development 
of subunit vaccines. Co-expression of viral proteins has been used to achieve higher 
yields and stability of the particles (Kimbauer et ai., 1993; Xi and Banks, 1991). 
Recombinant BV s have been extensively used to express a variety of viral proteins 
including the HIV-1 gag protein (Nermut et al., 1994). Despite the high level of 
expression of recombinant proteins, the baculovirus system is relatively expensive. 
Baculovirus expression systems provide a great tool nonetheless for the functional and 
antigenic properties of rBV expressed proteins. 
1.3.1.3 Expression in S. cerevisiae 
The advantage of yeasts as an expression system is that like bacterial systems they are 
easy to culture on inexpensive media and there is a formidable array of techniques for the 
manipulation of foreign genes. Since they provide an environment for post-translational 
processing and secretion the result is a product that is often identical or very similar to the 
native protein (Sudbery, 1996). The yeast S. cerevisiae has been widely used for the 
production of VLPs of many different viruses. Antigens of interest expressed in S. 
cerevisiae include HIV-1 Gag protein (Sakuragi et al., 2002; Jacobs et al., 1989) anti-
malarial antigens (Brady et al., 2001), polio virus subviral proteins (Rombaut and Jore, 
1997) and hepatitis B surface virus antigen (Valenzuela et al., 1982). Due to its 
application in the bread and alcoholic beverages, industrial scale fermentation facilities 
are already in place for large-scale production and sterility may not be of critical 
importance. 
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1.3.2 Options for low-cost vaccines for developing countries 
A vaccine strategy employing purified virus-like particle (VLP) preparations is too costly 
for widespread vaccination to be implemented in developing countries, where the highest 
incidence of HN occurs. Strategies applicable to these settings are thus under 
investigation. The requirement for delivering HN proteins in appropriately immunogenic 
fonn remains a problem, as well as additional features, such as low cost, stability and 
single dose efficacy. Live vectors for delivery of heterologous subunit antigens offer a 
number of advantages as a vaccination strategy. Both Gram-negative and Gram-positive 
bacteria, including Mycobacterium species, as well as a whole range of viruses, have 
been investigated for delivery of foreign antigens. These live recombina t bacterial and 
viral vectors are able to replicate and express heterologous antigens in vivo. CeU-
mediated and antibody responses may be elicited, and these vectors may be suitable as 
therapeutic and prophylactic vaccines. 
1.3.2.1 Live viral vectors 
Genes encoding relevant antigens can be spliced into recombinant expression vectors 
allowing for increased cellular production of the antigen and induction of humoral 
immune and cellular responses (Mackett et al., 1982). Viruses that can be used include 
vaccinia virus, alphaviruses and adenovirus. The advantages of vaccinia virus systems are 
the wide host range of mammalian cells that can be infected, the high expression levels, 
the ease of virus stock production and the fact that it remains the most successful and 
possibly best understood vaccine. A disadvantage of the system is that it requires bio 
safety level 2 for production. The vaccinia virus system has been successfully used for 
large scale (lOOOL) production of different proteins such as HN-l rgp160 by Pasteur-
Merieux and human pro-thrombin by Immuno AG (Wurm and Bernard, 1999). 
Sindbis virus or Semliki Forest virus (SFV) are the most studied alphaviruses used for 
heterologous expression (Lundstrom, 1997). The broad host range of SFV has made it 
particularly attractive for production of recombinant proteins since the extremely efficient 
SFV 26S subgenomic RNA promoter used in these SFV expression vectors, comprising 
of two plasmids (cloning vector pSFV1 the carries the replicase genes and pSFV2-helper 
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plasmid which encodes the structural proteins of the virus) and the high number of copies 
of RNA (200 000) per infected cell, leads to high expression. Scale up for alphaviruses 
has been established for SFV but this unfortunately requires high biosafety level 
production facilities (Lundstrom, 1997). 
Adenoviral vectors are not pathogenic in humans, can be made replication competent or 
deficient, and can be administered orally (Imler, 1995). Humoral, cell-mediated and 
mucosal immunity can be elicited to the heterologous antigens delivered by adenoviruses 
(liljeqvist and Stahl, 1999). Several viral antigens such as HBV surface antigen, the 
measles virus nucleocapsid and glycoproteins from herpes simplex virus and rabies virus 
have been expressed and delivered by adenoviral vectors. Recombinant polioviruses have 
used to express a variety of viral antigens including HBV surface antigen and SIV 
proteins (Tang et al., 1997; Vim et al., 1996; Crotty et al., 2001). 
Despite the numerous studies, including clinical studies, conducted involving live 
recombinant viral vectors performed, no such vaccine candidate has progressed past 
phase II evaluation, since profiles of the immune response elicited were not considered 
ideal. Liljeqvist et al., (1999) speculate that until the safety and immunological questions 
are solved, only certain specific vaccines such as HIV and cancer in addition to 
veterinary vaccines, would be the applications for virus-based vectors. 
1.3.2.2 Live bacterial vectors 
Live bacterial vaccines are relatively inexpensive to manufacture and are well suited to 
large-scale administration in both developed and developing countries. They have the 
added advantage that they can be administered orally, which is practical and reliable in 
large-scale vaccination programs (Shata et al., 2000). All field and clinical trials with 
Salmonella as a delivery system have been limited to attenuated Salmonella typhi, 
however a promising alternative as a vaccine vector is S. typhimurium for heterologous 
antigen delivery (Nardelli et al., 1997). 
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Bacille Calmette-Guerin (BCG) as vaccine vector has the advantage of the established 
safety in humans and its capacity to accommodate large fragments of foreign DNA 
(Lugosi et al., 1989; Jacobs et al., 1990). Current information suggests that rBCG 
vaccines may be beneficial to prime or retain memory responses to antigens, but are 
unlikely to be useful as a single component vaccine strategy. 
1.3.2.3 DNA vaccines 
DNA vaccines have emerged as an attractive vaccine strategy because they are stable and 
relatively cheap, quick and easy to produce. The DNA can be administered by a variety 
of routes, all of which result in DNA uptake by antigen-presenting cells (APCs) and other 
cells as well as expression of the DNA-encoded antigen (Steller, 2002). Expression of 
foreign proteins within host cells from naked DNA constructs allows for the induction of 
humoral and cell-mediated responses, whilst protein subunit vaccines may only induce 
antibodies (Ulmer et al., 1996a; Ulmer et al., 1996b). DNA can be propagated as 
plasmids in bacteria and purified with ease and at a low cost. Chen et ai., (2002) found 
that priming with DNA and boosting with a vaccinia virus-expressed subunit vaccine 
generated a stronger immune response than either of the two on their own. Immunization 
with DNA vaccines encoding Nef, Rev and Tat induced lymphoproliferation, cytotoxic 
T-lymphocyte (CTL) and antibody responses in asymptomatic HN-l infected patients 
(Calarota et ai, 1999) 
1.3.2.5 Cell-based vaccines 
Preclinical models have shown that administration of peptide with an appropriate 
adjuvant is important for enhancing the immunogenic stimulus (Vitiello et ai., 1995). 
Dendritic cells (DCs) have a critical role in in vivo antigen presentation and could as act 
as a useful adjuvant (Steller et al., 2002). DCs are significantly more efficient in inducing 
anti-tumor protection than immunization with peptides alone (Celluzzi et al., 1996) 
(Paglia et al., 1996). 
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1.4 PLANT-BASED VACCINES 
Interest in vaccine production in plants has expanded rapidly since there are considerable 
advantages in expressing antigenic proteins in plants. Posttranslational protein processing 
is comparable to mammalian cells (Bosch et al. 1994), allowing the expression of 
functionally active proteins including complex molecules such as antibodies (Hiatt et al. 
1989). Plants can be growth locally and cheaply using standard non-sterile methods, thus 
reducing the issues with distribution, storage and transport. The use of plants as 
bioreactors is of interest as they allow the production of large quantities of recombinant 
proteins at relatively low cost. The whole production is flexible and easily changed to 
market needs (Herbers and Sonnewald, 1999). The cultivation, harvesting, storage, and 
processing of a transgenic crop would also use an existing infrastructure and require 
relatively little capital investment (Ganz et al., 1996; Pen, 1996; Whitelarn, 1995). 
Kusnandi et al. (1997) have estimated that the cost of producing recombinant proteins in 
plants could be 10- to 50- fold lower than in E. coli. Plant derived products, whether 
purified or not, are less likely to be contaminated with human pathogenic microorganisms 
than those derived from mammalian cell cultures since plants do not harbour human 
infectious pathogens, therefore sterility is not a big concern. 
1.4.1 Stable transgenic expression systems 
There are two main systems for expression of foreign proteins in plants; these are 
transgenic and transient. In the first, stably transformed transgenic plants are produced 
using Agrobacterium-mediated transformation, particle bombardment or other standard 
transformation techniques. Nicotiana tabacum is widely used as a model expression 
system, but various other suitable plants including Nicotiana benthamiana, Arabidopsis 
thaliana, tomato, banana, oilseed rape, Ethiopian mustard, lettuce, rice, wheat and maize 
have been used. Agrobacterium is a plant pathogen that can transform a large range of 
hosts including plants, fungi and animal cells. Agrobacterium-mediated transformation 
allows the integration of a gene cassette (T-DNA) into the plant genome. The process 
requires incubation of plant tissue with a bacterial culture containing the recombinant T-
DNA. Plant tissue culture is then used to select for the recombinant cells, usually using 
an antibiotic resistance marker. The resulting transformed tissue is then regenerated into 
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plants. The time required for this process varies from 6 weeks to over 1 year depending 
on the plant species involved. Once a transgenic plant is obtained, the integration is stable 
and can be passed on by propagation using normal methods (Le., seed and cuttings) 
(reviewed in Newell et al., 2000). Expression levels in transgenic plants can vary 
considerably due to several reasons. Integration of the gene is essentially random and 
subsequent protein expression can be affected by copy number, positional effects and 
gene silencing. It is therefore necessary to screen a number of regenerated plants to 
determine expression levels. It is also necessary to select for plants that express stably 
over several generations. 
Exceptionally high levels of protein have been achieved by integrating genes into the 
chloroplast genome where the recombinant protein can represent as much as 46% of the 
total soluble protein (De Costa et al., 2001). Each plant contains thousands of 
chloroplasts, resulting in thousands of copies of the trans gene that can be expressed. 
Positional and silencing effects are avoided because DNA is integrated by homologous 
recombination. Polycistrons can be expressed in the chloroplast allowing expression of 
multiple proteins and because chloroplasts have fewer proteolytic pathways than the 
remainder of the cell, foreign proteins may not be subjected to as much degradation when 
expressed in chloroplasts (Bock, 2001). In addition to high level expression, chloroplast 
integration should reduce the potential for transgene spread via pollen because 
chloroplasts are maternally inherited in most plants (A wram et ai., 2002). However, 
chloroplasts are essentially prokaryotes so the same limitations to producing eukaryotic 
proteins in such systems apply. 
Although transgenic technologies have been used for the successful production of a 
number of experimental plant based vaccines, the time required to produce transgenic 
plants represents a major disadvantage, particularly if many different expression cassettes 
or promoter elements require evaluation. Therefore as noted below, a number of 
researchers have sought the more rapid expression systems offered by the use of plant 
virus expression vectors. 
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1.4.2 Plant virus expression systems 
1.4.2.1 Advantages over transgenic expression systems 
The second strategy is to infect non-transgenic plants with recombinant plant viruses that 
express trans genes during their replication in the host. The general approach adopted is to 
insert the foreign gene into the viral genome under the control of a strong subgenomic 
promoter. The resulting recombinant viruses can then be introduced into the appropriate 
host plant by mechanical inoculation, where after the virus can spread systemically 
throughout the plant. If the construct allows viable virus particles to be produced, the 
recombinant virus has the potential to spread from plant to plant. This property makes 
propagation simpler but may create containment issues. With few exceptions, most plant 
viruses do not integrate into the host cell genome. This property gives transient 
expression systems the advantages that foreign genes are not generally heritable through 
seeds and expression does not suffer from the positional effects that affect gene 
expression levels found in stably transformed transgenic plants (Awram et al., 2002). 
Furthermore, transient expression using viral vectors is a fast and relatively simple 
method for examining proteins for desired characteristics since the infected plants can 
produce high amounts of proteins within 1-4 weeks of inoculation. This method generally 
requires less investment in time compared to transgenic plants before an expressed 
protein can be examined. 
1.4.2.2 Problems affecting plant virus expression systems 
There are, however a number of difficulties involved with the use of plant virus vectors. 
Inoculation of plants can be inefficient and expensive. Most viral vectors are RNA 
viruses and inoculation of the plant is accomplished by mechanical inoculation of the 
infectious RNA transcripts onto leaves. These transcripts are susceptible to rapid 
degradation from nucleases and are preferably used quickly after production. Systemic 
spread of the virus from the point of inoculation is also required and it has been found 
that some constructs interfere with the subsequent movement of the virus from the initial 
infectious centre (Cruz et al., 1996). 
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The major problem associated with the use of plant viral vectors is genetic instability 
caused by the presence of the inserted foreign gene. Because the foreign gene is not 
required for the viral life cycle, and because mUltiple consecutive replication steps are 
involved in the process of systemic infection of a plant, the insert is commonly deleted or 
modified during infection. Some researchers have also found that certain vectors are 
unstable in E. coli plasmids making it difficult to maintain the infectious full length 
molecule that contains the intact foreign gene. Despite these difficulties, plant viral 
vectors exhibit significant advantages over transgenic plants for the production of foreign 
proteins. The short period of time required and the ability to infect grown plants with 
minimal manipulation allows for rapid analysis of many different constructs. The fact 
that these viruses can infect a range of different plant species means that the same 
construct can be used in several different plants to examine species effects on protein 
production and a number of different plant virus systems have been developed for protein 
expression (Awram et al., 2002). 
The host virus systems frequently used are cowpeas with cowpea mosaic virus (CPMV), 
tobacco with potato virus X (PVX), alfalfa mosaic virus (AIMV) and tobacco mosaic 
virus (TMV) (table 1.2). The product yields are generally higher than those from 
transgenic plants. In addition to expressing the entire coding sequence of a protein using 
a duplicated subgenomic promoter, another approach of transient expression is making 
chimaeric plant viruses that display epitopes I peptides on the surface of the virus capsid. 
This approach involves engineering of the virus coat protein to express the antigenic 
peptide as a translational fusion. Such recombinant coat protein monomers have the 
potential to self assemble and form recombinant virus particles displaying the desired 
antigenic epitopes on their surface. Because the coat protein accumulates to high 
concentrations and viruses can easily be isolated, this approach tends to result in high 
yields of heterologous proteins. Constructs that use native or heterologous coat proteins 
and sub genomic promoters, have enabled foreign proteins to be expressed to levels of 2% 
of the total soluble protein (Shivprasad et ai., 1999). 
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1.4.3 Enhancement of protein yield 
1.4.3.1 Factors limiting yield 
A major limiting factor in the use of plants to express proteins is often the low yield of 
recombinant protein that is achieved. An expression level of 1 % of total soluble protein is 
generally accepted as a minimal level for it to be economically feasible or practicable to 
purify protein from a genetically modified plant (Kusanadi et al., 1997). As a result, a 
number of methods have been developed to increase expression levels. These methods 
have been applied to transgenic expression and viral expression, although some methods 
may not work with certain viral systems. 
Expression can be affected by factors on several different levels. At a transcriptional 
level, the use of appropriate promoters, enhancers and leader sequences for the expressed 
protein must be detennined. At a translational level appropriate codon usage and removal 
of mRNA destabilizing sequences and polyadenylation signals from the foreign gene 
need to be addressed to enhance rnRNA stability. And finally protein stability is crucial 
for accumulation of foreign proteins at high levels. These factors in tum depend on the 
plant system chosen and the method of expression as well as the stability of the protein. 
Some methods used in enhacement of expression are explained below. 
1.4.3.2 3' mRNA stabilizing sequences 
One of the most effective methods of increasing protein yields has proven to be the 
addition of 3' mRNA-stabilizing sequences. Richter et al. (2000) found that swapping 
the 3' region from nopaline synthatse with the 3' regions from either the soybean vspB 
gene or the potato pinII gene resulted in increases in RNA levels that translated into 20 to 
50-fold increases in expression of hepatitis B surface antigen in potatoes. 
1.4.3.3 5'lJ1r1ls 
Another effective means of increasing protein production is by modification of leader or 
5' untranslated regions (UTRs). The sequence of the UTRs greatly affects the levels of 
protein synthesis by altering ribosome binding and the initiation of protein synthesis 
(Beachy, 1997). It is not well understood what features of the UTR cause the differences 
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in protein synthesis. The best-studied UTRs are of viral origin, but much work has also 
been done on characterizing the UTRs of chloroplast mRNAs (Cohen and Mayfield, 
1997). 
1.4.3.4 RNA stability and codon usage 
Plants may incorrectly recognize some sequences from foreign genes as mRNA-
destabilising sequences and polyadenylation signals, which will also reduce yields. Such 
sequences result in lower production of mRNA and reduce the half-life of the mRNA 
molecule (Awram et ai, 2002). In addition codon usage in plants may differ considerably 
from foreign genes derived from other organisms such as animal pathogens. This may 
result in reduced protein expression levels of the foreign gene in plants. Use of unusual 
plant codons in the foreign gene may result in stalling or stopping translation. 
Redesigning the coding sequence of the gene and/or removal of mRNA-destabilizing 
sequences can result in as much as 100-fold increases in expression levels (Strizov et al., 
1996). Optimization for plant codon usage of the gene expressing the heat-labile 
enderotoxin (LT-B) resulted in a 14-fold increase inexpression, but these levels stunted 
growth of the potato plants. The growth inhibition was overcome by targeting of the 
protein to tubers (Mason et ai, 1998). Rouwendal et ai (1997) enhanced expression of the 
gfp gene from Aequorea victoria in transgenic tobacco by resynthesising the gene to 
adapt its codon usage for that of plants (Rouwendal et ai., 1997). It has also been 
demonstrated that chloroplast genes transferred to the nuclear genome have adjusted to 
nuclear base composition and codon usage (Oliver, 1990) 
1.4.3.5 Leader sequences 
Mixed results have been obtained from use of specific leader peptides to target proteins to 
specific cen compartments or organs such as the endoplasmic reticulum, chloroplast or 
organs such as tubers. Several studies have found that targeting of proteins to the vacuole 
(Richter et ai, 2000), and tubers resulted in increases in expression overcame the toxic 
effects of proteins already wen expressed (Mason et ai., 1998). It is likely that increases 
in expression result from reduced degradation due to reduced proteolytic activity in 
seeds, chloroplasts, the endoplasmic reticulum and other targeted compartments. Some 
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studies have shown no increase (O'Brien et al., 2000) or reductions in expression (Mason 
et al., 1998) resulting from the use of targeting signals. 
1.4.4 Foreign antigens produ.ced in plants 
Production of vaccines and antigens in plants is a rapidly expanding field of research. A 
huge variety of different antigens have been expressed in plants using the various systems 
described above. A summary of the foreign antigens produced in plants is given in table 
1.3. 
TABLE 1.3: Summary of foreign antigens expressed in plants 
Potential application 
Hepatitis B virus 
Hepatitis C virus 
Murine hepatitis virus 
Dental caries 
Autoimmune diabetes 
Transmissible 
gastroenteritis 
coronavirus 
Cholera and E. Coli 
diarrhoea 
Oral vaccine against 
cholera 
Mucosal vaccines not 
requiring adjutants 
Norwalk virus 
Rabies 
HIV 
Plant 
Tobacco 
Lettuce 
Potato 
Tobacco 
Tobacco 
Tobacco 
Potato 
Maize 
Potato 
Tobacco/potato 
Maize 
Potato 
Cowpea 
Tobacco/potato 
Tobacco/spinach 
Tobacco 
Tobacco/ 
blackeyed bean 
Cowpea 
Tobacco 
Tobacco 
Tobacco 
Tobacco 
Protein 
Recombinant Hepatitis B 
surface antigen 
HVRI mimotopeslCTB 
Murine hepatitis epitope 
Streptococcus mutant surface 
protein SpaA 
Vibrio cholera toxin B 
subunit-human insulin fusion 
Glutamic acid decarboxylase 
Spike protein of TGEV 
Antigenic N-terminus of 
glycoprotein S (N-gS) 
E.Coli heat-labile enterotoxin 
LT-B 
V. cholera toxin CtoxA and 
CtoxB subunits 
D2 pepride of fibronectin-
binding protein B of 
Staphylococcus aureus 
Coat protein 
Rabies virus glycoprotein 
Rabbies virus B-cell epitope 
HN epitope (gp120) 
HN epitope (gp 41) 
p24 
Expression 
system 
AMT 
TMV 
TMV 
AMT 
AMT 
AMT 
AMT 
AMT 
AMT 
CPMV 
AMT 
AMT 
AIMVITMV 
CPMV/AMT 
CPMV 
*PVX 
AIMVITMV 
ATM 
TBSV 
Reference 
Mason et al. 1992, 
Thanavala et al. 1995; 
Tsuda et al., 1998; 
Richter et al., 2000; 
Kapusta et al., 1999 
Kong et al., 200 1 
Nemchinov et al., 2000 
Koo et al. 1999 
Tacket et al., 1999; 
Arakawa et al., 1998 
Lam et al., 2000 
Ma et al., 1997 
Streatfield et al., 2001 
Gomez et al. 2000 
Lauterslager et al. 2001; 
Richter et al., 2000; 
Tacket et al., 1998 
Streatfield et ai., 2001 
Fischer et al., 2000 
Brennan et al., 1999 
Dixon et al., 1997; 
Tacket et al., 2000 
McGarvey et al., 1995 
Yusibov et al. 1997 
Doran et al., 2000; 
Mushegian et al., 1995 
Brennan et al., 1999 
Marusic et al., 200 I 
Yusibov et al. 1997 
Zhang et al. 2002 
Zhang et al., 2000 
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Rhinovirus Blackeyed bean Human rhinovirus epitope CPMV Tacket et al., 1999 
(HR Doran et al., 2000;) 
Foot and mouth Blackeyed bean Foot and mouth virus epitope CPMV Tacket et al., 1999; 
(VPI) Beachy et al., 1999 
Alfalfa ATM Dus Santos et al., 2002 
Wigdorovitz et ai., 1999 
Carrino et al., 1998 
Arabidopsis ATM Wigdorovitz et al., 1999 
Tobacco TMV 
Canine parvovirus Blackeye beans VP2peptide *CPMV Langeveld et al., 2001 
Nicholas et al., 2002 
Arabidopsis VP2 peptide (2121) AMT Gill et ai., 2001 
Mink enteritis virus Blackeyed bean VP2 epitope *CPMV Dalsgaard et al., 1997 
Malaria Tobacco Malaria B-ceU epitope *TMV Tacket et al., 1999; 
Turpen et al., 1995 
Influenza Tobacco Hemagglutinin TMV Beachy et al., 1999 
Cancer Tobacco c-Myc TMV Beachy et al .• 1999 
Bovine rotavirus A Potato VP6 AMT Matsumura et ai., 2002 
Human rotavirus Tobacco PYX O'Brien et al., 2000 
Rabbit hemorrhagic Tobacco VP60 PPV Fernandez-Fernandez et 
disease virus ai., 2001 
Psedomonas Cowpea Outer membrane F protein *CPMV Brennan et al., 1999a; 
Aeruginosa infections peptide Brennan et al., 1999b 
Tobacco *TMV Gilleland et al., 2000 
*TMV Staczek et al., 2000 
Staphylococcus aureus Cowpea D2 peptide of fibronectin- *CPMV Brennan et al., 1999 
binding Erotein B ~FnBP) 
*Chimaeric plant virus capsids 
PPV: Plum pox virus; TMV: Tobacco mosaic virus; CPMV: Cowpea mosaic virus; PVX: Potato 
virus X; AMT: Agrobacterium mediated transfonnation; TBSV: Tomato bushy stunt virus; 
AIMV: Alfalfa mosaic virus; CTB: cholera toxin subunit B 
1.4.5 Immunogenicity of plant derived antigens 
The initial attempts to determine the immunogenicity of plant-derived antigens was 
disappointing and could be attributed to the impurities and low concentration of the plant-
produced antigen. The hepatitis B surface antigen (HBsAg) expressed in transgenic 
tobacco formed VLPs and a crude extract containing 3% by weight of the HBsAg was 
used to immunize mice. However, the immune response was observed to be lower than 
that induced by the yeast-derived protein (Mason et al., 1992). The expression was 
slightly higher (5 nglg fresh weight) in lettuce and induced low levels of serum antibodies 
in humans (Kapusta et al., 1999). Transgenic potatoes achieved a higher expression of 
HBsAg and oral administration of raw potatoes induced an antibody response that was 
greater than that required for protection (Kong et al., 2001). About 25-50% assembly was 
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achieved for Norwalk virus capsid protein expressed in transgenic potato and 
immunization of volunteers with 150 g doses (215-751Ilg of VLPs depending on the 
batch) resulted in modest serum IgG increase after 3 weekly oral immunizations (Tacket 
et a!., 2000). Good protection against E. coli LT-B and transmissible gastroenteritis virus 
(TGEV) has been achieved using transgenic com produced LT-B (5 or 50 Ilg) in mice 
and spike protein ofTGEV (2mg) in piglets (Streatfield et al., 2001). Immunization with 
a crude extract of transgenic Arabidopsis-expressed FMDV VP1 protein conferred 
complete protection (Carrino et al., 1998) whereas that expressed in alfalfa protected 12 
of the 17 mice immunized (Wigdorovitz et al., 1999). Human trial on plant-produced LT-
B antigen of E. coli using 50-100llg of raw transgenic potatoes showed that antibodies to 
LT-B were detected in 10 of 11 volunteers fed with the plant-produced antigen and the 
antibody levels were similar to those obtained when volunteers were subjected to 106 
infectious E. coli (Tacket et al., 1998). 
As an alternative to transgenic approaches, several pathogen-specific responses have 
been generated from purified transiently expressed recombinant virus. Chimaeric plant-
produced vaccines displaying a parvovirus epitope (17 residue peptide from the S 
protein) on the coat protein of cowpea mosaic virus (CPMV) expressed in black-eyed 
beans (yield of 1-1.2mg of virus particles per g fresh plant material) were able to protect 
11 of 12 animal immunized and subsequently challenged with MEV (Dalsgaard et al., 
1997). Transiently expressed FMDV VPl in tobacco plants using TMV protected 30 
mice immunized and challenged (Wigdorovitz et al., 1999). It has also been 
demonstrated that virus-like particles of the flexuous plant virus PYX displaying the 2F5 
ELDKW A epitope could induce high levels of HIV -1 specific IgG and 19A in mice 
immunized with recombinant VLPs (Marusic et al., 2001). 
These reports show the potential of plant-expressed vaccines as a cheap alternative to 
vaccine production systems. Evidence has not shown than any particular plant-based 
expression of foreign antigen method is best and success may depend more on the choice 
of antigen than on the method of expression and delivery (Awram et ai., 2002). 
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1.5 HIVNEF 
1.5.1 Nef structure 
All primate lentiviruses encode a nej; however, a related counterpart is absent from the 
genomes of the other animal lentiviruses (Luciw et al., 1996). The nef gene of HIV-1 
extends from the 3' end of env into the U3 domain of the 3' L TR. It differs from the HIV-
2 counterpart in which the 5' end of nef overlaps the 5' end of env in a different 
translation frame. 
The HIV-1 nef gene encodes 210 amino acids. Nef is translated from two multiply 
spliced early transcripts that are independent of the posttranscriptional function of Rev 
(Rev acts post-transcriptionally to regulate viral mRNA transport from the nucleus and 
splicing of long HIV transcripts which code for gag, pol, and env precursors). One 
transcript is monocistronic and the other is bicistronic and encodes both Rev and Nef 
(Schultz et ai., 1990). The 5' ends of most HIV-1 nefgenes have two initiation codons 
corresponding to Metl and Met20. Both initiation codons are used and the two forms of 
Nef are detectable in infected cells (Kaminchik et al., 1994). Analysis of Nef proteins in 
cells infected with diverse virus isolates has been done by electrophoresis in 
polyacrylamide gels under denaturing conditions (Ugner et al., 1992). Such analyses 
revealed a huge amount of intra- and inter-patient heterogeneity in the size of the Nef 
proteins ranging from 27 to 34 kDa. This heterogeneity is attributable to variations in 
sequence as well as differences in post-translational modifications. 
1.5.1.1 Second.ary structure 
Comparison of the predicted amino acid sequences ofHIV and SIV Nefs reveals both 
conserved and variable regions (Sherman et al., 1990). Figure 1.2 shows the most highly 
conserved features of the Nefproteins ofHIV-l, HIV-2 and SlY. The most prevalent 
form of the protein is that which is initiated at the codon corresponding to a methionine at 
position 1. The second amino acid is a conserved glycine residue. In infected cells, Met1 
is removed and and myrictic acid is covalently linked to G2 at the new N-terminus. This 
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I 
1 
I 
• 
Figure 1.2. Predicted structural features of Nef. The diagram shows conserved features ofthe Nef 
secondary structure. The diagram is taken from Luciw et al., 1996. 
myristoylation was shown to be essential in determining the sub-cellular distribution of 
Nef and has important implications on the normal function of the protein (Gang et ai., 
1992). Immunochemical and biochemical analysis of infected cells and cells transfected 
with expression plasmids show that Nef is predominantly localised to the cytoplasm and 
the inner surface of the cell plasma membrane (Gang et ai., 1992). Mutation of the G2 
residue prevents myristoylation and disrupts subcellular targeting of the protein to the cell 
membrane. Such mutant proteins are defective in the observed serine kinase activity 
associated with functional Nef (Sawai et al., 1995) and are unable to carry out other Nef 
functions (Gang et al., 1992). HIV-l Nefalso has a threonine residue in position 15. This 
residue has been shown to be a target for phosphorylation by protein kinase C (Guy et al., 
1990). This residue however, is not highly conserved. Other threonine and serine residues 
in Nef were also shown to be phosphorylated by this kinase, a case in point being Thr80 
(Kaneko et al., 2000). The sequence of amino acids that follows this is usually rich in 
basic amino acids for the next 15 or so residues (Luciw et al., 1996). Sequence 
comparison of independent HIV-1 isolates reveals a two to 14 amino acid insertion in this 
region at residue 24. These insertions are generally characterised by charged amino acids 
and include one or more proline residues (Luciw et al., 1996). A highly conserved acidic 
region is located at position 62 to 65 of HIV-l Nef and this region is predicted to be on 
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the surface of the folded protein because of its hydrophilicity. The region between 
positions 69 and 80 of HIV-l Nef contains repeats of the sequence Pro-Xa-Xa-Pro 
(Luciw et al., 1996). This proline motif is a feature of proteins that interact with the src-
homology region-3 (SH3) domain of several members of several tyrosine kinases 
involved in signal transduction (Saksela et al., 1995). The central region of Nef is 
conserved in primate lentiviruses (Luciw et al., 1996). This region consists of a stretch of 
about 30 amino acids, the majority of which have charged side groups and are predicted 
to lie on the surface of the folded protein. This conserved central region contains a 
sequence of six codons that overlaps a 16-nucleotide stretch of A and G residues. This 
polypurine tract is highly conserved and functions as a primer in reverse transcription 
(Luciw et al., 1996). Many HIV-1 Nefisolates contain the sequence G130-P131-G132-
I133N133. This sequence is predicted to form a ~-tum. Nef proteins of HIV and SIV 
have a leucine repeat in the middle and an acidic domain near the C-terminus. These 
features are reminiscent of leucine zippers and activation domains of the acidic class of 
transcription factors, which bind DNA (Luciw et al., 1996). 
1.5.1.2 Tertiary structure 
HIV-1 Nef has three conserved cysteine residues (C55, C142 and C205) which are 
reported to form intra-chain disulphide bonds (Zazopoulos et al., 1993). Studies have 
shown that the N-terminal residues of Nef are generally unstructured (Grzesiek et al., 
1997). This region of the protein is generally rich in glycine residues and the structure is 
therefore not influenced by side groups, which would limit rotation around the peptide 
bond (Luciw et al., 1996). This region of the protein is cleaved by a viral protease 
between amino acid residues W57 and L58 generating two fragments of ~7kDa and 
-20kDa (Grzesiek et al., 1997). In addition to their role as a target site for the HIV-l 
protease, residues that compose the cleavage site (W57 and L58) have been shown to 
participate in an intra-molecular interaction with a hydrophobic pocket formed by two 
alpha helices in the well-folded Nef core (Pandori et al., 1998). Cleavage therefore 
releases the wen-folded Nef core from the amino terminal membrane anchor potentiany 
freeing the Nef core for action within the virion or target cell. This core contains many of 
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th~ regions that are crucial Jor many or th~ Nd' functions and has bixn th~ suhj~c( or 
sev~nll studks inyolving X-nty cryslatlognlphy and nuckar magndic r~sonanc~ (NMR) 
(Grzesiek et aI., 1997). 
The core region ofHlV-1 Nef contains two large helices, III and H2 spanning residu~s 
Y81 to K94 and RIOS to Hll6 respectively (Grzesiek e/ aI., 1997). There are two smaller 
helical regions H3 and H4 of4 and 5 amino acids in lel1b>1h starting at S 187 and M194. In 
the llilmodified Ncfprotein the C-tenninal end of the flexible region bct".-een residues 60 
and 68 is attached to the rest of the protein at the hydrophobic pocket between helices HI 
and H2. HIV-J Nefeontains an extended, five stranded anti parallel ~ sheet consisting 
consecutively of HI, H5, 84, B3 and H2. Strand Bl consists of residues LlOO, 1101 and 
HI02. 82 consists of residues N126, Y 127. TI28 and PJ29. H3 is made up of residucs 
1133. R134. Y13S, PI 36 and L137. 84 eOOlprises residues Y143. K t 44, L 145, VJ 46 and 
P147. H5 is the longest of the ~-strands and consists of residues LJ81, E182, W183, 
R184, FI8S and DI86 (Grzesiek e/ at., 1997). 
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Fi2~'" 1.3. Backbone representation of lite .. dlnod structure or tbe Nd CBTe. Thi. ~ .. phk .... 
2enerated witb 1It¢ program MOLMOL ar>d i< !:Ikon r.Bm (~"-L.eSi"" eI <d. (1997). 
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The arrangement of strands and helices in the Nef protein appear to be somewhat 
irregular in nature. In particular, the large separation between helices HI and H2 forms a 
hydrophobic solvent exposed crevice. This structure is important in the binding ofNefto 
the SH3 domain of several cellular proteins and for interaction with CD4 (Grzesiek et al., 
1997). This open appearance of the protein led to the suggestion that the protein core 
would not be particularly stable. However, further detailed studies of the solution 
structure and backbone dynamics using l~ relaxation data do not support this suggestion 
(Grzesiek et al., 1997). Residues that form parts of HIV-l Nef helices and strands have 
heteronuclear nuclear Overhauser effects NOEs of -{).74, which is close to values 
observed for wen ordered regions in "stable" proteins such as staphylococcal nuclease 
(Grzesiek et al., 1997). A backbone representation of the refined structure of Nef is 
shown in figure 1.3. 
Experiments with HIV-l Nefhave revealed that the protein has a dimerisation constant 
that remains close to the concentration of the protein used. This means that ~50% of the 
molecules are in the monomeric form, and 50% are dimeric. Nef has also shown a 
tendency to form aggregates at millimolar concentrations, especially at pH values below 
8 (Grzesiek et al., 1997). 
1.5.2 NEF Functions and its importance as a molecular target for drug and 
vaccine development 
The function of Nef is somewhat obscure. Indeed over the years several studies have 
presented contradictory results. Some initial studies appeared to demonstrate that this 
gene was of little importance in the life cycle of the virus while other studies assigned 
critical roles in the virus life cycle to this gene. In some early studies it was suggested 
that Nef acts as a negative factor in virus replication by repressing the transcription from 
the LTR (Ahmad et al., 1988) hence it received its acronym "negative factor". Effective 
analysis ofNeffunction has been made more difficult by the general observation that this 
viral gene product is dispensable for efficient replication of both HIV -1 and SIV in 
culture (Hua et al., 1997). Furthermore, virus from some HIV -1 infected long term non-
progressors have been shown to have deletions within the nef gene (Micheal et al., 1995). 
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Thymic atropy and loss of T -cells in peripheral lymphoid organs with resultant 
immunodeficiency, has been seen in transgenic mice expressing the nef gene alone 
(Hanna et al., 1998) suggesting that Nef could be directly responsible for the depletion of 
lymphocytes and thymocytes during HIV infection. 
Further studies revealed that although variations in experimental conditions may give 
conflicting results. Nef is able to induce virus replication through T-cell activation in 
primary quiescent CD4 cells (De Ronde et al., 1992), is needed for maintaining high 
virus loads in persistent virus infections (Kestler et al., 1991), is the major disease 
determinant in transgenic mice (Hanna et al., 1998) and may contribute to the 
neuropathogenesis seen in AIDS patients (Koedel et al., 1999). These effects are enabled 
by at least four activities associated with Nef: induction of CD4 and MHC class 1 down-
regulation, enhancement of viral infectivity and alterations in cellular signaling pathways 
(Azad et ai., 2000) 
1.5.2.1 Cytopathic effects of Nef 
A number of studies suggest that the cytopthic effects ofNef could be related to its being 
targeted to the plasma membrane and other membranes by the sequence at the N-
terminus, which has an N-myristoyl group attached at Gly-2. Full length recombinant Nef 
and N-terminal peptides of Nef but not truncated Nef starting at the second methionine at 
position 19, possess membrane perturbing properties and are capable of fusing 
phospholipid vesicles (Curtain et al., 1994). 
The N-terminal region ofNef shows striking homology and similarity in tertiary structure 
to bee venom mellitin and when myristylated at the N terminus has a dramatic 
disordering effect on lipid bylayers (Curtain et ai., 1994). Fun length myristylated Nef is 
released into the extracellular medium when expressed in yeast (Macreadie et al., 1995) 
or mammalian cells (Guy et ai., 1990), and is expressed on the cell surface of 
baculovirus-infected insect cells (Fujii et al., 1996). The yeast derived extracellular Nefis 
present as a complex with membranous material (Macreadie et al., 1995), and the 
addition of the culture medium containing Nef to naive yeast cells leads to their death as 
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measured by their inability to form colonies on culture plates. These activities of the 
myristylated N-terminal region of Nef and its structural similarity to mellitin suggested 
the interesting possibility that when present in the extracellular medium it could be lytic 
to human cells. 
Addition of myristylated N-terminal peptides of Nef to the extracellular medium of 
human erythrocytes, CD4+ CEM cells or PBMC, caused very rapid haemolysis or cell 
lysis in a dose dependent manner (Curtain et ai., 1997). This effect has been seen with 
erythrocytes, monocytic cell lines, a variety of yeast and bacterial cells (Lowe et ai., 
1997). It is evident that the mysitylated N-terminal Nef peptide-mediated cell lysis is 
quite promiscuous suggesting that extracellular Nef-induced ctyotoxicity for eukaryotic 
and prokaryotic cells is exerted through a common effect on cell membranes (Azad et ai., 
2000). The myristylated N-terminal Nef peptide-mediated death of a variety of cells 
could, at least in part explain the deaths of various cell types within lymphoid organs 
during HIV infection (Lowe et ai., 1997). A role for soluble or cell surface associated Nef 
in bystander cell killing has also been suggested by others 
1.5.2.2 Modulation of cell surface receptors 
a) CD4 Downregulation 
In CD4+ cells, Nef is able to down-regulate the expression of CD4 mainly by enhancing 
its endocytosis as wen as lysosomal degradation, which leads to a decrease in the half life 
of this protein, however, synthesis and intracellular transport of CD4 molecules are not 
affected by Nef (Aiken et ai., 1994, Anderson et ai, 1994) A dileucine-based sorting 
signal (aa 160-165 EIDXXXLL) in Nef is used to address cellular sorting machinery 
(Craig et al., 1998). Nef functions in a multistep process, first by dissociating the CD4-
p561ck complex that leads to the exposition of an endocytosis motif present in the 
intracellular domain of CD4 (Bandres et ai., 1995). Thereafter Nef connects CD4 to 
clathrin-containing adapter complexes which function as vesicle coat components in 
different membrane traffic pathways (Greenberg et ai., 1997). Finally Nef targets 
internalized CD4 molecules to degradation by connecting CD4 to p-COP protein present 
in endosomes (Piguet et ai., 1999). Various other cellular proteins including vacuolar 
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ATPase, phopatidylinositol-3-kinase and p35 thioesterase may be involved in Nef 
induced CD4 andocytosis (Liu et al., 1997). In addition to the process described above, 
Nef is also able to suppress the function of a novel protein Nafl, which increases the cell 
surface CD4 expression (Fukushi et al., 1999). At least when strongly overexpressed in 
transient transfection systems, extracellular CD4 molecules have been shown to be 
deleterious for budding virions, either by inhibiting HIV -1 progeny virion release by 
binding to env proteins (Ross et al., 1999) or by decreasing the amount of Env 
incorporated, thus making the virion less infective (Lama et al., 1999). Hence the purpose 
of Nef induced CD4 downregulation appears to enhance the budding or infectivity of 
virus particles. 
b) MHC class 1 Downregulation 
The Nef induced MHC class 1 and CD4 endocytoses are separate processes: the domains 
involved in the MHC class 1 downregulation consists of an N terminal alpha-helix (aa 
17-26), an acidic stretch (aa 62-66) and a Pro-rich (aa 69-78) segment of Nef, whereas 
CD4 binding and downregulation is mediated through several amino acids in the core 
region ofNef(most importantly: aa WLE 57-59, GGL 95-97, RR 105-106, L 110, D 123, 
EE 154-155, DD 174-175) (Aiken et at., 1996, Liu et al., 2000). In addition, Neftargets 
the MHC 1 protein to the trans-Golgi network by connecting the cytoplasmic tail of MHC 
1 to the PACS-1 dependent protein sorting pathway (Piguet et at., 2000). Decreasing the 
amount of MHC class 1 molecules on the surface is one mechanism that HIV -1 uses to 
escape CTL response directed against virus infected cells (Collins et al., 1998) 
1.5.2.3 Enhancement of viral replication and infectivity through 
alterations in cellular signaling pathways and modulation of apoptosis 
Within a few hours of infection of cells, Nef stimulates the reverse transcription on 
proviral DNA (Aiken et at., 1995). Nef enhances the infectivity of virions in a producer 
cell-dependent manner Tokunuga et al., 1998) suggesting that interactions with cellular 
factors are needed for this process. The Pro-rich sequence (aa 69-78), a conserved RR 
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motif (aa105-106) and the dileucine motif (aa 160-165) are needed for optimal viral 
infectivity (Craig et al., 1998). 
Nef has several effects on cellular signaling pathways. First, through its well conserved 
Pro rich motif it is capable of binding to the SH3 domains of several Scr family tyrosine 
kinases including Hck, Lyn, Lck, Fyn (Lee et al., 1996). The Hck kinase activation 
caused by Nef has been reported to cause malignant transformation of fibroblasts (Briggs 
et al., 1997). In CD4+ cells, Nef s association with Lck causes suppression in the 
essential function of Lck in the activation induced apoptosis. This delays cell death 
during HIV infection, thus allowing increased virus production. Nef also delays apoptosis 
by inhibiting a p53 dependent apoptosis pathway through its interactions with that protein 
(Azad et al., 2000). That interaction is dependent on the N terminal regions of both 
proteins. 
Secondly, Nef associates with serine kinases, including various isoforms of protein 
kinase C (Smith et ai., 1996), members of the mitogen activated-protein kinase (MAPK) 
pathways (Greenway et al., 1995) and PAK2 (Renkema et aZ.,1999). Nefmay also effect 
on P AKs indirectly by activating their regulators (Liu et ai., 2000). 
Thirdly, Nef may alter Ca2+ homeostasis in a variety of cells (Manninen et ai., 2000). 
Finally, the direct binding ofNefto an important component ofT-cell receptors may lead 
to activation of healthy T-cells without antigen stimulation, apoptosis due to the Fas-
ligand induction and T-cell receptor down-regulation thereby further protecting infected 
cells (Xu et al., 1999) 
1.5.2.4 Destruction of the humoral immune response 
Nef causes B-cell dysfunction by several mechanisms. Firstly, the gradual destruction of 
CD4+ helper T -cells will lead to impairment of B-cell function as well. Secondly, biased 
or restricted antibody V-region gene usage may limit the available repertoire of 
antibodies against HIV -1 and opportunistic infections (Muller et al 1993). Thirdly, the 
elevated levels of B-cel1 bearing IL-6 receptor in HIV -infected subjects, together with 
enhanced production of IL-6 (Boue et ai., 1992), can contribute to the 
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hypergammaglobulinemia. Finally, the decreased level of CD70, a TNF-related 
transmembrane protein induced by the activation of lymphocytes on B-cells fron HIV 
infected subjects is involved in the low IgG production after T-cell antigen stimulaton 
(Wolthers et al., 1997). Changes in expression of other cytokines and cytokine receptors 
may also contribute to the destruction of the humoral response (Wolthers et ai., 1997). 
1.5.3 Ner as a vaccine candidate 
1.5.3.1 Therapeutic and Prophylactic Implications 
Therapeutic strategies that prevent the death of bystander cells while promoting the eady 
death of HIV infected cells could play an important role in the preservation of the 
immune system, and would be a useful addition to currently used antiviral strategies. This 
could be achieved by targeting Nef. The evidence given above suggests that Nef can 
cause death when present in the extracellular medium, but when inside infected cells it 
seems to protect the cell from apoptotic death. Rationally designed inhibitors that bind 
specifically to the membrane active regions of Nef could stop extracellular Nef from 
binding to and permeabilizing cell membranes and thereby prevent Nef induced cell 
death. Specific antibodies that bind to these regions of Nef could also be important 
therapeutic or prophylactic agents (Azad et al., 2000). Because Nef can also inhibit 
apoptosis and act as a positive factor for for increased virus production, therapeutic 
approaches that reverse the Nef-induced inhibition of apoptosis of infected cells could 
result in selective elimination of infected cells (Azad et al., 2000). 
1.5.3.2 Epitopic Regions of Nef 
The Nef protein is very immunogenic and is rich in CTL epitopes. Several studies have 
focussed on characterising these regions. Identification of the epitopic regions in HIV-l 
Nef has been carried out by administering HIV -1 nef DNA sequences epidermally in 
mice transgenic for the human major histocompatability complex (MHC) class 1 
molecule, HLA-A201 (Sandberg et al., 2000). Ten potential HLA-A2 binding 9-mer Nef 
peptides were identified by a computer-based search algorithm. By a cell surface MHC 
class 1 stabilisation assay, four peptides were scored as good binders, whereas two 
peptides bound weakly to HLA-A2. After DNA immunization, cytotoxic T lymphocyte 
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(CTL) responses were predominantly directed against the NEF 44-52, 81-89 and 85-93 
peptides. The 45-52 and 85-93 peptides as well as the 139-147 peptides also generated 
specific CTL responses to peptide immunization (Sandberg et ai., 2000). 
A more recent study by Mashishi et ai., (2001) sought to identify the epitope specific 
CD8+ T cell responses to subtype C Nef as these would be important in the development 
of a subtype specific vaccine. Anti-Nef CD8+ T cell responses were identified in recent 
HN -1 subtype C infected individuals from Southern Africa. A combination of the IFNy 
ELISPOT assay and intracytoplasmic cytokine staining were used to identify regions 
within Nef containing CTL epitopes. Samples were obtained from 69 individuals within 
their first year of infection and screened with a subtype C-based set of overlapping 
peptides synthesised based on a nef sequence from prevailing virus in South Africa. 
The results of this study showed that 70% of the individuals recognized Nef, with 75% of 
responders targeting three epitope regions. Twelve individuals (25%) recognised the 
peptide PGPBVRYPLTFGWCF with a mean frequency of 958 ±543 sfu/lOe6 PBMC; 
eight individuals (15%) recognised the peptide PVRPQVPLRPMTYKA with a mean 
frequency of 762 ±576 sfu/l0e6 PBMC and fifteen individuals (31%) recognised the 
peptide YKAAFDLSHFLKEKG with a mean frequency of 802 ±586 sfullOe6 PBMe. 
HLA-restriction assays show this epitope to be restricted by both HLA-A*02 and -A*30, 
akin to the RSL YNTV ATL Y epitope in p 17 Gag. Out of the three epitope responses, 
there was a hierarchy of immunodominance, where exclusive recognition of the 
YKAAFDLSHFLKEKG was seen in 1/3 of responders; PGPBVRYPLTFGWCF by 1/5 
and PVRPQVPLRPMTYKA by 1/10 responders. 
These data show that early infected individuals with subtype C HN-l display a highly 
focussed CD8+ Tcell response to Nef. Three immunodominant epitope regions consisting 
75% nef responses were found within a narrow span of 73 amino acids. This 
immunogenic region is highly conserved between subtypes A, Band D, making it 
desirable to include in vaccine candidates (Mashishi et al., 2001). 
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1.6 SELECTION OF VIRAL STRAINS SUITABLE FOR INCLUSION IN mv-
1 CANDIDATE VACCINES FOR SOUTHERN AFRICA 
Viral strains used in the design of a vaccine for southern Africa need to be shown by 
genotypic analysis to be representative of the circulating strains, and not of unusual 
outlier strains. In addition, it is important that a vaccine strain has the phenotype of a 
recently transmitted virus, which is non-syncytium inducing (NSI), macrophage tropic 
and uses the CCR5 co-receptor for entry (R5 viruses). R5 viruses are the most commonly 
transmitted viruses and predominate in patients with advanced AIDS. In order to select 
this phenotype, many vaccine developers have focussed on using viral strains from 
cohorts with high incidence rates where dates of seroconversions are known (Williamson 
et al., 2003). In South Africa, a well established sex-worker cohort in KwaZulu-Natal 
was used to select appropriate strains for development of an HIV vaccine. Viral isolates 
from 15 acutely infected individuals were sequenced in the env, gag and pol genes and 
were phenotypically characterised. These sequences were compared with a similar 
collection from asymptomatic individuals from the Gauteng region as well as other 
published subtype C sequences in the Genbank database, including sequences from other 
southern African countries. Two potential vaccine strains - DU151 and DU422 - were 
selected from the acute infection cohort: the selection was based on amino acid homology 
to the consensus in all three regions, CCR5 tropism and ability to replicate in tissue 
culture. The complete genomes of these isolates have also been sequenced and shown to 
be HIV -1 subtype C throughout, with no evidence of recombination (Williamson et al., 
2003). The strain selected for use in this thesis is the DU151 strain. 
1.7 OBJECTIVES OF THE PROJECT 
Nef has been expressed in many systems but no literature could be found showing the 
expression of Nef in plants. The aim of this project was to investigate the production of 
HIV-l subtype C Nef in plants using a TMV-based plant virus vector pBSGI057 in 
Nicotiana benthamiana. The production of this protein in plants could provide a potential 
cheap source of antigen that could act as part of a candidate vaccine. Primarily, 
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expression of Nef as a free protein was to be investigated. The significance of codon 
usage on expression levels was to be studied by comparative analysis of expression of a 
wild type gene against a synthesized nef gene reflecting plant codon bias. Expression of 
free Nefin Nicotiana benthamiana would be preceded by rapid expression ofNefprotein 
in an E. coli expression system. This bacterially expressed protein would be used to 
develop immunoassays for detection and quantification ofNefin Nicotiana benthamiana. 
The second part of the project would investigate expression recombinant TMV particles 
decorated with immunodominant peptides from the Nef core region harbouring CTL 
epitopes, with the aim of purifying them and possibly investigating their immunogenicity. 
Two different peptides would be selected from the Nef core region based on their ability 
to stimulate CTL responses. Oligonucleotides encoding the each of the peptides would be 
fused to the N or C-termini of the TMV cp gene to be expressed as translational fusions. 
Expression of the decorated capsid proteins and their ability to assemble into rTMV rods 
would be investigated. In the event that such particles were produced a further aim was to 
purify characterize them physically and possibly study their immunogenicity in a small 
animal model. 
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2.1 INTRODUCTION 
HIV-l Nef has been successfully over-expressed in several systems including yeast 
(Macreadie et al., 1995) mammalian cells (Guy et al., 1990) and baculovirus infected 
insect cells (Fujii et ai., 1996). As outlined in the previous chapter, the use of E. coli as 
an expression system benefits from the bacteria's well characterized genetics and the 
availability of a large number of cloning vectors (Baneyx et al., 1999). The bacterium can 
also be grown rapidly at high density on inexpensive substrates. This advantage 
outweighs the concern that overproduction of heterologous protein in the cytoplasm of E. 
coli is often accompanied by misfolding and segregation into insoluble aggregates known 
as inclusion bodies. This means that there is no guarantee that the in vitro refolding will 
yield large amounts of biologically active products. However, the production ofNefin its 
native, active condition was not a priority for this project although such a protein might 
improve the accuracy of the assay that would be developed using bacterially expressed 
Nef as a control reagent. 
Several studies have reported procedures to purify recombinant Nef. Glutathione-S-
transferase (GST}-tagged Nef was purified to homogeneity in its native conformation 
using glutathione sepharose matrix. However, given the size of the GST tag and its 
potential effect on the overall protein structure, this approach requires a proteolytic 
cleavage step which can affect protein recovery (Lee et al., 1996). In contrast Nef or His-
tagged Nef (His(6}-Nef) was purified as such using heparin affinity column (Kohleisen et 
al., 1996) or immobilized metal ion affinity chromatographies (IM-ACs) (Federico et al., 
2oo1) respectively. IMAC is a very powerful method for purifying recombinant proteins 
with histidine affinity tails in their native state or in denaturing conditions. In contrast to 
GST tag, the relatively small size of the His tails have in general, minimal effects on the 
overall structure and biological functions of proteins (Janknecht et al., 1997). 
The pPrOEXTM HT Prokaryotic Expression System (Life Technologies™) is designed for 
the expression of foreign proteins in E. coli. The protein is expressed fused to a 6 
histidine sequence (His}6 for affinity purification. The gene of interest is cloned into the 
multiple cloning site of either pProEXTM HTa, pPrOEXTM HTb, or pProEXTM HTc. The 
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DNAs differ from each other with respect to their reading frames relative to the 6x 
histidine affinity tag. The trc promoter and lacIq gene enable inducible expression of a 
cloned gene with IPTG. Upon expression, the histidine sequence is at the amino terminus 
of the fusion protein. The histidine sequence has strong affinity for Ni-NTA resin matrix 
making it simple to purify the desired protein. The plasmids also contain the pBR322 
origin of replication, the 13-lactamase gene conferring ampicillin resistance. 
Rapid expression and purification of HIV -1 Nef using this system would provide a 
reagent that could be used to develop immunological diagnostic assays for detecting Nef 
in plants. The reagent could also be used for generating anti-Nef antibodies should the 
need arise. That would however be beyond the scope of this project as several anti-Nef 
antisera are available commercially. 
2.2 MATERIALS AND METHODS 
2.2.1 Amplification and subcloning of nef gene. 
The complete genome of the HIV-l subtype C isolate DU151 from a recently 
seroconverted acutely infected individual was obtained as a cloned and sequenced DNA 
pDU151 from Dr Joanne Van Harmelen at The Institute of Infectious Diseases and 
Molecular Medicine (IIDMM) at the University of Cape Town's Faculty of Health 
Sciences. To alleviate safety concerns arising from the extremely cytotoxic nature of the 
N-terminal region of the Nef protein as reviewed in the literature survey, it was decided 
that all work on this gene should exclude the first 59 codons of the gene. 
Two synthetic oligonucleotides to be used as PCR primers were constructed, based on the 
published sequence ofDU151. 
The upstream primer (Fprim) 
5'CCITAAITAAGGATCCATGCAAGCACAAGAGGAGGAAC 3' was constructed to 
include 19 bases of the nefsequence (underlined) which would anneal 177 bases into the 
nef sequence thereby eliminating the first 59 codons of the Nef ORF. A Pac I site for 
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cloning into pBSGI057 and two added cytosines on the 5' end to promote Pac 1 
digestion once cloned into the intermediate vector were also included. A Bam HI site for 
cloning into pProEX HT and an ATG start codon (in bold) for transcription of the cloned 
net sequence were also included. 
The downstream primer Rprim (5' CGGCTCGAGfCAGCAGTCTTTGTAATACTCC 
D was constructed to anneal to the 3' end of the net gene (underlined). An Xho I site for 
cloning into pBSG 1 057 and pProEX HT, one cytosine and two guanosine nucleotides to 
promote Xho 1 digestion were also added. 
PCR amplification was carried out as outlined in appendix A3 and the resulting product 
was gel purified and ligated into the pGem-T Easy (Promega®) vector to give pGemNef. 
pGemNef was used to transform high efficiency DH5a. competent cells (appendix A8) 
and plated onto LA plates with ampicillin. Resulting colonies were selected and grown 
overnight at 37 C in 5ml LB with ampicillin. Plasmid DNA was extracted by miniprep. 
Extracted DNA was analyzed for the presence of the required insert by restriction 
enzyme digestion with Pac I and Xho I from (Roche® Biochemicals) and their 
appropriate buffers. Restriction digests were analyzed by agarose gel electrophoresis. 
Two clones which showed the expected clavage patterns with Pac l/Xho 1 digests were 
subjected to large scale plasmid DNA extraction using the Nucleobond™ kit (Machery 
Nagel) according to the manufacturer's instructions. Purified plasmid DNA was 
sequenced by a modification of the dideoxy chain termination method of Sanger et al. 
(1977) for dsDNA templates using the universal -80 forward primer (5'-
CGCCAGGGTTTTCCCAGTCACGAC-3'; Pharmacia Biotech) and -80 reverse primer 
(5'-GAGCGGATAACAATTTCACACAGG-3'; MWG Biotech) fluorescent-labeled 
Cy5-Far Red primers from the Thermosequence™ cycle sequencing kit (Amersham Life 
Science). Cycle sequencing reactions were performed on an ALF-Express™ DNA 
Sequencer version AMV2.0 (Pharmacia Biotech). Labeling and termination reactions 
were carried out in the presence of 7-Deaza dGTP. Analysis of generated sequences was 
done using DNAMAN for Windows, version 4.13 (Lynon Biosoft, © 1994-1996) 
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2.2.2 CloDiDg of nef into pProEXTM HT 
0.5J.1.g pProEX Hfb DNA was digested with BamBI and XhoI. The digested DNA was 
electrophoresed in a O.S % TBE agarose gel and the band containing the digested DNA 
excised from the gel and the cut plasmid DNA was purified. 0.5J.1.g pGemNefDNA was 
digested with Bamm and XhoI. The digested DNA was electrophoresed in an agarose gel 
and the band containing the excised nefDNA was excised from the gel and the desired 
DNA was extracted. 
The nef DNA and the cut pProEX IITb DNA were ligated overnight at 4°C in a 
vector:insert volume ratio of 1:S with 2 units T4 DNA ligase in ligation buffer 
(Promega). DNA from the ligation reaction was used to transfurm competent DHSa. E. 
coli (appendix AS). Plasmid DNA from resulting colonies was extracted after growing 
overnight cultures by the miniprep method using reagents and materials from the Roche® 
Hydrobond™ plasmid DNA extraction kit. The nature of the DNA was determined by 
restriction endonuclease digestion with BamB I and Xho I and gel electophoresis 
(appendix AS). The plasmid containing the cloned nefgene was designated pProNef 
pTrc 
Histidine tag 
pProEXHTh 
4750bp 
------- BamHI 
Xhol 
pProNe! 
5200bp 
Figure 1.1: Plasmid maps sbowing tbe doning proeednre to create pProNe! 
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2.2.3 Small scale induction of Nef protein expression in E. coli 
A single colony of pProNef was used to inoculate 2ml of LB media with 100J.1g1ml 
ampicillin. This culture was incubated overnight at 37°C with agitation. The following 
day, lOml of LB media with 100J.1g1ml ampicillin was inoculated with 0.1ml of the 
overnight culture and grown at 37°C with agitation. Once the culture reached an OD 
(AS90) of between O.S and 1.0, 1ml was removed and centrifuged for 1 minute in a 
microcentrifuge. The supernatant was discarded and the pelleted cells were resuspended 
in 100J.11 of PBS. This was the uninduced sample. To the remaining culture, IPTG was 
added to a final concentration of 0.6mM and the culture was returned to 37°C with 
agitation. 1 ml aliquots of cells were removed at 1, 2 and 3 hours after induction and the 
AS90 measured. The cells were centrifuged for 1 minute in a microcentrifuge and the 
pellets resuspended in 100J.11 of PBS. These were the induced samples. 0.2 AS90 of each 
sample was placed in a separate microcentrifuge tube and mixed with an equal volume of 
2X SDS sample buffer. The samples were then boiled for 10 minutes and resolved by 
SDS-polyacrylamide gel (5% stacking and 15% resolving) electrophoresis and the 
resulting gel was stained with 1 % Coomassie brilliant blue (in 4S% methanol and 10% 
acetic acid) and de stained by repeated changes of 45% methanol and 10% acetic acid 
(appendix A12). 
2.2.4 Large Scale Induction of Nef Protein in E. coli Expression 
A single colony of recombinant pProNef was used to inoculate lOmI of LB media with 
100J.1g1ml ampicillin. The inoculated media was incubated overnight at 37°C with 
agitation. Sml of this overnight culture was used to inoculate 500ml of LB media with 
100J.1g1ml ampicillin. The culture was incubated at 37°C with agitation until it reached an 
OD (AS90) of between 0.5 and 1.0. At this point a Iml sample was removed as an 
uninduced control. The remainder of the culture was induced with IPTG to a final 
concentration of 0.6mM and incubated at 37°C with agitation for 3 hours. After 3 hours 
the cells were harvested by centrifugation at 10000 x g for 10 minutes. The supernatant 
fluid was decanted and the wet weight of the resultant pellet determined. The pelleted 
cells were then stored and -20°C prior to protein purification. 
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2.2.5 Purification of Inclusion Bodies 
PeUeted bacterial cells were resuspended in 4 volumes of lysis buffer [2OmM Tris-HCI 
(pH 8.5 at 4°C), 5mM 2-mercaptoethanol, ImM PMSF]. The suspension was then treated 
with lysozyme to a final concentration of 100mglml and left for 30 minutes at room 
temperature. The lysozyme treated suspension was then divided into Iml volumes in 
microcentrifuge tubes and sonicated until 80% cell lysis was achieved. The degree of 
lysis was measured by overall drop in AS90 of the suspension. This crude extract was 
pooled and centrifuged at 15000 x g for 20 minutes. 
Inclusion bodies were purified and washed by the method of Sambrook et al. (1989). The 
pellet fraction of the crude extract was resuspended in 9 volumes of lysis buffer [2OmM 
Tris-HCl (pH 8.5 at 4°C), 5mM 2-mercaptoethanol, ImM PMSF] containing 0.5% Triton 
X-IOO and 10mM EDTA (PH 8.0) and incubated for 5 minutes at room temperature. The 
suspension was centrifuged at 12000g for 15 minutes in a microcentrifuge. The 
supernatant was decanted and the pellet resuspended in 100J..l.l of water. The washed 
pellet was resuspended in 100J..l.l of lysis buffer containing 8M urea and incubated for 1 
hour at room temperature. This solution was added to 9 volumes of 50mM KH2P04 (PH 
10.7), ImM EDTA (pH8.0), 50mM NaCI, and held at room temperature for 30 minutes 
with the pH adjusted to 10.7 with KOH. The pH was lowered to 8.0 with HCI and the 
suspension stored at room temperature for 30 minutes. The suspension was centrifuged at 
12000g for 15 minutes at room temperature in a microcentrifuge. The supernatant was 
removed and both fractions analysed by SDS-PAGE to determine the degree ofinc1usion 
body solubilization. 
2.2.6 Purification of Nef by Affinity Chromatography 
This procedure was carried out with the intention of purifying the Nef protein while 
simultaneously refolding the protein by gradually reducing the urea concentration. The 
affinity chromatography column was loaded with 2ml of Ni-NTA resin (Life 
TechnologiesTM) and equilibrated with buffer A [20mM Tris-HCI (PH 8.5 at 4°C), 
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100mM KCl, 5mM 2-mercaptoethanol, 10% glycerol, 20mM imidazole] containing 8M 
urea, while maintaining a flow rate of O.Smllminute. The solubilised protein was loaded 
onto the column. The column was washed successively with 2ml volumes of buffer A 
containing 8M, 7M, 6M, SM, 4M, 3M, 2M, 1M, O.SM urea respectively and a fina14ml 
buffer A. The column was washed with 4ml of buffer B [20mM Tris-HCI (pH 8.5 at 
4°C), 1M KCI, SmM 2-mercaptoethanol, 10% glycerol] and a further 4ml of buffer A. 
Bound protein was eluted in O.Sml fractions with buffer C [20mM Tris-HCI (PH 8.S at 
4°C), 100mM KCI, SmM 2-mercaptoethanol, 10% glycerol, 100mM imidazole]. All 
fractions were analysed by SnS-PAGE to determine their protein content. Fractions 
containing purified Nef were subjected to protein quantification by Bradfords assay 
(appendix A 13). 
2.2.7 Immunoassays 
Several polyclonal and monoclonal antibodies against Nef were available and the 
availability of my bacterially produced Nef allowed me to assess them for their potential 
reactivity to nU1S1 Nef. This would allow me to set up a viable immunoassay for 
determining the presence of Nef protein in the Nicotiana benthamiana based expression 
system. Table 2.1 below shows different antisera and mAbs tested in the laboratory. All 
commercially available antibodies were to the Nef of HIV-l subtype B, which is 
prevalent in Europe from whence most of these reagents were imported. 
~ntlbody name or source ~pecificity IRaised in 
l.UKMRC iHN-l subtype B Nefmonoclonal aa64-68 !Balb C mouse 
~.ARP 3107 iHIV-l subtype B Nefmonoclonal aa71-90 lRat 
~.LIN-7 iHN -1 subtype B Nef polyclonal ~bbit 
~.Chemicon iHN-l subtype B C-terminal Mouse 
~.Clive Gray(NN) iHN-l subtype B NefPolyclonal Sheep 
Table 2.1: Anti Nef antibodies used in immunoassays 
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2.2.7a Western blotting 
Western blots were carried out on purified protein after separation of proteins by a 15% 
SDS-PAGE. lmmunoblotting was carried out according to the method in appendix A14. 
All 5 antisera were tested against Nef at dilutions in blocking buffer of 1: 1000, 1 :2000 
and 1 :5000. Secondary antibodies conjugated with alkaline phosphatase were added at 
dilutions in blocking buffer of 1: 5000 for goat anti rabbit, 1: 10000 for goat anti mouse 
and 1: 50000 for the mouse anti-sheep following the manufacturers (Sigma) 
recommendations. Blots were developed using NBT and BCIP. 
2.2.7b ELISA 
An initial pilot indirect enzyme linked immunosorbent assay (ELISA) (Barbara and 
Clark, 1982) (appendix A15) was carried out using the 5 antisera against bacterially 
expressed Nef. Anti-Nef antisera were diluted in PBS with Tween-20 in the following 
dilutions; 1: 1 0, 1: 1 00, 1: 1000, 1: 10000 and 1: 100000. The corresponding alkaline 
phosphatase conjugated secondary antibodies were also diluted in PBS-Tween at the 
following dilutions; 1: 5000 for goat anti-rabbit, 1: 10000 for goat anti-mouse and 1: 
50000 for the mouse anti-sheep. These were the recommended dilutions for western blots 
as specified by the manufacturers and are more concentrated than is usually required for 
ELISA. This ensured that secondary antibodies were wen in excess so that any reaction 
win be easily discernible from background levels. 
Having determined which antibodies were reactive, dilutions of primary antibodies of 
1:1000, 1:5000 and 1:10000 and secondary antibody dilutions of 1:500, 1:1000 and 
1 :2000 were used to determine the optimal dilutions and ratios for detection of proteins 
by indirect ELISA. 
44 
Un
ive
rsi
ty 
of 
 C
ap
e T
ow
n
Chapter 2: Expre,sion of Hn:::'1 Nef jn E. CQIi 
2.3 RESULTS AND DISCUSSION" 
2.3.1 Amplification, suhdoning nnd ~eqllf'ncing of Ilej'gf'ne 
The nef gene was successfully amplified to give the expected fragment at (l.5kh as is 
,hown in Figure 2.2. rhe strongest amplifiealion waS achined lIsing 3.5mM MgCl2 ;11 
the reaction mix_ 
2 3 4 5 6 7 8 
Fi2U'" 2.2: Co.t .1.<lTopho,",i, af peR produ<t, froID amptifi<atioD of n</"ith th~ addition of PQC 1 
and Xho 1 ,"",,«ian ,it ... Th ... uction w,," <ard«! out with a m"llne,ium titmtian in an ~rrort to 
Ol'timi. . th~ peR. Lan~ L :\-lark ... : lan~ 2, O.5m~\ ~\gCl,: ta"" 3, L5m~1 MgCl,: tan. 4, 2.5m:\-\ 
M2Cl,: lan. 5, 3.5mM !'.120,: lan~ 6, na fannrd prim .. ': t.n. 7, no ... v ..... prirn~ .. and lan~ 8, no 
trmplate. 
The l'OITect ineorporalion of re,lrielion sites Pac 1 and Xho t in the c-iooed peR product 
\\ia, coo.finned by digeslion of extrncled plasmid DNA from the dOries with these m'o 
enzymes to excise the lie/insert. 
A majority of the screened clone, contained Ihe reqllired re,triction ,ites and c·outd then 
be sequenced. Sequencing of Ihose that did 1101 have hoth sites would I~ter show that in 
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some cases, the Pac I site was somcl.imes lost as an artifact of the PCR while the Ham HI 
sit~ internal to the Pac I site was always retained, 
pGEMnef clone was checked by sequencing and th~ resulting sequen~~ was aligned with 
the known I)U151 sequence for companson. Th~ result or!he two-sequen~~ alignment is 
sho"'n below 
fust. uLgr."",nt of DNA ~~q'~~ r:ce~ DU151~EF,D ~nd GaC' .... llefxl 
Uppe::c lille , J:;151N~F D, from 175 to 623 
Low~'" lin" , pGEMn~f , f::com 20 to 468 
DU151f.IEF. D ,G,,-mar:e fxl id~!ltity_ 100, 00% (4~9/ 4 49) g~p_ O. 00 ' (01449) 
175 CJ'o.NJC"CAAGNJG"GGAACC!l.GAAt;;rAGGTTTTCCIIGTCAGACCTCAOOTGCCTCTAAGA 
1111II II i III ) i 1111111111 ; 11111111111 iii 11111111 I 1111 111111 
.0 CFlAGCACMGAr:';::'AGGAACCAGAAGTAGGTTTTCCAGTr:,AGACCTCAOOTGCCTCT_>.AGA 
23 5 CCAATG-'\,CTTATAAGGCAGC.l\.TT=TCTCAGCTIClllllAANI.GAANl.GGG=ACTG 
1111 i i 1111 ! I I II! 111111 ,11 111 II! I ! 11111111 11111 i I II : 111 111 : : 
80 CCMTGACTT"T_>.AOOCAGC"TICGATCTC"GCTTCTTTTTAAAAGMNl.GG=JC"CTG 
2 95 GAAGOOTTAATIT"CTCTAAGAAAA/J."CAN:;ACATTCTTGATITCTGGGTCT ATCACACA 
1111111111111 i 1111111 111 1111111 I ' i 11111111111 i 1111 i i III iii II 
140 GAAGGGTTMTTTACTCTMGAAAJ'.GACAAG"C!l.TTCTTG"TTTGTGGGTCTATCAC"CA 
J 5 5 CAA=ACTTCCCTGATTOOCAAAACT"CACACCGGG"CC!I.=GTC"GACTTCCl,CTG 
Ii! 111111 i 1111 i 1111 i 111111111 i 111111111111111 i 111111111 II i II 
200 CAAGGCT ACTTCCcrGATTGGCAAAACTACAC."CCGGGACCAGr:,cGTCAGACTTCC"C'l'G 
41, AC(7TTr:r.ATGCTGCTTCAAGCTAGTGCCAGTTGACCCAGAGGAAGTAGAAGAOOCCAAC 
,111111 ! : III : 1111 : ! 11111 : I i 1111111 : : : i 11111 : 1111: 1111: 11111 
.60 ACCTTTGGATGGTGCTT CAAGCT"G":GCCAGTTG"CCCAGJl.GGAAGTAGAAGAGI'';CCAAC 
4 7~ AAAGGAGAAAACAACTGTTTGCTACACC(7TTGAGCCAGCATOOAATOC_AGGATGC.~G."C 
i III : : Ii , 11111 11 : : 1111 : : ; 111111111 : : , 11111 : i i III , i 1111111111 
3.0 AAAGG"GAAAACAACTGTTTGCT"C!l.CCCTTTG"GCC!l.GC"TOOAATOOAGGATGCAGAC 
535 AC'.!\GAA=ATTAAACTOOGl'G 111'Gl\C."GCAGTCTAGC."CGCAGACACCTGGCCCGCGI'.G 
1111 ' iii 1111 i 1111 ; 1111 i i II11111111I1I11111 I11111111 1111111 
3 eo AGAGAAG"T."TTAAAGTGGGTGTITGAC!l.GCNITCTl\GCfo.CGCAGAC"CCTGGCCCGCGAG 
595 AAAC!l.TCCOOl\GTATTl\O.AAGACTGCTG 
III: 111111 i 1111111111 ' ! 11111 
44 0 AAAC!l.TCCGGAGT."TTACAAAGACTGCTG 
Alignment of the '~quence, showed 1 OO~'O sequence identity. 
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2.3.2 Cloning of nef into pProEXT" HT 
Restriction analysis of DNA resulting from ligation of pProEX HTb with the nef gene 
was done by digestion ",ith Bam HI and Xho L Digestion w0111d excise the inserted nef 
gene to give a 0.5 kb lxtnd upon electrophoresis ofthe digested DNA on an agarose gel. 
This band was present in DNA from sever,d clones. One clone was designated pProNcf 
and used in all subsequent work. 
2.3.3 SmaU Scale Induction ofNefProtein in E. coli E:J:pression 
1 2 ] 4 , 6 
-
2J,~ 
liig.", 2.3: SDS·P A(;E oftor~1 prumn rrom a .mall-scol. iIIduciion "rpproNd'. l.ane 1, I'rulein 
,tanduds: Lon.2, unindu.ed E. oolih .. boring pProNd: L.o03, E. ooliharvost.d 1 hour afto. 
induction: l..mo 4, Ii. <'Oli harve.tN 2 hOlt'"" aft •• induction: l.an. 3, E. coli h ....... red 3 hou~ 
after indu.tioll: Lon.6, indu«d E. coll .. ilh pP."EX HTb. 
Small scale induction of protein cxpression in pProNcf harboring cells produced an 
increa~e in expression of a protein migrating just below (he 28kOa protein standard 
(figure 2.3). This size is dose to the predicted molecular weight of25kDa lOr (he product 
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of the cloned nefgene carrying a hexa-histidine tag (His(6}-Nct). Charactcrization orthe 
band as His(6)-.r-;cf was Iatcr eonfinned by wcstern blot (figure 2.7). Fmm lane 2 in 
Figure 2.3 it ean be seen that thcre i.~ a low levcl of constitutive expression onr.., pmlein 
in the unin<luced ~ells. where the Hi,(6}-Nefhand is not prominent There is an inl-TeaSe 
in the expres~ion onhi.~ pmtein al 1 hour allerinduetion (lane 3) and the highe~t levels of 
exprcssion of'this protcin appear after 2 and 3 hours (lanes 4 and 5), wr..,re the Hi~6}­
Nefband i.~ extremely pn.>minenL No sueh hand i.~ generated Irom the induction of cell.~ 
containing the pProEX HTb plasmid (lane 6 of figure 23). This resull conlinn.~ 
expressIon of the nrf gene in pPn):tWf and demon.~trat..", that the highest level of 
expression of the protein under the induction conditions used is achieved by induction fur 
3 hours. 
2.3.4 I,arge &ale Tndndinn orNefPrntein in E. coli E"pres~ion 
kU, 
n.o 
52.~ 
35.4 
29.0 
2 1.5 
1 2 3 4 5 
Fi~u rt 2.4, SVS-P AG E .r poliN and '"porn.t.nl fr .... io~. oflyscd I.rgo , ... k Induotion .. U 
p"par.tilln •. Lane I, Prol.in m,~""ular .. rigbl 'I:lndard" lano 2, lotal protoin from unindu""", 
cell" I.n. 3. 101.1 pmlein from indUL..,.) cells: 10 n. 4, Su pemot.nl fcaNilln fCllm inducod cell" 
lanr 5, p<:ll .. rrom ;IIduocd «:lis. 
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Bas~d 011 (he finding~ of th~ small scale induction, a larg~-scale induction of cells 
containing pProNefwas carried lOr 3 hours. SUS-PAGE analysis (figure 2.4) showed the 
majority of the protein was present in the pellet fraction, after ee!llysis (lane 5), while a 
small amount of the protein was found in the supernatant fraction (lane 4). 
2.3.5 Purification of inclusion bodies 
Inclusion bodies from cells induced with !PTG were isolated and solubilized. The SDS-
PAGF in Figllfe 2.5 shows the re~ulting proteins. Note that the gel wa~ run under visibly 
sub-optimal conditions due to the presenc~ ofurea and detergents in th~ protein solutions 
being resolved. 1 he first step of the two step process removed all other cell debris and 
purified t!Jt, inclusion bodi~s_ The pre~nce of the His(6)-Nefprotein in the resulting 
pellet rraction is confirmed in lane 3. 1 he second step was the solubilization which 
involv~d disrupting (he purified bodi~~ with urea. Tht,"TC wa~ a hand representing Nefin 
the soluble supernatant fruction obtained rrom this step in lane 4 indicating succe~sfi.tl 
solubilization of the protein, In this statc, the protein should be suitable for purification 
by affinity chromatography. 
,no 
~2.9 
35.4 
29.0 
21.5 
1 2 3 4 , 
F;,:ure 2.5: SDS-rACE of all fraction. ""ulting fTom purifi<ation ond solubili ... tion of inclusion 
bodi ... Lue I, fJrol<in moletular welgkt <tandard" Lan .. 2 &3, ,ufJornatlnt and pdtct from 
in~tu.toJl body ;,;olalion: Un .. 4 & 3, peJIct and supom.{UI1'rom ..,tubm,"tion or Inrlu.ion bodlts. 
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2.3.6 Purification ofNefby AffInity Chromatography 
Affinity cbromatograpby to purifY His(6)-.'<cfwas carried out using a modified procedllfc 
to simliltancol1.~ly retold the denatured protein (figure 2.6). The duted tTaction.~ show 
highly purified protein withullt an oftbe other proteins present in the erude extract loaded 
onlo the col limn. The puriJied protein wa~ pooled and quantitated by 8radfurd's assay. 
['he pooled protein W<IS lOund lo he at a wncenlr4tion uf about 4j.1g per m!. The protein 
was ofhigh enough qualitylhal it euuld have bet:n ust'd to produce pulyclunal antibodies 
in r"bbits against I"'" I IIV -I .'<ef protein and for the optimi~lItion of ELISA techniques lor 
detectiun ufHTV -1 Ncfexpressed in other systems. 
'"" 52.9 
35.4 
2~.O 
21.5 
I 
== 
-
2 3 4 5 6 
• 
Fi~uR 2.~. S[)S-PA{a: or .Iutioll r ..... tion' .<sulting from affinity cltro matogropby .onduoted to 
purify Ner. Lan. I, prot.i. mol.ouloc wright standard" Lane 2, .rud. protctn I .... dtd onto 
.bromato~ .. phy .nlumn: Lane' 3, 4, 5 & ~,eluted rro<tioll' from Ni-NTA o~ln"'ll. 
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2.3.7: ImmunOlHsays 
2.2.7a WtUtru bloo 
The oocl~rially e;'!pres"Cd His(6)-Nef "'"Ill I'lrodu..:t:d as a ~cry pure :<am]lle hy alTimly 
~hromalOg:ruohy. This prov ided a pot..., ti~1 rnlg~"fll and po!liliH control fOT otlt...-
procedures. The Iden\1\y of the 25kDa band proJ""cd hy th~ pProNtf clone could bt: 
confirmed by re~cti on wl lh the anti-Ncf anti bOOie8 ~vail ahl e to u" In Jlgllre 2.7, five 
amls<''f~ were te.~tcd to Ihe bac l~ri ally ~xpre!;.<ed Hi~6)·Nef to oonlirm liS identity and 
~l3bhsh which ~nriserum can be U3l'1l in other procedures 
Marker , 
11.'.0 
,,. 
52.9 
35.4 
H.5 
t" .' ·~ 2.7: II ... ,,, • • bloll O' , bt b.n~ri.J~· ~.".~wI '"of pn''; • • F.3ril .'rip ." .. pn>bod .. ;.~ a 
Iliff ..... anri"'d~. I ,~.e I. I IKMlle.:: (""' ...... .011: b ... 1. Aftr 3 107( .............. 1); I~.~ 3. UI I' _7 
( .... lr); la ... 4. e ..... I ... I"", •• d .ool) a.tlla.~ 5. M V \1>"11"1 .. ,,,,1). 
Only the XIV . ho:t.-p polydondl anliS<:fUlll prodllO; td ft n:;aCllOn wilh N~r .howin.ll a clear 
hand at 2SJ..Da w h <:l~ (he ' h~(6J·N d band ,,~s pl~Sr;n t. 
Un
ive
rsi
ty 
of 
 C
ap
e T
ow
n
____________ _ ______ S,:.h~t';:r 2; ExprcssiqJ!i'fHlV-l Nefin E, coli 
2.3.7h ELISA 
In indirect ELISA ",actions un purified lIis(6)-Nefusing the five antibodies, only the 
NIV JXllyclonal antibody produced a positive serological reaction (figure 2.8). This 
antibody produced 00 readings at 4SOnm of ahove 2.0 at the highest concentration of 
His(6)-Nef tested. None of the other antibodies produced any reaction ahove the 
background level, except the UK MRC monoclonal antibody. This anlihody appeunx! to 
generate readings slightly above background 00 ""adings but this w.." probably not 
sign; Ii cant as the error hars incorpurates Icvel s helow the 0.5 leveL 
,-------------------
" 
, 
0 , 
• ~ 
~ 
" • 0 
~ 
• < 
" 
Reactivity of various antibodies to bacterially expressed His(6)-
N,f 
--+- LJ<'-'RC (rrooo) 
____ ARP3107Irmoo) 
UV.7(poty) 
---c>f- O1erricon (tID"') 
_____ NIY (pOly) 
1 :10 1.1000 1 nxxxl 1:'00000 
dilution of Nef 
------------
Figu ... 2.8: R",ult. Dr ELISA ,udio •• to t .. t th ••• a<ti~jly oh~a~.bl. Inlibodits 10 blet£ri.lly 
np,es,rtl His(6)-Nd. 
Optimisation of the ELlSA of Nefusing the N1V sheep polyclonal anti Nef antiserum 
was carried out and the results in figure 2_9 show that a primary antibody at a dilution of 
] in 5000 and a secondary antibody at a dilution uri in ]000 gave the best signal and the 
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Chapter 2: Expression oflllV -1 Neiin£_ ,,01; 
best ratio of positive signal to backgrOlmd. Ofal! the dilutions tested, these dilutions were 
the most optimal for usc in the detection of Nef in Nico/iona benlhamiana upon 
""PT"',sion using th" TMV-vector hased expression system. 
Optimization ofHis(6)-NefELISA 
• 1:10 dilution of HI.(6Hlof 
, .• 
• 1 ;100 dH"\i<>n of His(IiJ_Hef 
"Nogatl • • control (BSAJ 
, -
, .• 
, 
Q.5 _ 
o 
1 :1000 10 1;1000 10 1;1000 & 1 c5D00 " 1 :!Iaoo " 1 :500a & 1:10000 10 1:10000 & 1 :10000 " 
1:1000 1 ;5000 1;10000 1;1000 1:5000 1:10000 1:1000 1:5000 1:10000 
Primary and ... condary antibody dilutions 
Figu,"" 2.~' optimilJltion of ELISA (or N.fu,iD~ the NIV ,h..,1' p"lyd"nal anti_Nd antiserum. 
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2.4 CONCLUSIONS 
The HIV-1 nef gene was successfully amplified from the cloned DU151 isolate DNA 
pDU151. Restriction sites for Pac 1, BamH 1 and Xho 1 were added and the first 59 
codons were eliminated to address serious safety concerns that are associated with the 
cytotoxic effects of the N terminal region of Nef. The amplicon was examined once 
ligated into pGemT-Easy and grown up for screening. Clones of the amplicon in pGemT-
Easy that showed the presence of the required enzyme sites were confirmed by 
sequencing to align perfectly with the known sequence of the DU151 nefgene. 
The nef gene was excised using BamH 1 and Xho 1 and inserted into vector pProEx HTb 
to produce pProNef. A small scale induction of clones harboring this plasmid showed that 
the heterologous protein was well expressed upon induction with IPTG. This was 
observed by the increase in size of the band corresponding to His(6)-Nefat 2 and 3 hours 
after induction (figure 2.3). It was also established that expression peaked at 3 hours 
after induction and this informed the method ofIarge scale induction. 
Large scale induction for production purposes was carried out in 500ml volumes for 3 
hours and the cells were harvested by centrifugation. The cells were treated with 
lysozyme and sonicated to harvest protein. The majority of the protein of interest 
remained in the insoluble fraction of the protein preparation, while only an insignificant 
amount of protein was to be found in the soluble fraction (figure 2.4). The strong Trc 
promoter leads to overproduction of His(6)-Nef in the cytoplasm. Such overproduction, 
along with unfamiliar host chaperones, is known to result in misfolding and segregation 
into insoluble inclusion bodies (Baneyx, 1999) and it is likely that this is what happened 
with His(6)-Nef. This necessitated an additional purification step in which inclusion 
bodies were separated and harvested and then solubilised for further purification. This 
situation may have been circumvented by reducing the level of induction through 
manipulations of temperature, optical density and time of induction. Recent work by 
Finzi et al. (2003) shows that large amounts ofNefbecome soluble when Nef-expressing 
bacteria are grown at 30 C (Finzi et al., 2003). Modification of codon usage may also 
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contribute in optimization of expression. For example, the arginine codons AGA and 
AGG are rarely found in E. coli genes, the presence of such codons in cloned genes 
affects protein accumulation levels and mRNA and plasmid stability, in extreme cases it 
inhibits cell growth and hence protein synthesis (Zahn, 1996). 
Purification and solubilization of inclusion bodies involved the use of the strong 
detergent Triton-XlOO and urea at high concentrations. The fraction of soluble His(6)-
Nef protein was increased in this process (Figure 2.5) with much of the host bacterial 
protein remaining insoluble. Affinity chromatography resulted in a very pure sample of 
the desired protein (Figure2.6). Two contaminant proteins are known to co-purify with 
His-tagged protein expressed in E. coli (Finzi et al., 2003). The first is SlyD (GenBank 
database accession number P30856), a protein that was also referred to as wondrous 
histidine-rich protein (WHP) (Wulfing et al., 1994). The second is GTP cyclohydrolase 1 
(GCH1; GenBank database accession number P27511). Both proteins are rich in histidine 
or have some affinity for transitional metal ions making them likely to co-purify with His 
tagged proteins in IMAC. However, neither protein reacts with Nef-specific polyclonal 
antiserum (Finzi et al., 2003) and thus should not present a problem in the development 
of immunoassays using His(6)-Nef. Should the need arise to remove contaminant 
proteins (e.g. for antibody production), the heparin binding properties of Nef can be 
exploited to get a very pure preparation ofNef (Kohleisen et al., 1996). 
In figure 2.6 it is clear that much of the protein is lost in the IMAC process. The 
concentration of His( 6)-N ef in the eluted fractions was determined by Bradford's assay to 
be 41lg per ml. The capacity of the resin was sufficient to bind aU the protein passed 
through and so loss of protein may have been due to insufficient binding to the histidine 
tag because much of the protein was still misfolded and the His tag may have been 
occluded from interaction with chelated nickel ions in the resin. 
Western analysis of the protein using available antibodies confirms that it is indeed 
His(6)-Nef (figure 2.7). Of the five Nef-specific antisera tested, the only the NIV sheep 
polyclonal antiserum is reactive to the subtype C DU151 isolate encoded Nef. The lack of 
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reactivity with the monoclonal antibodies is most likely as a result of inter-subtype 
variation of the nefgene. All of the antisera used were obtained from Europe. They are aU 
raised against the nef gene of HN -1 subtype B which predominates in Europe. It is 
therefore unlikely that the monoclonal antibodies would have reacted to the subtype C 
Nef. Furthermore, because of the strong denaturing conditions used in the purification of 
His(6)-Nef, the conformational epitopes to which the monoclonal antibodies map would 
also not be present. This result underscores the importance of generating reagents 
specific to the local subtypes of HN -1. Polyclonal antisera appear to have enough cross 
reactivity to allow widespread use in immunoassays. In at least two other studies 
involving Nef raised in mammalian cell culture, the same polyclonal antibody raised in 
sheep against GST-Nefhas been the antibody of choice (Renkema et al., 1999; Hiipakka 
et al., 2001). It is not immediately clear why the other polyclonal antibody available 
(LIV -7) was also unreactive in both immunoassays. Although antibodies are generally 
stable and robust, is possible that poor storage could have led to degradation of this 
particular antibody. 
As a final step, a dilution series of primary and secondary antibodies was tested in ELISA 
reactions ofNef (figure 2.9) and the optimal ratios were achieved with a primary sheep 
polyclonal anti HN -1 Nef antibody at a dilution of 1 in 5000 and a secondary alkaline 
phosphatase conjugated mouse-anti-sheep monoclonal antibody at a dilution of 1 in 1000. 
Conditions for diagnostic ELISA reactions for the detection of Nef in the Nicotiana 
benthamiana based system would be informed by this result. 
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3.1 INTRODUCTION 
3.1.1 TMV 
Tobacco mosaic virus (TMV) is a single stranded RNA virus and is the type member of 
the family Tobamoviridae. It is transmitted between Nicotiana plants through abrasions 
and breaks in the cell walls via direct physical contact. It is perhaps the best-studied virus 
infecting plants: in 1898 it became the first agent described as a virus (Beijerinck, 1898) 
and in 1982 it became the first plant virus genome to be sequenced (Goelet et at, 1982). 
Members of the group Tobamoviridae encapsidate a plus sense RNA genome of about 
6.5kb into rods 300nm long and 18 run in diameter, with a central hole of 4run in 
diameter. 
A 
B 
c 
!VIP 
~ 
.. 
CP_ 
Figure 3.1: Schematic diagram of the TMV genome. (A) Organization of the TMV genomic RNA. 
Boxes represent open reading frames. Lines indicate non-translated sequences. (8) Schematic 
diagram of overlapping replication proteins. Shaded boxes represent domains similar with 
methyltransferases (MT), helicases (BEL), RNA dependent polymerases (POL). IR is the intervening 
region. (C) Subgenomic RNAs for the movement protein (MP) and capsid protein (CP) and their 
encoded proteins (Taken from Knapp et aI., 2001). 
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The TMV genome comprises a single positive sense RNA molecule 6395 nucleotides 
(nts) in length, containing four open reading frames (ORF) (fig 3.1) (Goelet et al., 1982). 
The 5'-terminus of the TMV genomic RNA is capped with 7-methyl guanosine. The 5'-
proximal ORFs that encode the overlapping 126 and 183 kDa replication proteins initiate 
at nt 69 and terminate with amber and ochre stop codons at nt 3417-3419 and nt 4917-
1919, respectively (fig 3.1B). Both proteins are translated directly from the genomic 
RNA and are required for efficient replication (Ishikawa et al., 1991). The 30 kDa 
movement protein (MP) (nt 4903-5709) and the 17.5 kDa capsid protein (CP) (nt 5712-
6191) are expressed from individual 3'-co-terminal sUbgenomic mRNAs (sgRNAs) (fig 
3.1C). A third sgRNA encoding a potential 54 kDa protein corresponding to the C-
terminus of the 183 kDa protein (Sulzinski et al., 1985) has been found to associate with 
polysomes in tobacco leaves (Zaitlin, 1999). The movement protein is required for cell to 
cell movement of the virus and associates with plasmodesmata, intercellular cytoplasmic 
channels, to modify their size exclusion limit (Wolf et al., 1989). Additionally the MP 
cooperatively binds single stranded nucleic acids in vitro and interacts with plant 
cytoskeletal elements (Carrington et al., 1996; Mas and Beachy, 2000). In addition to its 
coding function, the mp gene contains an origin of assembly sequence (OAS), from 
which assembly of viral RNA and coat protein into virus particles initiates (Zimmem, 
1983), and a sub genomic promoter sequence that, in the natural virus genome, directs the 
synthesis of the mRNA encoding the coat protein (Grdzelishvili et al., 2000). The 
17.5kDa coat protein (CP) is produced late as the most abundant protein in infected cells. 
TMV RNA and CP aggregate spontaneously to form virions. Both the CP with its ability 
to assemble into virus particles and the OAS are involved in long distance movement and 
systemic spread of TMV and the virus particle is essential for such movement (Saito et 
al., 1990). TMV particles are extremely stable and infectivity in plant sap survives 
heating to 90°C (Turpen and Reinl., 1998). 
3.1.2: TMV based expression vector 
One research area that distinguishes TMV from other plant VIruses has been its 
widespread use to express foreign products in plants over the last decade. The ability to 
effectively manipulate RNA viruses through a cDNA copy allows for simpler cloning 
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strategies and increases their appeal as viral vectors. The cDNA copy can then be 
transcribed in vitro to produce infectious RNA molecules (Donson et al., 1991). TMV 
vectors currently in use generally contain heterologous cis-acting elements and will 
tolerate the insertion of foreign sequences of useful lengths (Shivprasad et al., 1999). 
Recently, a variety of foreign sequences have been expressed in plants, including whole 
proteins, peptides (Gilleland et al., 2000; Nemichov et al., 2000), RNA sequences to 
silence host genes (Kumagai et at 1995) and foreign proteins with pharmaceutical 
applications such as neomycin phosphotransferase and even whole antibodies and VLPs 
(Krebitz et al., 2000; McCormick et al., 1999; Wigdorovitz et al., 1999). Monopartite 
TMV vectors are based on a design in which the foreign gene is generally inserted into 
the full length viral genome. One such TMV vector system has been constructed by 
Large Scale Biology Corporation., Vacaville CA. 
The TMV-based vector pBSGI057 (figure 3.2) encodes the TMV-MP and CP of the 
TMV US strain also known as tobacco mild green mosaic virus (TMGMV) which is less 
virulent than the type member Ul strain and accumulates low levels of CPo The TMV 
vector contains genes encoding replication associated genes as well as a modified gene 
encoding the green fluorescent protein (GFP) of Aequorea victoria. Infection of tobacco 
plants with RNA transcripts of this vector result in high levels of expression of GFP. GFP 
expression is a marker of infection and can be visualised using UV light. Expression is 
accompanied by moderate curling of leaves and reduced growth, which are typical 
symptoms of TMV infection. Replacement of the gfp gene with a heterologous gene 
enables high-level expression of heterologous proteins in Nicotiana benthamiana. The 
pUC vector backbone with the selectable ampicillin resistance gene and the colE 1 origin 
of replication is fused to the viral genome to enable genetic manipulation in E. coli. The 
system was first used to express enkephalin in inoculated tobacco (Nicotiana tabacum) 
and the kanamycin resistance gene in Nicotiana benthamiana in 1991 (Dons on et al., 
1991). 
In this chapter, the gfp gene was replaced with the nef encoding sequence in an attempt to 
express high levels of Nef in Nicotiana benthamiana. The expression of the nef gene is 
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track~d by simultan~ously infecting control plants with pBSG1057 RNA trnnscripts. The 
spread of the TMV in:li:ction is monitored by ch~cking for the appearance ofGFP in the 
leaf tissues of the host by illumination with UV light. It is assumed that the inf~ction of 
plants with the recombinant ne(exprcssing vector will spread and become systemic at a 
similar rate. It was hoped that this system may be used for cheap, large-scale production 
oi"rcagents and possible IllV-1 antigens such as Net: 
pHS(;JOS7 
1040Jbp 
protein (183kDa) 
Figure 3.2' PIo,mid mal' "f TMV based .'pression veel"r pBSG 1 (157 
Production of proteins in plants can be viewed as a process similar to farming where 
charactcristics ofthc plants will influence the yield. Under gro",,1h cOlxfitioll5 where most 
environmental conditions are optimized and constant the g~n~tic variation in the crop 
specics used becomes an increasinglyccntral detenninant of the eventual yield.Nicoliunu 
benlhumiana breeding lines have been devdopt'd over the y~ars with increasingly 
specialized traits fur research and otherpurposes. For our purposes, the permissiveness of 
the lin<;" or its lack ofresistanc~ to infection. as well a~ its size at harvest and ontog~nic 
characteristics are all important factors which will detennine the eventual yield. Two 
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breeding lines of Nicotiana benthamiana were compared. One, designated LSB, was 
provided by Large Scale Biology and was developed to be particularly permissive for use 
in TMV vector related research. The other, designated UCT'95, was provided by the 
University of Cape Town and has also been used for research over the last few years. 
The successful determination of permissiveness is dependent on the administration of an 
equal dose of inoculum to the two strains. Bawden and Price (1959) showed that although 
there is no obligate synergism between intact TMV particles as infectious agents, the 
infectious nucleic acid behaves differently and has an abnormally steep dilution curve. 
This has been evident in the reports of my colleagues who experience erratic infections 
using the transcribed pBSGI057 RNA. For the purpose of standardizing the infectious 
dose of recombinant TMV, dried leaf material from plants already infected with 
pBSG 1 057 transcripts and showing signs of systemic infection was homogenized and 
used as inoculum. 
Due to low levels of expression with many genes introduced into plants, several methods 
have been employed in efforts to enhance expression (reviewed in chapter 1). 
Optimisation of codon usage has been shown to greatly enhance expression of 
heterologous proteins in plants. Rouwendal et al (1997) enhanced expression of the gfp 
gene from Aequorea victoria in transgenic tobacco by resynthesising the gene to adapt its 
codon usage for that of plants. It has also been demonstrated that chloroplast genes 
transferred to the nuclear genome have adjusted to nuclear base composition and codon 
usage (Oliver, 1990). In this work, I set out to compare total protein accumulated using a 
vector construct containing the wild type net gene with that of one in which the gene was 
resynthesised to reflect plant codon bias. 
3.2: MATERIALS AND METHODS 
3.2.1 Comparison of plant host breeding lines 
The vector pBSG 1057 was obtained from Dr Kenneth Palmer at the Large Scale Biology 
Corporation in Vacaville California, USA. A large-scale plasmid DNA extraction of 
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pBSG 1 057 was carried out by the Nucleobond™ method. Production of RNA transcript 
ofpBSGl057 and a luciferase gene under the control ofa T7 RNA polymerase promoter 
as a control DNA was carried out using the RIBOMAXTM Large Scale RNA Production 
Kit (Promega) by the method specified by the manufacturer. Three week old Nicotiana 
benthamiana plants at the four leaf stage from the UCT'95 batch were used as initial host 
plants. The plants were mechanically inoculated using 50111 of the RNA reaction and 50111 
of DEPC water. Inoculation was carried out using autoclaved cotton buds. The cotton 
buds were dipped in celite and then into the RNA solution and gently rubbed onto the 
leaves in such a way that the leaves were not visibly abraded. Plants were monitored 
daily for the presence of symptoms and the appearance of GFP. Visualisation of GFP was 
done in a dark room with a long wavelength (32Onm) ultraviolet lamp. Once the infection 
had become systemic leaves were harvested and placed and sealed in universal 20ml 
bottles containing silica gel and desiccated for 3 months. About 500mg of dried leaf 
material was crushed and resuspended in 4ml PBS. This suspension was used for the 
inoculation of 10 plants from the LSB breeding line and 10 plants from the UCT'95 
breeding line. Plants used in this experiment were 3 weeks old, were at or just past the 
four leaf stage of development and were selected for their uniformity. with all plants over 
3cm in height and none having grown larger than 5cm. The plants were observed on a 
daily basis and all visible physiological and ontogenic changes were noted. Expression of 
GFP as an indicator of infection was monitored by illuminating plants with a long 
wavelength UV lamp. 
3.2.2 Production of plant codon optimised nel 
The HIV -1 subtype C nef gene from codons 60 to 207 was redesigned to reflect a plant 
codon bias based on the Nicotiana benthamiana codon usage. A Translation of the 
sequence of the subcloned DU151 nefgene was used to regenerate the nefgene based on 
the codon usage table of Nicotiana benthamiana provided by Genbank. This codon 
optimized nef gene (conej) was synthesized and delivered as the plasmid pGemconef with 
a Pac I andXho I restriction site on the 3' and 5' end of the gene respectively for cloning 
into pBSG 1057 (see figure 3.2). This plasmid was constructed by Geneart™ Inc 
(Germany). 
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3.2.3 Cloning of nefand conefinto pBSGI057 
0.5J.Lg ofpBSGl057 DNA was digested with 1 unit each of Pac I andXho I. The digested 
DNA was electrophoresed in a 0.8 % TBE agarose gel with 0.5J.Lg/ml ethidium bromide 
and the band containing the digested DNA excised from the gel and the cut plasmid DNA 
was purified and stored at 4°C. 0.5J.Lg pGnef and 0.5J.Lg pGemconef DNA were digested 
with 1 unit each of Pac I and Xho I. The digested DNA was electrophoresed in a 0.8 % 
TBE agarose gel and the bands containing the excised nefand conefDNA were purified 
from the gel. 
The excised nef DNA and the Pac I1Xho I digested pBSGI057 DNA were ligated 
overnight at 4°C at a vector:insert ratio of 1:8. A similar reaction was set up with conef 
DNA and the digested pBSGI057 DNA. Ligated DNA was used to transform competent 
DH5a E. coli. Plasmid DNA from resulting colonies was extracted from overnight 
cultures by the miniprep method. The nature of the DNA was determined by restriction 
endonuclease digestion with Pac I and Xho I and agarose gel electophoresis. Clones of 
pBSG 1 057 containing nefDNA were designated pBSGNEF while those containing conef 
were designated pBSGCONEF. 
3.2.4 In vitro transcription of recombinant TMV constructs 
Large-scale plasmid DNA extractions of all pBSGNEF and pBSGCONEF were made 
using the Nucleobond™ kit. Production of RNA transcripts of pBSGI057, pBSGNEF 
and pBSGCONEF and a luciferase gene under the control of a T7 RNA polymerase 
promoter as a control DNA was carried out using the RIBOMAXTM Large Scale RNA 
Production Kit (Promega) by the method specified by the manufacturer. A total of lOJ.Lg 
of plasmid DNA template and Illg of control DNA was used in the reactions. Results of 
the in vitro transcription were determined by electrophoresis in a 0.8 % TBE agarose gel 
with 0.51lg/ml ethidium bromide at lOOV for 20 minutes. IJ.LI of transcribed RNA was 
loaded on the gel and a total of 300ng of untranscribed plasmid DNA was also loaded as 
a control. 
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3.2.5 Mechanical infection of Nicotiana benthamiana 
Three week old Nicotiana benthamiana plants at the four leaf stage from the UCT'95 
breeding line were used as host plants. The plants were mechanically inoculated using 
50f..l.l of the invitro transcription reactions and 50f..l.l of DEPC water. Inoculation was 
carried out using autoclaved cotton buds. The cotton buds were dipped in celite and then 
into the RNA solution and gently rubbed onto the leaves in such a way that the leaf 
surface was not visibly abraded. Initial inoculations were carried out in duplicate with 
two plants inoculated with pBSG 1057, pBSGNEF and pBSGCONEF respectively and 
two plants with water as a negative control. Plants were monitored daily for the presence 
of symptoms and the appearance of GFP. Visualisation of GFP was done in a dark room 
with a long wavelength ultraviolet lamp. Once the infection had become systemic leaves 
were harvested and subjected to tests for the presence of the desired RNA and protein. 
3.2.6 RNA extraction, reverse transcription and peR amplification of 
cDNA 
The upper leaves of recombinant TMV infected plants were cut from infected and control 
plants and care was taken not to include the inoculated leaves as part of the sample in 
order to eliminate the possibility of residual inoculated RNA reacting in the reverse 
transcription and PCR steps that followed RNA extraction. IOOmg of leaf material from a 
harvested plant was placed in a mortar and homogenized in liquid N2. A portion of the 
homogenized leaves was used to extract RNA while the rest was used for protein 
analysis. RNA from leaf material was extracted into TRIZOL (Appendix AlO). 
RNA extracted from each plant was used to conduct reverse transcription and PCR 
amplification of the resulting cDNA in a single step (Appendix All). C. therm™ DNA 
polymerase™ (Roche™) has magnesium dependent reverse transcriptase activity 
allowing reverse transcription and polymerase chain reaction to be performed in a single 
reaction mixture when used in conjunction with Taq DNA polymerase TM in what is 
termed a one step RT-PCR. Primers used were appropriate to prime the reverse 
transcription reaction as well as the PCR reaction that followed. As a positive control for 
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the RT-PCR reaction, RNA extracted from the pBSGI057 infected plants was subjected 
to RTPCR using an internal gfp primer set. 
The following primer sets were used. 
For pBSGNEF: 
Forward primer: 5' -CCTTAA TT AAGGATCCATGCAAGCACAAGAGGAGGAAC-3' 
Reverse primer: 5' -CGGCTCGAGTCAGCAGTCTTTGT AATACTCC-3' 
For pBSGCONEF: 
Forward primer: 5'-ATCTCGCGAATGCTTCAAGCTCAAGAAG-3' 
Reverse primer: 5'-TCCTCGAGACAATCCTTATAATATTCTGG-3' 
ForpBSG1057: 
Forward primer: 5'-GGTTTAATTAAAATGGAGCCAGTAGATCCTAG-3' 
Reverse primer: 5' -GGATCTCGAGGATATCCTCCACCTTC TCTTCG-3' 
3.2.7 Detection of proteins in harvested leaves 
Homogenized leaf material from plants infected with each construct which was not used 
in RNA extraction was used for detection f proteins by SDS-PAGE and Western blot. 
This homogenized leaf material was suspended in 0.5ml of PBS and vortexed. The 
homogenate was centrifuged for a minute to remove large particulate matter and the 
supernatant plant sap extract was transferred to a fresh tube. The plant sap was placed in 
SDS-PAGE loading buffer and incubated at 80 C for 10 minutes. 1O1l1 of this was then 
resolved a 15% SDS-PAGE gel. For concentration of plant sap 109 ofleaves from a fresh 
batch of plants infected with pBSGNEF and pBSGCONEF respectively were 
homogenized in a food processor. The homogenate was suspended in PBS to a final 
volume of 10.5ml and centrifuged at 3000x g for 5 minutes to pellet down the insoluble 
leaf material. 5ml of sap was removed from each homogenate. 
3.2.8 Concentration of plant leaf extract 
Concentration of plant sap was achieved by ultrafiltration of the plant sap through an 
anisotropic membrane. Centrifugal force drives solvents of low molecular weight solutes 
through the membrane into a filtrate vial. The membrane support contains a circular 
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outlet with ducts for solvent flow (Figure 3.3). Retained micro solutes are above the 
membrane inside the sample reservoir at a greatly reduced volume, while the filtrate will 
contain microsolutes of molecular weight below the cutoff value of the membrane. A two 
step process was used to concentrate all the proteins between 30 and 10 kDa in molecular 
weight. 
Fillmte--
~11tmtugal Force 
Figure 3.3. The Millipore Centricon ® centrifugal filter device shown in its configuration during the 
filtering process. The retentate is recovered by inverting tbe device and centrifuging in the retentate 
into the retentate vial (taken from Centricon filter device user's manual 99259, Rev. V 11/01). 
In the first step, a Centricon® YM-30 centrifugal filter device with a 30000 molecular 
weight cut off was used. Samples containing sap from pBSGNEF and pBSGCONEF 
infected plants in PBS were added to the sample reservoir (2ml maximum volume). The 
devices were sealed by attaching a retentate vial to the top of the sample reservoir. The 
covered devices were the attatched to a filtrate vial and placed in a fixed angle centrifuge. 
The Centric on YM-30 centrifugal devices were centrifuged at 5000 x g for an hour after 
which more sample was added to the sample reservoirs and the centrifugation repeated. A 
total of 5ml of plant sap per device was filtered. The filtrates containing proteins smaller 
than 30kDa were then conected and recentrifuged using Centricon® YM-IO devices. 
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Centrifugation was carried out at a speed of 5000 x g for an hour after which more 
sample added to each tube. Filtration was carried out until aU the sample had passed 
through the membrane. The retentate was recovered by placing a retentate vial over the 
sample reservoir and inverting the unit. The units were then centrifuged at 3000 x g for 3 
minutes to transfer the concentrates into the vials. A total of 200J.lI of concentrate was 
recovered per device. The recovered retentates were then subjected to tests by Western 
blot and ELISA. 
3.2.9: Immunoassays 
3.2.9a: Western blotting 
Proteins in plant sap samples were resolved by SDS-PAGE using a 15% gel. Resolved 
proteins were transferred onto nitrocellulose immunoassayed by the western blotting 
method detailed in appendix A14. The polyclonal antisera tested against the plant sap are 
listed below in table 3.1. Gels were run in duplicate with only one of the gels used for 
blotting while the other was stained with coamassie blue for visualisation of the proteins. 
Primary Secondary 
antibody Raised in Source Dilution antibody Source Dilution 
Rabbit 1:1000 Goat anti SIGMA 1:5000 Anti-TMV MCBDept rabbit 
VCT 
Mouse anti 
Anti-Nef Sheep NIV 1:5000 SIGMA 1:50000 
sheep 
Table 3.1: Polyclonal antisera used in western blots on plant extract 
3.2.9b: Indirect ELISA 
Plant sap from harvested leaves and concentrated plant sap were each subjected to 
indirect ELISA (Appendix A15) using the polyclonal anti-Nef antiserum raised in sheep. 
Reactions of each dilution of 1: 10, 1: 100, 1: 1000 and 1: 10000 were done in triplicate on 
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adjacent wells on the ELISA plate for extracts of plants infected with pBSG 1 057, 
pBSGNEF, pBSGCONEF and a healthy plant, concentrated extract from plants infected 
with pBSG1057, pBSGNEF, pBSGCONEF and a healthy plant with bacterially 
expressed His(6)-Nef used as a positive standard. Results were taken from the mean 
value of the three reactions of each sample. 
3.2.10 Quantitation of N ef by western blot 
Quantitation of a protein by western blot first requires the establishment of the dynamic 
working range (DWR) for the particular method and assay conditions. The DWR is the 
range in an assay where the immunolabeling slope increases significantly with increasing 
protein load. In western blots, samples with very low or very high immunoreactive 
signals are typically outside of the DWR and such samples cannot be reliably quantified 
in the blot. 
Upper limit of DWR 
Wens of a polyacrylamide gel were loaded with increasing amounts of bacterially 
expressed His(6)-Nef in the following order; 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.5 and 
5.0J.Lg respectively. The proteins were resolved on the gel and transferred to a 
nitrocellulose membrane. The blot was then probed with anti Nef antiserum at the 
established optimal dilution of 1 :5000. Membrane from the developed western blot was 
visually captured by the Genegenius® bio-imaging system and subjected to manual 
densitometric readings using the GeneTools version 3.00.13 program from Syngene®. 
Arbitrary densitometric units for the immunolabeled bands were detennined and plotted 
versus total protein loaded per lane (in J.Lg). The upper limit of the DWR was established 
as that level of protein at which the signal saturates and the immunolabeling signal begins 
to plateau and fluctuate. Quantification above this region is unreliable. 
Lower limit of DWR 
Wens of a SDS-PAGE were loaded with increasing amounts of bacterially expressed 
His(6)-Nef in the following order; 0.0125, 0.025, 0.05, 0.1, 0.2, 0.3, 0.4 and 0.5J.Lg 
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respectively. The proteins were resolved on the gel and transferred to a nitrocellulose 
membrane. The blot was then probed with anti Nef antiserum at the established optimal 
dilution of 1 :5000. Membrane from the developed western blot was visually captured by 
the Genegenius® bio imaging system and sUbjected to manual densitometric readings 
using the GeneTools version 3.00.13 program from Syngene®. Arbitrary densitometric 
units for the immunolabeled bands were determined and plotted versus total protein 
loaded per lane (in J..Lg). The level at which the signal becomes unreliably weak and 
unquantifiable is the lower limit of the DWR. 
Quantitation of Nef in concentrated plant sap samples 
Once the DWR was determined, a standard curve was run on the same gel as the samples 
of interest, and quantitation of the levels of Nef was made by interpolating the signal 
from the sample within the DWR of the standard curve. The standard curve was made by 
loading wells with 0.05, 0.1, 0.2, 0.4, 0.6, 0.8 and 1.0llg of His( 6)-N ef respectively and 
loading adjacent wells with 30J..Ll of concentrated plant sap from pBSGNEF and 
pBSGCONEF infected plants. These volumes ensured that plant produced Nef protein 
levels fall within the DWR. All blots were carried out in duplicate and the average of the 
two quantities calculated from each standard curve was used. In order to establish the 
reproducibility in the result of the quantitation ofNef, the process of infection of plants 
with pBSGNEF and pBSGCONEF, harvesting and concentration of leaf material and 
quantitation of Nef by western blot was repeated twice more. Because of variations in 
transfer of proteins to the blotting membrane and other possible variables, a new standard 
was run for each quantitation. 
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3.3: RESULTS AND D1S(.1TSSION 
3.3.1 Comparison of plant host hreeding lines 
Th~ ",suIL~ (figure 3.4A) show that initial fluorescent spot;; were vi;;ible on plants from 
th~ UCT'95 batch 2 da)'S after inoclliation with RNA while the LSD batch showed these 
initial ~igns 0 finJec(iun aller only 3 da)'S post-inoculation. The infection progressed at a 
A) 
B) 
t; 
• , 
, 
• ,
• 
• 
• , , , 
• , 
, 
• 
• 
• ,
Time taken before appearance of disease symptoms in two 
plant lines 
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,// 
, ,---;-' i 
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, 
• 
, 
Days after inocula~on 
Mean length ofvegetative growth phase after planting out 
of Medling ~t 3 weeks (. I .. ~f .tag .. ) 
Fi~u", 3,(, Gnph •• howinl(differenoe. in A)timetak.n boro,.., app .. nonceofdi>ea •• symptoms and 
D) mean l<fIgth of vegetative growth ph •• e betw .... LSD and UCT'93 straIn. or Niet>liana 
bmlhamianlJ. 
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Ugu"" 3.~: Healthy NlMli",," MnlhltmuJnQ pllut, rrom die LSB (left) Iud UCT1995 (right) pint 
lin .. at h ..... ..t timo I( day •• /toe 1110 inocul.tiun d.te. 
faster rate in tbe UCT'95 tmtcb ",ith all plants ~llO'>Ving ~igIlS of infection by day 4 while 
in the r .SA line. all plants ~howed infection at day 6. 
Long distance movement of the VJruS. whicb was manifested by the presence of 
fluorescent spots in the apical meristem, occurred more rnpidly in the UCr'95 line than 
in !hc LSR line. As such, the plants in the UCr95 line were ready for harvesting at 7 
day~ po,t-inoculation while those in the LSR batch were ready alier 9 days. FigW'll 3AR 
tracks toc main ontogenic changes occurring in the two breeding lines in tenus of the 
length of the vegetative growth period whicb is concluded by the onset offlowering. The 
result show~ tbat in the plant> from LSR plant line there were vi~ible 8ign~ of the 
initiation ofnowenng aller 14 day8. In the UCT'95 plant line there arc signs oftlowering 
aller 20 days post inoculation. The change of an apex from vegetative to the flowering 
state represents the outcome of an internal autonomOU8 progre~8ion which i8 modulated 
to varying degrees, depending on tbe cultivar. by low temperature and photoperiod 
(MiltholJle and Monroy. 1979). In the pre8enCe of uniform temper<llUTe8 and photoperiod 
the more rapid progression towards flowering of plants from the LSB batch can be 
allributed to a genetic predi~posilion to do w. 
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]iigure 3.5 ,how, the appearance of the plants at harvest time, Clear diJTercnces in the 
ontology of the plant. are visible with the UCT'95 plant line having a higher number of 
larger and broader leaves. This b"""'-'ing line is also still in its vegetative grov.1h stage 
while the LSB plant line is well into it, nowering stage of growth. As a result, the 
amount of biomass generated per plant by the UCT'95 plant line was on u,'erage 30"1" 
higher than that of the LSB batch. 
3.3.2 Production or plant codon optimised nef 
The HIV-l subtype C nef gene was re-S}l1thesized by (ienearfn-, and delivered a, plu,mid 
pG=cone[ The new sequence shared 75.82% identity ,,;th the wild t)l'e gene. The 
sequence below shows the modified DNA sequence of the plant codon optimized nef 
gene w,th the expected translation, 
Tr~n~ l do~on o f N~=op t : 1 - 4 68) 
'Jlljve y ~ ,'l COO" 
Tot~~ ~llL'lO " cjd n'Jmbe~, l~,C ~.'li_ 18 2 GC 
'"' ''"x ORr , 1 -4 65 , 155 ,'.1\, MW_ 1~2UU 
1 A'; C "CGC'AA'; :'CTT~AA2CTCAAGAAGAA2AACCAGAAGTI:G2TT"i:"i:CCAGTTAGA~~A 
1 MLQAQElillPllVGI"PVRP 
G 1 ~A~.GTTCCA2"i:TAGA~~J'. AT2ACTI:A'AAG2CTG 2"i:'TTGI'-'CTTT2"i:TTT"i:TTCTTAAG 
2 1 Q v P L R ~ M T Y ~ A A I" D L S V V L ~ 
121 GAAA.~ 'Y'GTGG"'C' · ; GJ'.AG:''''~'; '; A'; T "A T"CTJ'.AGAAGAGACA.·.GA"'ATT ~" · "GA' ; :::"; '" 
41 E ~ ~ ~ L Ii ~ L I Y S ~ K R Q D r L D L 
1~ 1 TG3GTIT",C" T.~~Cl'AGG'i:'''TTTTCCAG.''ITGGC='T''T.''CTCC.>.G3T ~~.''22T 
61 W V Y H T Q G Y V ~ D W Q N Y T P G P G 
2 41 2TI~.2ACTTCC.~CTTACTTTT.Y'TT.}GTGTTIT1\1\2CTTGTTCO.2TTG."TCO.Gl\.i\Gl'A 
51 V R L ~ L T F G KeF ~ L V P V D P ! Il 
3 U 1 2', · , :'A.· .GAJ'.:'C; J'.J'. "'A.·.GGG'nAAA.~"' J'.J'.'; '; G"'l~ ""C"; CA"'~~l\CT" "; CTC1\l\Cl\ = 
1 0 1 VilE A N K GIN N C L L H P L S Q H G 
35 1 ,,"'G:'A.· .GA "'GC; GA.,.AGAGJ'.A:"' · "C' · "AJ\(;; G:':"""; '; 'n.', ,· ; ~" " 'C; C' 'TG ~T''2,'.1\G.>' 
12 ·1 M E DAD REV L K W V F D S S L A R R 
4 2 1 OSCT'i: GCT"G.>'2"l'0.!-.GCl\ TCCAGAA'~. TTl\ Tl' A GGA TTGT Cl'CG.'_G 
1 ~1 H L A R Il K H ~ E Y Y K D C 
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3.3.3 Cloning of "efand " .. nefinto pBSG10S7 
DNA Ii-om pGemnef and pGemcOIlef was Sliccesfllily llsed to ~on<truct pBSGNEF and 
pBSGCONEF. The succesful introouctiOll of the n,fam! conefgenes into pHSG I 057 as a 
replacement of g/p was contirmcd by endonuclease digestion. The plasm ids pHSG:\IFF 
amI pHSGCONEF arC digested with Pac 1 and Xho 1 to excise the inserted lIr[and (Our[ 
gen~ s respe~ti~ely am! the presenec of 500bp bands on the gel after digestion indicated 
that correctly si7ed fi-agments had heen rcleased. corrcsponding to the expected size of 
the nefand mneJfi-agmenls. 
3.3.4 Tn vitro transcription of constructs 
In vitro transcription prodllCts were deteded on a 0.8% agarose TBE gel (Figure 3_6). 
1"his checl <howed the pre<eoce of <llfficient RNA transcript Ii-om the rTMV con<tructs 
to initiat~ an illfection in Nicotiana henlhamiana. The R)'[A appear; in the f"fm of a 
smear for pHSG 1 057 (Ialle 3), pHSGNRF (lane 4), pHSGCONEF (lane 5) dlle to 
degradation that occurs during electrophoresis_ The smaller control luciferase gene 
generates a larger quantity of R:\IA hccause of its ~maller ~ize and its more specific 17 
R"A polymerase promoter_ Untrmlscrihed pHSG1057 pla<mid DNA is Il"en ill lalle 2. 
1 2 3 4 5 6 
'" 
1 '-5 
5_~S 
,." 
1.TO 
1.99 
1.00 
0.81 
., 
Fi¥uro 3.~: Agam •• g.1 .howin~ ill vitro traw,odp'" of pl",n,id,. Lan" 1. IJP,I 1 D~A marbr: 1 ..... 2. 
pllSGlft57 pla'mid f)l\A; lau 3, pFlSGlOS7 ,ron,erlpUon; I~n. 4, pBSUN[.ll Iran.nipli ... : Ian< 5, 
pllSGCONEF transcription and lane 6, oontrol pl .. mid !r~""<ripti"n. 
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3.3.5 Mechanical infection of Nicoliana bcnthamiana 
:>k'chanieal inoculation of plams resul ted in successful infection and expression of GFP 
after scver~l days in the pllSGl 057 infected conlrol plan IS. The presence of infe<;tion in 
plants iooculated "ith pllSGNEF and pBSGCO"lEF "as contirmed by the presence of 
mild symptoms a week aller inoculation. 
3.3.6 RNA Rxtraction, ~"erSc transcription and peR amplification of 
clli'iA 
Rl"-i'C R of I{'>..(A from p lanls infected wi th the Iwo conslruc't, yielded ampli (jed DNA 
~igure 3.7, RT_PCR ufR~A •• tra<t.d from plant •. Lon. 1, lP,,1 m.rkor: lon02, plJ~G~Er and 
pBSGCOI'(EF inr«t.d plant RNA "jth .n pri"",r. and RT <t.p OKlitttd, I.". 3. pBSG1037 pl."mid 
"j,b gfp pri~ .. r.; I.". 4. pBSG~l:F plo,mld D~A ".jlb ,,"f]>lime,~: lone, 3 ud 6. pBSGl'"EF 
Inf«,e<[ plan' R~A "jIb nef prim ... : Ian. 7, pBSGCO~F:r pl .. ",jd f)~A with eond prlmor" Ian., 8 
tD 1 n. pBSGCO~I'F inr~L1ed plan' R'lA "ith eonrf primor.: lono 11. pUSG IOS7 inf<L1.d plant RI'iA 
witb gfp pri~'o" ond 10". 12, )'p.,1 m.,·kor 
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fragments at the expeded ,ize of 450bp indi~ating the presence of ncf and conefmRNA. 
A, Can be seen in lane 2 (Iigure 3.7) where all Ihe constructs and primers were included 
bul the reverse transcription step was omilled, there was 00 priming up of D\lA 
indicating that Ihere was no residlLal D\lA ITom the inoclLlation of plants. Borh positiye 
controls where the reaction was calyied out with plasmid DNA gove the expected 
rea~lion. In lane 11, gjp RJ\A amplified wilh Iwo internal pnmers 10 give a hand of about 
200bp. 
~.3.7 Analy"i" or plant e-.:tract for N~f 
~.3.711 SUS-PAGE and western blot analysis 
SDS-PAGF analysis of plant extract (figure 3.8A) showed Ihc pre",n,;e of rTMY 
infoclion by the pre,ence of a TMV coat protein band at about 22kDa in lanes 5 and ~. 
This was the only significant protein lLnder 3llkDa visible by staining of resolved 
unconccnlrated proteins with C""massie bllLe 011 tbe gel. Western bIoi probed wilh anli-
TMV ami,erum confinns tile identity of this band in lanes B5 and ~. Concenlration of the 
"'p leads to an increase in the amount ofTMY coat protein thai is vi,ible in the gel (lanes 
A2 arid 1\3). Dimerisat;on of the TMY coal protein pm1icles under bigh concentration 
produces a second band which runs at about 35kDa and thi, is seen in lanes 1\2 and A3. 
Borh large bands react whC11 probed with anti-Tlv[V antiselUm in lanes B2 and B3. 
Concentration of the plant sap produced another band at 21kDa (lanes A2 and A3) which 
readeu when probed witb anti-Nefantiserum in lane C2. There wa, also a reaction with 
the battenally expressed His(~)-\!efpositiye control in lane CS. There was no reaction in 
the lanes loaded with healthy plant sap tested against either the anli-Nef(C5 and (6) or 
ant;-TMV (B5 and B6) antisera. The control samples ofbotl! the plant extract (lanes B7 
and CI) as well as the concentrated healthy plant ex:tract (lanes B4 and (4) were all 
lLnreactive in westel1l blots. 
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3.3.7h Indinet ELISA 
Indirect ELISA carried out on plant extract of plants infected with pBSGNEF and 
pBSGCONEF (Figure 3.9) showed weak but significant serological ""action at a 1:10 
dilution. A I :lOO dilution of plant ex!met produced a ",action only ~lightly above the 
background level resulling (tom absorbance reading.~ of wells loaded wilh PBS. The 
reaction ofth", pBSC,cONEF plant ~xtmel wa~ stronger than that orthe pBSGNEF plant 
The serological reactions were lne""a~ed in the eoncentmted plant extracts or both th<l 
pBSGCONEF and pBSGNEF with the ionner again producing a Mronger r<ladion. Th<l 
conc~ntml<ld healthy plant ~ap react<ld more strongly than the unconeentra1ed sap but 
both ""mained "",ar backgrolmd lev<lls. Th~ bacterially exp""ssed His(6}-Nd was a 
positive control for the ""action and produced the strongest positive reaction at all 
dilutions. 
,., 
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~,,-----------------j -+- pBSGCONEI'""no 
_ .~___ : ::'th1 pion! up oono 
UD 
Sample dilution 
Fi~u ... ,j.9: ELlS" nomlb nfplant ,op .. ,ted to Nfionti,.rum. The Nfi +v. i. bactorially expressed 
Nfi. Filter «moontTated plant .ampl .. an .uffixed .. jth tlte .. ord C<ln<. 
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3.3.8 Quantitation of Nef by western hlot 
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meanTotal Nef 
Densitometric value Mean total Nef Volume [Net] in plant per plant sap loaded from duplicate loaded on loaded on gram ofleaf (fresh 
immunoblots 
(Interpolated on western blot 
western blot weight) 
standard curve) 
A) 22945 O.241lg 
8) 21641 
pBSGNEF A) 22407 O.281lg 8) 27067 O.238pg 30pl 
A) 23164 
O.159pg 
8) 20987 O.1951lg 
A) 39416 O.5251lg 
8) 40123 
pBSGCONEF A) 41770 O.495Jig O.523pg 
8) 40049 30p) 
39229 
O.349pg 
A) O.551lg 
B) 39711 
Table 3.2: Calculated mean levels of expression of Nef in plants expressing pBSGNEF and 
pBSGCONEF based on average quantitated levels in three separate infections of Nicotiana 
bentham;ana with the two constructs. 
Quantitation of levels of Nef expressed in Nicotina benthamiana was carried out by 
western blot after initially determining the DWR for the conditions under which the 
western blot was run. 
In Figure 3.10 the upper limit of the DWR is established. The graph (Figure 3.l0B) 
shows the densitometric values increasing in a linear fashion between 0.25 and 1.0J.lg to 
230000 units after which there is a sharp jump in the densitometric reading of the band at 
1.5J.lg to 270000 units. After this value there is no longer a linear relationship between the 
amount of protein added and the densitometric value generated by the band. The blot 
(Figure 3.10 A) itself becomes saturated and smudged such that densitometric values 
cannot be reliably read from 1.5 J.tg upwards. 1.0J.lg was designated the upper limit of the 
DWR. 
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The lower limit of the DWR was established in figure 3.11. There is a steady decline in 
the densitometric values of the bands from 0.5 to 0.1 Jlg. There is a steep drop in the curve 
at values lower than 0.1 Jlg (Figure 3.11B). The bands on the blot are barely visible below 
O.1Jlg (Figure 3.11A) and therefore O.lJlg was designated the lower limit of the DWR. 
Quantitation was then carried out by running standard curves on the same blot as the 
samples of interest. Figure 3.12 shows the quantitation of Nef produced in the first of 
three infections of Nicotiana benthamiana with pBSGNEF and pBSGCONEF. The 
standard curve was generated by running quantities ofbacteriaUy expressed Nefbetween 
1.0 and 0.05 Jlg (figure 3.12A) along with the samples of concentrated plant extract of 
pBSGNEF and pBSGCONEF infected plants. The curve was plotted using an Excel 
spreadsheet and a smoothed curve was generated. Densitometric values generated from 
the Nef bands were used to generate an estimate of the total amount of Nef in the plant 
extract. The assay was carried out for three separate infections and the results were 
pooled and averaged in table 3.2. These figures were used to calculate the concentration 
of soluble and quantifiable Nef in each plant per gram of fresh tissue. The recombinant 
TMV vector pBSGNEF produced an average of 0.159Jlg of Nef, while pBSGCONEF 
produced 0.349Jlg ofN ef per gram of fresh leaf tissue in Nicotiana benthamiana. 
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3.4 CONCLUSIONS 
Climate and weather can be proclaimed the most important determinant factors for both 
plant production and crop productivity. However, in a greenhouse setting where these 
factors are controlled other factors become more significant. Because the desired product 
results from the product of a viral infection, the following characteristics of the plant 
varieties need to be considered. 
Permissiveness: Infection depends on a lack of the host's ability to combat the infection. 
Because inoculation of plants may be the most expensive part of the process (due to the 
high price of in vitro transcription procedures), the ease and speed at which an infection 
is established could have a significant bearing on the price of the product. 
Severity of symptoms: The severity of TMV disease symptoms has a bearing on the 
growth of the plant and therefore on the yield of protein to be harvested. In aU plants the 
symptoms were pronounced but no significant differenc  in severity was observed 
between the two breeding lines. Furthermore, symptoms only became evident after the 
infection had become systemic and the plant was nearing readiness for harvesting. 
Ontological and physiological changes: The basic aim of using this system was the 
generation of biomass containing rTMV or heterologous proteins encoded by the rTMV 
genome. For this purpose the plants used were chosen for infection during a period of 
high rates of vegetative growth which starts at 3 weeks after planting out of seedlings. 
Vegetative growth is a convenient overall term to describe all those activities associated 
with the generation and expansion of leaves, the formation of lateral apical meristems and 
the growth of some of these as branches and the concurrent expansion of the root system 
(Milthorpe and Moorby, 1979). Vegetative growth in anyone axis is in almost all species 
terminated by flowering and it is clear that TMV accumulates poorly in flowering tissue 
(unpublished data). A longer sustained period of vegetative growth is therefore in the best 
interests of maximizing yields of biomass. 
In the plants from LSB line, there were visible signs of the initiation of flowering after 14 
days. In the UCT'95 line there were signs of flowering after 20 days post inoculation 
(figures 3.4 and 3.5). The change of an apex from vegetative to the flowering state 
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represents the outcome of an internal autonomous progression which is modulated to 
varying degrees, depending on the cultivar, by low temperature and photoperiod 
(Milthorpe and Moorby, 1979). In the presence of uniform temperatures and photoperiod 
the more rapid progression towards flowering of plants from the LSB batch can be 
attributed to a genetic predisposition to do so. As a result of the prolonged vegetative 
growth, the amount of biomass generated by the UCT'95 batch was on average 30% 
higher than that of the LSB batch. 
In all aspects taken into consideration, the UCT '95 variety outperformed its LSB 
counterpart. While neither plant appeared TMV resistant, the UCT '95 variety seemed 
more permissive as the disease history appeared to be accelerated in this variety. Coupled 
with its longer period of vegetative growth, and resultant larger bi mass, this translated 
into easier and quicker infections with recombinant TMV and greater yield of product 
when this variety was used. AU these attributes made the UCT'95 cultivar a more flexible 
research tool and a better potential crop variety in the production of proteins using the 
TMV based vector system. 
The HIV -1 neJ gene constructed by Geneart™ to reflect an optimized codon usage for 
plants, and the wild type gene were successfully cloned into pBSG 1057 as replacements 
of the gfp gene. RNA transcripts were made (figure 3.6) and these were used to inoculate 
Nicotiana benthamiana plants. Plants were harvested a few days after the control 
infections had shown systemic spread as the spread of the two constructs may have been 
slower than that ofthe pBSG 1 057. 
RNA was extracted from plants infected with the two constructs and the control plants. 
The RNA was subjected to RT-PCR and the results confirmed the presence ofneJmRNA 
in plants infected with pBSGNEF and pBSGCONEF (figure 3.7). This qualitative assay 
was unable to distinguish between intact rTMV genomes and sgRNAs encoding the insert 
gene. 
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Examination of the extract of plants infected with the two constructs by SDS-PAGE 
showed the presence of TMV coat protein. This was a sure sign of infection but no 
visible sign of the heterologous protein was present (Figure 3.8A lanes 5 and 6). 
Filtration of the plant extract using a Centricon® YM-30 centrifugal filter device and 
concentration using a Centricon® YM-IO centrifugal filter device produced a new protein 
band just below the hugely expanded TMV CP band at 21kDa (Figure 3.8A lanes 2 and 
3). 
Western analysis of the plant extracts from plants infected with pBSGNEF and 
pBSGCONEF confirmed the presence ofTMV CP (Figure 2.8B). Nefwas not detectable 
in the unconcentrated extract. Concentrated plant extract from both pBSGNEF and 
pBSGCONEF infected plants was shown to contain Nef (Figure 3.8 C lanes 2 and 3). 
ELISA performed with anti N ef antiserum revealed the presence of N ef in the 
unconcentrated extract at low levels (figure 3.9) and an increased reaction was seen in the 
concentrated plant extract. 
Nef was produced in the system by both constructs and accumulated at levels detectable 
by ELISA but detectable by western blot only after concentration of plant extract. A 
similar level of expression was obtained by Kasarev et al. (2001) in the production of Tat 
as a free protein using a TMV vector based system in Nicotiana benthamiana. 
Quantification of protein by western blot 
Quantification of heterologous protein can be done by several means. While sandwich 
ELISA would probably be the most accurate, it is rarely used for the quantitation of 
heterologous proteins in plants and there are few publications describing its use (Bruyns 
et al., 1998). Researchers appear to favour western blotting or dot blots for quantitative 
measurements. Western blotting has some advantages in this particular case, as the 
resolving of proteins prior to blotting allows the separation of the protein of interest from 
the large quantities of TMV-CP that are present in the concentrated extract (figure 3.8A) 
prior to the immunoassay. It is likely that such a disproportionately large quantity of 
TMV-CP would interfere with the efficient immobilization ofNefin either ELISA or dot 
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blot assays. Pre-absorption with anti TMV-CP antibodies is likely to have been 
insufficient to remove such overwhelming quantities of CP and may have caused 
problems with reproducibility. Western blotting is also a well established technique in the 
laboratory and it requires small amounts of antiserum. The quantitation process was 
assisted by computer aided manual densitometric analysis of bands generated by 
capturing developed membranes with Genegenius® bio imaging system and subjecting 
them to readings using the GeneTools version 3.00.13 program from Syngene®. 
The dynamic working range for quantitation using western blotting was determined to lie 
between 0.1 and 1.0J!g of protein using the bacterially expressed His(6)-Nef as a control 
reagent. Standard curves were set up using this reagent and these were run on each gel 
with the samples being quantitated. There is a difference in the electrophoretic mobility 
of the proteins being quantitated and those of the standard curve. The reduced mobility of 
the bacterially expressed His(6)-Nef is largely due to the hexa-histidine tag and 
differences in posttranslational modifications the protein may undergo in the two systems 
such as glyco~ylation, sulfation and phosphorylation. The actual difference in molecular 
weight between the two is 3.8kDa. This difference is negligible in the context of 
quantitation of total protein from the standard curve. Samples from three different 
infections were tested and averages of 159ng for pBSGNEF and 349ng of Nefper gram 
of fresh leaf tissue in Nicotiana benthamiana with pBSGCONEF were the calculated 
yields. The level of expression amounts to less than 0.0007% of total soluble protein. 
This is low when compared with expression of the therapeutic antibody 38C13 (ScFv) by 
McCormick et al. (1999) in tobacco using a TMV based system. 38C13 (ScFv) is a B-ceU 
lymphoma treatment and idiotype vaccine and it was produced using a TMV subgenomic 
coat protein promoter and a Rice a-amylase signal sequence at 30.0 J!glg leaves 
Nicotiana benthamiana. Nemichov et al. (2000) showed that plants infected with 
recombinant tobacco mosaic virus (TMV) engineered to express the HVRlICTB 
chimeric protein, contained intact TMV particles and produced the HVRI consensus 
peptide fused to the functionally active, pentameric B subunit of cholera toxin. In these 
experiments, the amounts of chimeric CTB per 100 mg of total soluble protein varied 
within a range of 70-950 ng, which is 0.07-0.9% of TSP and approximately 6 to 80mg 
87 
Un
ive
rsi
ty 
of 
 C
ap
e T
ow
n
Chapter 3: Expression ofNefin Nicotiana benthmiana using a TMV-based vector 
per gram of leaf tissue. A lO-fold increase in protein concentration in the plant extract 
was also obtained using Centriprep concentrators (YM-IO). Using the same vector, 
Jaffray et al. (2003) was able to produce HIV-l subtype C Gag VLPs similar to those 
produced in baculovirus. These were found to accumulate at a rather low 5ng/g of leaf 
tissue, which was insufficient to succesfully isolate and conduct immunogenicity 
experiments. The low yield may be attributable to the relatively large size of the gag gene 
relative to nef and genes used to express plantibodies for example. There are no reports in 
the literature of expression of free protein using the TMV vector system to levels 
exceeding 80~g/g fresh weight of leaves. However, encouraging results have been 
obtained by fusing heterologous genes to the coat protein of TMV which is known to 
accumulate to high levels in infected leaves. Using this approach, researchers have 
reported expression levels as high as 800~g/g of fresh weight (Pogue et al., 1998). The 
subsequent chapter will explore this approach further. 
Codon optimised vs wild type nef 
The DNA sequences of the wild type and codon optimized sequences have about 75.82% 
identity. The codon optimized gene contains 110 silent nucleotide changes compared to 
its DU151 counterpart used in this study. Results in this work show an improvement in 
expression with the use of the plant optimized gene. However, codon optimization is in 
its infancy and with current knowledge, it is difficult to determine at which level codon 
usage is most influential. Stability of the DNA helix, mRNA stability, amino acid 
composition and codon choices are all factors which will affect or be influenced by codon 
usage (Boudraa and Perrin 1987). While DNA stability may be influential in transgenics, 
it is not a factor in transient systems such as the TMV -based vector system. However, 
because the heterologous gene in the vector is translated off a subgenomic RNA, it is 
possible that the stability of this species is enhanced by the optimized sequence. The 
translatability of the mature mRNA has implications on its accumulation in transgenic 
plants. Unfortunately, current knowledge of parameters affecting RNA stability is 
restricted in plants (Vancanneyt et al., 1990). The relationship between the host amino 
acid composition and its codon usage is difficult to gauge (Boudraa and Perrin 1987) and 
so little can be said in relation to this. 
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In E. coli, yeast and plants, synonymous codon choice patterns are related to the 
abundance of isoaccepting tRNAs and this is positively correlated to the level of gene 
expression (De Amicis 2000). This last factor may possibly be the most significant in 
improvement of expression in the transient expression system. 
Enhancement of expression achieved by optimization of the codon usage was such that 
expression levels still remained at levels wen below the level of 1 % of soluble protein 
that is needed for commercial feasibility (Henry Daniell, 2001). Future investigations 
may explore the option of optimizing the codon usage to that of TMV to increase 
expression further. Virus genomes frequently have a G+C content significantly different 
from that of their host species, reflecting a different codon usage pattern of unknown 
significance (Strauss et al., 1995). DNA shuffling technology and mutagenesis have both 
been used in improvement of the movement protein of TMV (Toth 2002). This has 
resulted in the development of a movement protein vastly improved in its stability and 
efficiency. While the same technology could be applied to heterologous genes for 
improved expression it is also likely that the improved vectors that will result from 
increased efficiency of the movement and other proteins will enable greater expression. 
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4.1 INTRODUCTION 
4.1.1 TMV Coat Protein 
The abundance of TMV CP in infected plants and the purification advantages presented 
by the unique physical properties of the TMV virion structure make it an ideal candidate 
for a vaccine epitope display system. The structure of TMV has been refined at 2.9A 
from X-ray fiber diffraction studies. A right handed helix is formed from about 2130 
identical coat protein (CP) subunit of 17.5kDa (Cunningham and Porter, 1998). The 
TMV rod structure is illustrated in figure 4.1A. 
The core of a single TMVCP subunit (figure 4.1B) contains a bundle of four antiparallel 
a helices projecting away from the RNA binding site. The region at high radius contains 
the N and C termini as well as a loop connecting the so-caUed right-slewed (RS) and 
right-radial (RR) a-helices. This four helix domain is one of the more common and 
simple protein folds. The stability of the structure is b sed on the packing of hydrophobic 
side chains on the interior and the orientation of hydrophilic groups on the surface 
(Cunningham and Porter, 1998). 
The structure of the CP subunit and the rod shaped viruses offer flexibility for the 
location and context that antigenic peptides are presented by fusion options on the Nand 
C terminal regions and with constrained surface exposed loop regions. The density 
display is unparalleled in these systems with greater than 2100 peptides exposed per 
virion. In fact, this high density is potentially problematic with the solubility of the 
particles being affected. Where such issues are relevant, an alternative strategy has been 
employed to counter this effect. A "leaky read through" amber codon at the end of the 
TMV coat protein gene will promote the translational extension of a genetic fusion at a 
ratio of every 1I10th to 1I20th coat protein (Turpen et al., 1995) as opposed to a direct C-
terminal fusion where all coat proteins possess the peptide fusion. The less dense display 
of peptide additions from these C-terminal approaches may promote better virion 
solubility and/or assembly (Turpen et al., 1995). As illustrated in the literature review, 
results from immunogenicity assays on antigens generated using the epitope display 
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method have already shown much promise. The Vaccine Group at the University ofCapc 
lOVin is also interested in developing as part of the vaccine effort, immunogens that arc 
able to induee production of high levels oflllV specifie antibodies fur neutralization as 
well as CTL responses using this method. 
A 
Fi~u ... 4.1' ClrtOOll' "'preoenting the ,c ... ctu,"" "f TMV .icu, partld .. (A) and tho TMV CP .ubunit 
tel"liar-y I',,,t.in IimNu,"" (8). Tbc region at hi~h radiu. on theTMV cr ,ubunit b on tho tight band 
.ide (Taken r ... ,m ww .... irology.nN) 
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To thi, end, intermediate clomng vedors lor cloning additional oligonlLcleotides or DNA 
sequen,es to the 5" or 3' euds of the TMV CP gene m pBSCil057 were ,on,tmded (F. 
Tanzer, University of Cape Town). This allowed for the atla,hmem of epitopes on the N 
and C tcnnini of the T/I.1V coat protein encoded hy pBSCil057. In this section, I aimed to 
investigate the possibility of expressing two HlV-l Nef CTT. epitopes using the plant 
viral epitope display method. 
4.].2 Selection .. r Ncf eTT. cpitopes 
The Kef protein is very immunoge1,i, and is ri,h in Crr.-indudng epitopes. Several 
studie' relating to the mapping of the immunogenic regions of the protein are rev ie\ved in 
Chapter 1. For this purpose the most immunodominant and frequeutly recognised peptide 
in a study hy Mashishi eI af (2001) was chosen as the primary epitope. The peptide 
YKiv\l'VLSHFLKEKG constitutes the HI helical domain of the Nef ,ore (Crzesiek et 
u/ .. 1997) (also see ligure 1.3) and wa, recognised by 3]% of individuals tested. It was 
de.,ignated KP31. 
A second epitope FFPFVCiFPV was desil,'nated FYI. Ibis peptide is a parl of the 
epitopi~ regiou that was remgnised by 15~';' of tested individuals and forms part of the 
type II polyproline helix domaiu that is the !irst major domain after the pmtease deavage 
site in Nef. 'tbis second peptide is smaller and should have a ,lightly less constrained 
stlucture than NP] I. 
The aim \VaS therefore to con,tTllcl and pUlify four rTMVs from pBSGl057 with ea~h 
bearing CP subunits decorated \vith One of the two peptides as N or C tenninal l\lsions. 
Such rTMVs would present CIL epitopc, li-mn Nef at a high deusity On a large 
parti,ulate antigen. 'Ibis would make an ideal ingredient for a ,andidate vaccine that 
seeb to induce some form of cellular inununity against [ltV infection. Should the 
particles be succe"flLlly purified, a funh er aim was to test their immlLnogeni~ity in small 
animals such as mice. 
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4.2 :\IATERJALS A~n ;vrF:THODS 
4.2.] Construction and cloning of Nef epilope gene fusions 
The pro,e8S by whi,h the Nd epilOp" gern. fusion vocto[S w~re ~reated j, illustrated in 
ligurc 4.2, which ~lso shows the COl]stlllCtion ofpRSONSNT'31 and pRSGC3NT'31. The 
, ,,m,, proc"" was lollowcd in the constmction of pBSGN5EPl and pBSGCJEPI. 
A. Preparation of veClon for creation of coal protein fusion constructs 
lnlcnmxliatc vc,tors used in the construction of coat protein fusion gCll"S were 
conslrud",-l by Dr Fiona Tanzer in the Department ofMolccular and Cell Biolog)' at UCT 
as follows: The coal protein gene in the pBSGIOS7 VCClor was cxcisoo using 1m, Sal I 
and PSI 1 restriction siles. The excised region was subcloncd into a standard pUC\9 
doning ve~I.or. The TI1V cool protem gene in the pUC19 veClor was then modified by 
~ite directed mutagene,is via peR ,uch thai" cloning ,ite with the restriction ~ites ,Vru 1 
~nd ,"loll immediately adja~el1l to each other ""th th ~ ,Vru 1 sit~ on th ~ 5' sid~ w~r~ 
introdu,ed, This doning sit~ was S"P~ratdy introduc~d at both th ~ 5' ~nd th~ 3' ~nd of 
th ~ coat prot~n g~n ~ and d~sib'l1~ted pUCN5 and pUCC3 r~sp ~ctiy~J y (figmc 4,2A). 
Thesc , 'cetors would allow the introduction of a gene in frame with the coat protein gene 
to be expressed as either a C or N terminal fusion. 
B. Construction of lIe/epitope oligonucleotides 
The s.cquenees of the oligopeptidcs sclectoo for expre%ion a, coat protein fu~ion~ 
(NP31:YKAAFDLSHFLKDKG and EP I:EEPEVGFPV) were enter~d into t h<. 
ONAman :T!l (l.ynonRiosoft) y~r~ion 4.13 computer program and the expected m"A 
seyuences reflecting" plant endon bi~s wer~ obtai""d u~ing this program. Where there 
were ambiguities, individual nucleotide, were sel~t~d based on a codon usage (able for 
N icolialllJ benlhumianIJ found On lhc NCBI web-page. In ea~h cas~ th ~ codon with the 
high ~~t u~ag~ or fraction wa~ s ~kctcd so as to truly' relleel the .II,'irotian" benth"mi""" 
endon usage "nd bia8. Th<. r~sulting s~qu~n' ~ w~s then modi lied (0 include on the 5' ~nd 
a sticky ~nd of a cut Nru 1 8jt~ ~nd on the J' end, a 'li~ky end of a Cut ,Vol I site. 
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Cbapter 4: l!xprmjoll ofNefCIL epjtoocs as TMV-CP fumQ~ 
The following oligonucleotide. were '}'I1tbesized in the Oligonucleotide Synthesis 
100boratOf)' of the Molecular alld Cell Riology Depaltment, UCI'. 
NPJlf 5'-TACAAUGCI'UlTITIUA'ITCTCATTTICIGAAGGAAAAG-3' 
:"<PJ I r 5' -CTITTCCTrCAGAAAA TUAUAA TCA..uAGCAGCCTTCiT A-3 ' 
LPlf 5'-CGAGAAGAACCAGAAGTTGGIIIICCAGTTGC-3' 
EPlr 5'-GGCCGCAACTGGAAAACCAACTTCTCiGTTCTTCTCG-J' 
'T'h<. lwo ~P31 and lbe lwo FPI oligonuclootides were botb annealed by heating to 95"( 
lor 10 minutes and snap coolillg on ice. 
C. Ligation of oligoDlideotide~ with the fusion ycctor •. 
1 'he annealed 01 igonllcieotides were then dOllOO into pUC:"<5 and p UCC3 '" follow._ l,llg 
of pUCl\") and I)lg of pUCC3 D:"<A wCI"C digesloo wilh 1 ullil each of Not 1 and NHI I. 
The digested DNA was gel purified in a O.S'\i, IBE agarose gel (appendix A). The 
annealed oligonucleotides were ligated 10 lhe digesled pUC~5 and pUCC3 DNA by 
in~llbating lhe DNA al a vedor lO insert ratio of 1 :8.I'his gave excess of oligonucleolide 
in relati011 to the vector and reduced the amount of self ligalion by allY veclor molecules 
not fully digested with both enLymes. The resultillg ligated products were used to 
transform high dllcim~y DH5a compelmt cel ls and plated onto ampicillin plale'" 
Resulting colonie. were picked and grown overnight and plasmid DNA was extracted by 
the miniprep method. 
Screening of the plasmid DNA was by PCR usmg lhe following primer sets. 
pUCNSNPJl 
Forward prinK'I: 5'-T ACAAGGcrCiCI 'I 'I 'I 'GA TCTG-J-
Reverse primer: 5' -CT ATTGTTGTGACiA TTTCC-3" 
pUCONPJl: 
Forward primer: 5'-CCI'IAI'ACAAI'CAACTCTCCGAGCC-3' 
Reverse primL1": 5' -( I I I I CCITCACil\AAATGAGACAG-3' 
pUCN5~:P] 
l'orward primer: 5' -CGAGAACiAACCAUAAG1TGGTTTTCCAGTTCiC-J" 
Re\"el1<e primL1": 5'-CTATTCiTIGI'GAGATTTCC-3' 
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pUCC3EPl 
Forward primer: 5'-CCTTATACAA TCAACTCTCCGAGCC-3' 
Reverse primer: 5' -GGCCGCAACTGGAAAACCAACTTCTGGTTCTTCTCG-3' 
Clones showing a positive PCR reaction were sequenced to confirm the presence of the 
coat protein fusion gene in frame. Confirmed clones were designated pUCC3NP3, 
pUCN5NP3, pUCC3EPl and pUCN5EPl. 
D. Insertion of coat protein fusions into pBSGI057 
Illg each of pUCC3NP3, pUCNSNP3, pUCC3EPl and pUCN5EPl DNA was digested 
with Sal 1 and Pst 1. This excised the TMV DNA incorporating the CP fusions from 
these constructs and the DNA was gel purified from a 0.8% TBE agarose gel. The ends of 
the purified DNA fragment were dephosphorylated by incubating the DNA with 1 unit of 
shrimp alkaline phosphatase (SAP) (Roche) for 30 minutes at 37 C. The phosphatase was 
inactivated by incubating the solution at 65 C for 15 minutes. Illg of pBSG 1057 DNA 
was also digested with the same enzymes and the plasmid backbone without the CP gene 
was similarly gel purified. The dephosphorylated Sal IIPst 1 coat protein gene fragments 
were ligated to the Sal lIPst 1 pBSG 1057. The ligated DNA was used to transform high 
efficiency DH5a. competent cells and plated onto ampicillin plates. Resulting colonies 
were then picked and grown overnight and the plasmid DNA extracted by the miniprep 
method. The presence of terminal fusions on the coat protein gene was checked using the 
same primers used in the preceding section C. Clones with DNA yielding positive PCR 
reactions were designated pBSGN5NP31, pBSGC3NP31, pBSGN5EPl and pBSGC3EPl 
respectively. AU the pBSG1057-based fusion constructs retained the gfp gene which 
acted as a marker of infection. 
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4.2.2 In vitro t:ransc:ription of const:ructs 
Large-scale plasmid DNA extractions of pBSGI057, pBSGN5NP31, pBSGC3NP31, 
pBSGN5EPl and pBSGC3EPl respectively were carried out by the Nucleobond™ 
method. Production of RNA transcripts from pBSGI057, pBSGN5NP31, pBSGC3NP31, 
pBSGN5EPl and pBSGC3EPl and a luciferase gene under the control of a T7 RNA 
polymerase promoter as a control DNA was carried out using the RIBOMAXTM Large 
Scale RNA Production Kit (Promega) by the method specified by the manufacturer 
(Appendix C). The success of the in vitro transcription was determined by electrophoresis 
of transcription products on a 0.8 % TBE agarose gel. 
4.2.3 Mechanical infection of Nicotiana benthamiana 
Three week old Nicotiana benthamiana plants at the four leaf stage from the UCT'95 line 
were used as host plants. The plants were mechanically inoculated by micro-abrasion 
using 50f.!1 of the RNA reactions and 50f.!1 of DEPC water per plant. Inoculation was 
carried out using autoclaved cotton buds. The cotton buds were dipped in baked celite 
and then into the RNA solution and gently rubbed onto the leaves in such a way that there 
was no visible abrasion of the leaf tissue. Inoculations were carried out with RNA 
transcripts of pBSG 1057 as a positive control, pBSGN 5NP31, pBSGC3NP31, 
pBSGN5EPl and pBSGC3EPl and with water as a negative control. The plants were 
maintained in the UCT Molecular Biology plant rooms. All constructs contained the gfp 
gene and therefore aU plants were monitored daily for the presence of symptoms and the 
appearance of GFP. Visualisation of GFP was done in a dark room with a long 
wavelength ultraviolet lamp. At 14 days after inoculation, leaves were harvested and 
tested for the presence of recombinant CP RNA and protein. 
As a bioassay for the production of virus particles in vivo, the infectivity of homogenates 
of inoculated leaves showing fluorescence was tested on fresh young plants. Plants were 
monitored for symptoms of infection and fluorescence for 2 weeks. 
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4.2.4 RNA Extraction, reverse transcription and PCR amplification of 
eDNA 
Innoculated leaves showing expression of GFP were harvested for RNA extraction and 
detection of proteins. 100mg of leaf material from a harvested plant was placed in a 
mortar and homogenized in liquid N2• RNA was extracted using the TRIZOL method 
(appendix A). 
RNA extracted from each plant was reverse transcribed and the resulting cDNA 
amplified by PCR using C. therm™ DNA polymerase™ (Roche™). These reactions 
were carried out in a single tube for each RNA sample in a thermocycler a one step RT-
PCR procedure formulated by Roche TM (appendix A). As a positive control for the RT-
PCR reaction, RNA extracted from the pBSG1057 infected plants was subjected to RT-
PCR using an internal gfp primer set. 
For the remainder of the constructs, the following primer sets were used. 
pBSGN5NP31 
Forward primer: 5'-TACAAGGCTGCTTTTGATCTG-3' 
Reverse primer: 5' -CTA TTGTTGTGAGA TTTCC-3' 
pBSGC3NP31: 
Forward primer: 5'-CCTTATACAATCAACTCTCCGAGCC-3' 
Reverse primer: 5' -CTTTTCCTTCAGAAAATGAGACAG-3' 
pBSGN5EPl 
Forward primer: 5' -CGAGAAGAACCAGAAGTTGGTTTTCCAGTTGC-3' 
Reverse primer: 5' -CTA TTGTTGTGAGA TTTCC-3' 
pBSGC3EPl 
Forward primer: 5'-CCTTATACAA TCAACTCTCCGAGCC-3' 
Reverse primer: 5' -GGCCGCAACTGGAAAACCAACTTCTGGTTCTTCTCG-3' 
pBSGI057 
Forward primer: 5' -GGTTT AA TT AAAATGGAGCCAGTAGATCCTAG-3' 
Reverse primer: 5' -GGATCTCGAGGATATCCTCCACCTTCTTCTTCG-3' 
99 
Un
ive
rsi
ty 
of 
 C
ap
e T
ow
n
Chapter 4: Expression ofNef CTL e.pitopes as TMV -CP fusions 
4.2.5 Harvesting of leaves for detection of proteins 
100mg of leaves were crushed and homogenized in liquid nitrogen by mortar and pestle. 
This homogenized leaf material was suspended in 0.5ml of PBS and vortexed. The 
homogenate was centrifuged in a microfuge for a minute at room temperature to remove 
large particulate matter and the supernatant plant sap recovered. The plant sap was placed 
in SDS-PAGE loading buffer (Appendix A12) and boiled for 10 minutes. 10J.l.l of boiled 
plant extract in loading buffer was loaded per well of a 15% SDS-PAGE gel and 
electrophoresed. 
4.2.6 Western Blotting 
Proteins resolved by SDS-PAGE were transferred onto nitrocellulose by the semi-dry 
blotting method and tested to antisera by the western blotting method in appendix F. The 
polyc1onal antisera tested against the plant sap are listed below in table 4.1. An SDS-
PAGE gels were run in duplicate with one of the gels being blotted while the other was 
stained with coomassie blue for visualisation of the proteins. All antisera were diluted in 
blocking buffer with 2% milk powder. 
Primary Secondary 
antibody Raised in Source Dilution antibody Source Dilution 
Rabbit 1:1000 Goat anti Sigma 1:5000 Anti TMV MCBDept rabbit 
VCT 
Antigfp Goat anti Mouse Qiegen 1:5000 Sigma 1:10000 
mouse 
Table 4.1: Polyclonal antisera used in western blots on plant extract 
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4.3 RESl:L TS AND DISCUSSIOI'i 
4.3.1 Construction lInd cloning of Nd epitope gene fusions 
The intcrmediate vedoTll pUCC3 and pUCNS WNe dig~,t~d with l'ku 1 al1d l .. '()/ I. The 
Tcsults of digc.tion with /.,'", 1 and Noll a", showl1 in figure 4.3. Because of the 
proximity of the restriction sites, digestion at both 8ites appears similar to a single 
enzyme digestion. The digestion was lhcrcioTC carried out lor a prolonged time to e1l8l1re 
digestion with both enzymes. Since the 8)TIthctic oligonucleotid~s U8ed ill the ligations 
wGTe unpho,phorylaled, th~ digBst~d wctor was not l",ated with alkaline phosphatase to 
prevcnt sclf ligation. Rathcr, the excess or annBalBd s}llth~tic oligonucl eotide ensu",s the 
prev~ntion of vector relegation in th~ eVBl1t that any vector molecule8 were digested with 
only one of th~ two enzymes. Thi, results in a large number ofpositive colonies irom the 
8ubseq\lel1t trondormation ofD1I51l with the ligation mix. 
o"i 
11.5 
~.C~ 
U4 
U~ 
1.7Q 
'.00 
0.' 
L-ane 2, uodigested pI'CC~; I._on. 3, pliCC3 dtg",ted Nru I/.No/l; Lan. 4, pliCN5 digested 
8m 11-""'" 1; Lane 5, undi~ •• t.d pUCN5 and iane 6, )J Poll D'" A mal'lor. 
Scrcening or the colonie8 by PCR resulted in a high proportioll of positive reactions. 
Figure 4.4 shows all agarose gel with results the PCR "'r~elling of clones resulting from 
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ligation of pLCe) with the ol igomldeotide NP31. One sample of extracted DNA 
yieldillg ]Xlsitive results wa< <eqlenced to confiml the presence of the oligonuclcotide 
and to estahlish thaI it wa, insuled ill frame. The sequenced DNA wa< "sed in the 
construclKlI1 oflhe pBSG1057 ha,ed vect()r. 
11.5 
M8 
2.~~ 
1.70 
'.00 
n.~l 
"' 
11.5 
5.08 
,." 
,.w 
1.70 
'.00 
0.81 
" 
, , , , 
• 
, 
" 
, 
" 
fleun 4.4, R .. ult, of f'(:R s<-•• "j,,~ ofclou .. r",ulti"~ from U~.ll~n of pUCe3 ",lib !~P31. 
L.n. I, ).JP,/ I D!~A nlarl«r: L.n", 2_8, peR prudnrt frum S roloni'" r .. nlting frnm 
pUCC3!NP31 lig.tioo , • ..,tio" Lane 10, D:"OA from S >rr •• nM col.ni ... ubjerted to PeR 
"itb no forward prim~r; La, .. 11, '10 r~'rs~ primer ."d I.". 12, 11<1 T.q polymera ... 
, , , , , 
• 
Fl~"ro 4.5, A~oro" .ho,..lt!~ 0 r.~, peR oI"e~ of "R8G'I'I-'1l31, pBSGCl~~J1. pIlSG~5U'1 0 0<1 
pBSGCJEP1. Lon . 1,).1 '" 1 Dl'iA Jrulrxtr: L'Mel pBSGM~PJ1; L.o, J, pDSGC3'1lJl: L.ne4. 
pBsc.MF.P'; Lne 5, pBSGOEP1: Lone G •• 1I t.mpiat, D1'A'" ,""Y,ne pli .. ", .nd no f,"ward 
primm: L.n . 7, oM t.ropl>.<e D1'.'I.·' r......"rd prJ ... ,,, .nd nO r".". pri",,,. >Ad Lan, 8, N" Dl'iA. 
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Sequenced D:'>IA irom intermcdiate vectors pUCC3l\'P31, pUCNSNP31, pUCC3FPl and 
pUCNSEPl was used to construct thc pBSG1OS7 bascd vecl(m. Figure 4.S s]rows the 
digcstion ofthesc vectors and pBSG 1057 wilh Sail and Pst L 
r.igation of the Sal liPs! I in8ert from the intermediate v«tor8 and Sal IIPst 1 dig(:;SlCd 
pBSGIOS7 backhone resulted in formation of the vector conSil'ucts pBSGC3NP31, 
pBSGl\SNP31, pBSUCJHPI and pBSU~5FPL Extractcd D:'>IA irom colonies 
harlxlUring these con,(ructs was te,too by PCR to ensure the presence of (he 
oligonucleotide.s in the yectol's hefore embarking on large scale prcparation, ofD:-:IA for 
transcription of RNA. Jiigure 4.6 shows the results of the screening of lhe four construe". 
1H 
5.GS 
' " ,.% 
,.ro 
UG 
G. ~1 
4.3.2 In vitro trllnscriptinn or constructs 
Fi~ure 4.' : Re,ult. <of in-vitro transcription of pDSG:"i5NP31, pBSGC3NP31, pHSGN5El'I 
.nd pBSGC3EPI. u.n. 1, )j P,t I D"IA nlarker; Lane 2, pBSG[I;5NP31 DNA; Lan. 3, 
pBSGN5NP31 RNA; Lone 4, pBSGC3N1'31 DNA; La". S pHSGC3:\P31 R"I."; Lone " 
pBSGN~EPl DNA; l .. one 7 pBSG1'5EPI RNA; L.on e 8, pBSGC3El'J D:"i,\; L.ne 9, 
pBSGC3El'l RNA and Lane III, ",.nufanurc ... «lntrol pl.,mid {raJlstriptio •. 
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In vitro transcription of large scale preparations of the constructs pBSGC3NP31, 
pBSGN5NP31, pBSGC3EPI and pBSGN5EPI resulted in generation of sufficient RNA 
lran.cript to initiate an infection by manual inoculation of plants, Figure 4.7 shows the 
result. of the in vitro lranscription 00 a O.8~" TBE agarose geL 1111 of the Rt"A transcript 
is loaded onto the gd and so whlle the levels of MA in lanes 5 and 7 may be low in 
relation to lanes 3 and 9, it is mOre than sutl'icientto cause infection in young plants. 
4.3.3 Mechanical infedion of nicQtiana bentllamiana 
The inoculation of plants with RNA from the I\vo fusion constructs pBSGN5NP31 and 
pflSGC3NP31 re.ult~d in attenuated infections m comparison to the pBSG 1057 conlrol 
infection. The initial appearanc~ of ,}mptoms hy way of fluorescent spots wa. dday~d in 
hoth fusion constructs, with the tiTSt flUOfCSC(:tlt spots appearing after 7 days, The spots 
grew at a slow~r pac~ than control (pBSGI057 infected) plants and th~ cell to cell .pread 
of the infection was insumci~nt to cOver the entire inoculated leaf (tigure 4.7), 
"Jbe infection from the fusion constructs remained confined to the inoculate<! leaf and 
appeared to only spread along the vein of the leavcs and progress towards the stem 
starting at about 10 days post inoculation. The fluorescencc never went beyond the 
moculated leaf c,'en when lett to progress for longer than 3 weeks. There w~re no major 
difrerenc~s hdween the N -terminal and C -terminal fusion con.tructs. 
Repeated attempts to passage the virus and bulk up the infection using homogenates of 
infected leaves from both fusion constructs failed to produce a new infection. 
Inoculation of plants with transcripts ofpBSGN5EPI and pBSGC3EPI produc~d result. 
similar to those seen in the previous infections. There were few notahle difj"renc~s, 
namely, infections appeared to manifest quicker with tluorescent spots appearing after 5 
days and the fluorescence appeared to cover a slightly larger area of the leaf. Although 
~xpression of GFP wa. mainly concentrated near the veins and towards the stem, there 
was a more pronounc~d outward spread of OFP into the leaf from infcction loci. 
However, ,ev~ral fundamental similarities persisted. The infections wcre much slower 
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than the conU'oJ (pBSG 1057) infections. The infection also remained confined to the 
inoculated kaf and the homogenat~s of th~ inoculated kav~s were not infectious after 
repeated att~mpts to pa5sag~ and hulk up th~ inf~ction. 
4.3.4 RNA F.xtrllction and RT -peR 
RKA waS ~-"lraGl~d Ii-om (h~ inocl.llal00 I~av~s of th~ inf~Gt~d plants a5 we!! a5 from 
adjacent top l~av~s al (h~ apical m~rist~m. Th~s~ RNA sample5 were subjected to RT-
PCR to kst lor (h~ pr~senG~ of (RNA of th~ GOat protein fusion gen~s. The r~sult5 in 
figure 4.9 show that the coat protein fusion genes were detectable in aU of the inoculated 
leaves but not in the top lem'e5, 
,u 
'"' U~ i." UO 
'.00 
~.~1 
" 
Fi~ul'~ 4.8: R .. ult. of RT-l'CR of RNA oxtr.clod from loa,'e, infu1& "'ith p8SGN5"l'31, 
pIlSGC3Nl'31, pBSG~5[PI .nd pBSGeJEPI. Lane 1, )j p,t 1 DNA lnar~or: UJIC 2, 
pDSGN5J'1o'l'31 ino<ulatod loaf; Lanc~, pBSG~5NP31 plant top l~af, 1 .. an. 4, pDSGC3NP~1 
inoculatod loof) L.ne 5 pBSGC3NP31 plant tI,p l •• f; Lane 6, pDSG"5El'1 ino<ulolod l.af; 
Lano 7 pBSGN;F:.Pl plant top lcof, t.uo 8, ]lBSGC3[PI inoculotod loaf; Lall< 9, 
pDSGC~El'1 plaUT top leaf oud Lane 10, pBSGI057 with ~fp primo .. ; LOllO II, uuinf.t1ed 
pla~t wilb aU primo" and Lan. 12, pDSGN5NP~1 ]llumid D~,\. 
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4.3.5 SDS PA(;E lind Wes!f'rn Blotting 
Protein extl'lK-'ted from the inreded leaves was analysed by SOS PAGE. Figure 4.1 0 
shows a SOS PAGE of the extruct ofleaves inoculated with pRSGC3NP31. 
pI3SGN5NP31. pI3SC'JC3EPI and pRSGN5EPl. 
, , ; • 
, 
• 
kDo 
92.0 
". 
29.0 
-
Figure 4.9: SDS-J'AC" of pint ntr~ct ofl",,¥., infoct.d "ith pHSGN3N P31 ,pHSGCJ:\P 31, 
pDSCI\SE:PI ud pDSCC311PI. lane 1, BIORAD low mole<ular weigbt protein marku; 
Lon. 2. pBS{;NSNPJ1: Lane 3, pHSCC3I\P31: Lou 4. pDSGI\SEPI: Lan~ ~. 
pHSGCJNP31: Lan. 6. pun: TMV_Cr: Lon. 7. pDSGHlS7 aod Lan. 8, ktaltby pla .. t. 
GFP was visiblc in all the inoculated leaves and the presence of the GFP and it, position 
after rnigr<ltion by eleclrophoresis was conllrmed by westcrn blot probed with anti GFP 
monoclonal antibody (Ilgure 4.IIA). Thc western blot ,vas able to confirm the prescnce 
of GFP at high levcls in leaves inoculated with the constructs p13SC'JC3NP31. 
pI3SGN5NP31. p13SGC3EPI and pHSGN5EPl as well as in the plant inlected with 
p13SGI057. 
The sccond western blot (tigure 4.118) was probed with an anti TMV CP polyclonal 
antiserum. The western blot is quite heavily OVCITXPOSed and it revcals the prescncc of 
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high levels of CP in the pBSG I 057 infected plant ,md there i, a reaction with the purified 
rTMV particles loaded in lan~ 6_ Jll lan~s 4 and 5 there is ~vid~nc~ of low lewis of 
expression ofrTMV C1' in I~aves inf<lCt~d with pBS(;K5EPI ami pBS(iC3EPL 
, , , , 
• 
kD, 
92.0 
-52.9 
35.4 -~ 
29.0 
--21.5 
kD, 
92.0 
52.9 
"., 
29.0 
21.5 
Figure 4.10: Wf~tern blot, or plant extract from leave~ infected with 
ptlSGN5NP31. pl:lSGC3:"1!P3J. ptlSGl"S[,Pl "nd pDSGC3[PI. A. i, probed with anti GFP 
anti,e,-urn "lIile D.;, p,-.bod wit. ~nti 'IlIV anti,.rum. Loading in OOI.h blot. i, tho .am •. 
Lan. I. BIOR~D low motrrular w~ighl prolein m"rku; Lane 2, pBSGN5'11'31; Lan. 3, 
pBSGC3NP31: Lane 4, pDSGI\~F.Pl, Lan. 5, pBSGC1'11'31; Lan. i, pure T"V_CP; Lan. 
7, pBSG1057 and Lan. 8, b~allby pl.IlI. 
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4.4 CONCLUSION 
Two regions of the HIV -1 subtype C Nef core region were cloned into pBSG 1 057 as coat 
protein fusions on both the N and the C termini. Oligonucleotides encoding the 
immunodominant helical region of the Nef core HI containing the mapped CTL epitope 
NP31:YKAAFDLSHFLKEKG and a smaller epitope EPl:EEPEVGFPV, were placed on 
the C and N termini in frame with the coat protein gene to be translated as a fusion. The 
use of intermediate vectors in the form of pUCN5 and pUCC3 enabled easier 
manipulation of the DNA since pBSG 1 057 is a large vector with a low copy number in 
bacteria. The intermediate vectors also contain the M13 forward and reverse binding 
regions where these primers can be used for sequencing purp ses. PCR and DNA 
sequencing were used to confirm the successful construction of the vectors pUCC3NP31, 
pUCN5NP31, pUCC3EPl and pUCN5EPl. The CP fusion genes in these vectors were 
excised using Sail and Pst 1 restriction digests and placed into the pBSG 1 057 backbone 
that had been digested with the same enzymes (see figure 4.2).The presence of the 
epitope fusion genes in the vectors pBSGN5NP31, pBSGC3NP31, pBSGN5EPl and 
pBSGC3EPl was confirmed by PCR (figure 4.6). 
The constructs were all transcribed into infectious RNA (Figure 4.7). This RNA was used 
to infect young plants and the plants were monitored for the presence of infection. The 
initial signs of infection were seen after 7 days in plants inoculated with the NP31 fusion 
constructs and in those inoculated with the EPI fusion constructs initial spots appeared 
after 5 days. The highly attenuated state of the infection was particularly evident in the 
way that the infection spread. In the case of the NP31 fusions, after the appearance of an 
initial fluorescent spot at a single focus on each leaf, the area of fluorescence enlarged 
very slightly over the next few days until it reached a vein. The fluorescence then 
appeared to spread along this vein aU the way to the bottom of the leaf and into the stem 
(figure 4.8). A similar pattern of spread was seen in leaves infected with the EPI fusion 
constructs. In both cases, it is notable that there was no difference in the infection 
between the N-terminal and the C-terminal fusions. In both cases, the infection was 
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limited to the inoculated leaf and no fluorescence was seen beyond the junction of the 
leaf stem to stalk of the plant. No rTMV CP RNA was detectable beyond the inoculated 
leaf either (Figure 4.9). This is evidence of the infectious nucleic acid's inability to 
execute long distance movement. As a bioassay for the production of virus particles in 
vivo, the infectivity of homogenates of inoculated leaves showing fluorescence was 
tested on fresh young plants. The infectivity should roughly estimate the amount of 
assembled virus particles, since naked genomic RNAs are more RNase-sensitive and less 
infectious than virus particles (Saito et al., 1990). None of the homogenates tested were 
infectious. The reason for this becomes clear upon analysis of the plant by SDS PAGE 
and western blot. In figures 4.10 and 4.11B, there is evidence of poor accumulation of 
CPo In particular, both pBSGN5NP31 and pBSGC3NP31 accumulate rTMV CP at levels 
undetectable by western blot. In the case of pBSGN5EPl and pBSGC3EPl there is also 
poor accumulation of CP to levels detectable by western blot but at levels several much 
reduced relative to those seen in pBSG 1 057 infected plants. There appeared to be a little 
more rTMV-CP pBSGN5EPI inoculated plant than in the pBSGC3EP1 inoculated plant. 
Such poor accumulation of CP has implications for long distance movement which 
requires virus assembly (Dawson et al., 1988). The cell to cell movement of infectious 
RNA requires only the movement protein and that type of movement is evident in the 
enlargement of the initial fluorescent spots. This mode of spread alone is however not 
sufficient to cover even the inoculated leaf. Martens et al. (2001) showed that the 
expression of GFP targeted to the ER reflected the sink-source transition in leaves. In this 
case, the movement of GFP is restricted to cell to cell movement and is therefore also 
restricted to the cytoplasmic sleeve. This is reflected in the patterns of spread of the GFP 
in rTMV inoculated plants seen in figure 4.8, which reflects a directed spread of GFP 
toward the midribs, petioles and stems. Expression of ER-targeted GFP was shown to be 
restricted to companion cells, but free GFP was trafficked across the pore/plasmodesma 
contacts, approached the assimilate stream and was transported source-to-sink (Imlau et 
al., 1999). It is likely that this was also the case in these experiments. It is also likely that 
macromolecular trafficking of RNA occurred from companion cells to sieve elements 
across the sieve/pore plasmodesmata contacts typical of this cell pair. This is the method 
by which assembled virus effects long distance spread. 
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The reasons for such poor accumulation of coat protein particles are not immediately 
clear but several inferences can be made based on these results and those of similar work 
carried out by researchers at LSB Corporation. Several factors may playa role. Not least 
is the fact that the vector used is designed primarily for use in expression of free proteins. 
To optimise expression of free protein, the coat protein gene used in construction of this 
vector is that of the TMV U5 (TMOMV) strain (Shivprasad, 1999) which has a milder 
symptomology and accumulates much lower levels of coat protein than the UI TMV CPo 
Indeed several researchers have found that CP genes from other viruses are more 
accommodating terminal fusions. For example the protein-protein interactions in AIMV, 
allows the formation of particles of various shapes such as spherical, ellipsoidal and 
baciliform depending on the size of RNA to be encapsidated (Shaw, 1996). The AIMV 
CP has been expressed from a TMV based vector for easier manipulation and this has 
enabled the expression of a variety of peptides including the entire tat gene as epitope 
fusions (Belanger et al., 2000). Use of the AIMV has enabled the number of amino acids 
that can be expressed as a terminal fusion to increase from 25 with TMV -CP (Turpen et 
ai, 1995) to 38 (Belanger et ai, 2000) 
In a study by Palmer, 18 different neutralizing and CTL epitopes from human pathogenic 
papillomaviruses were expressed as N-terminal and 60s loop fusions to the TMV coat 
protein. In the study it was found that N-terminal display of some epitopes resulted in 
either no accumulation of coat protein, poor accumulation or high accumulation with 
very low solubility and assembly capability. The factors determining which epitopes will 
express well have not been conclusively determined but epitopes with constrained 
structures appear more likely to interfere with expression of coat protein and solubility 
and consequently, with infectivity. In another example expression of the 19 amino acid 
loop sequence from domain 4 of the Baccilus anthracis protective antigen was 
unsuccessfully attempted as an N-terminal fusion of the TMV CPo The epitope was 
rescued by insertion at the 60s loop position where the structure could be displayed in its 
native form. The NP31 epitope is generated from the highly conserved and constrained 
helical HI domain of the HIV -1 Nef core region and it is possible that given this context 
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and the already poor accumulation of the TMGMV CP to which it was fused, the protein 
did not accumulate to any significant levels. It is unlikely however that the epitope fusion 
gene disrupted expression at a transcriptional level as rTMV mRNA was detectable in 
extracted total RNA from the leaf. A more likely explanation is that the fused epitope 
caused irregular folding of the protein causing it to be ubiquitinated and targeted to the 
26S proteosome for reprocessing. However, this process alone cannot account for the 
almost total disappearance of rTMV CP from the examined plant extract as it is known 
that other functional viral proteins such as the movement protein are able to carry out 
their normal function despite being subject to this process (Gillespie et ai, 2001). An 
alternative explanation is that the epitope fusion caused a drastic reduction in solubility. 
There are several reports indicating that CP solubility and thus the ability to assemble 
into virus particles can be affected by terminal or internal additions of peptides 
(Bendahmane et al., 1999). Because the analysis of plant extract is restricted to that 
which remains soluble it is likely that the insoluble CP fusion products were retained in 
the insoluble material that was centrifuged down in the preparation of the plant extract. 
This would explain the presence of increased amounts of CP in the plants infected with 
the EPI fusion products. The much smaller epitope is likely to have affected the 
solubility of the CP particles to a lesser degree leaving more such particles available. This 
may have had implications on the movement of the infectious RNA as it is possible that 
with low quantities of soluble TMV there may have been formation of some RNA-CP 
aggregates such as helical aggregates short rodlets of TMV containing encapsidated 
RNA. These structures have been described in transgenic tobacco expressing relatively 
low levels of the TMV CP (Beachy, 1990). Such aggregates would possibly be loaded 
into the phloem and allow increased short distance spread of the infectious RNA through 
the loading veins of the leaf but are unlikely to be robust enough to withstand the plant's 
vascular environment long enough to effect systemic spread of the infection. This would 
also explain the increased levels of local spread of GFP expression in leaves inoculated 
with EPI fusion constructs relative to those inoculated with NP31 fusion constructs 
(figure 4.8). The requirement for assembled rTMV remains as this form elicits much 
higher antibody responses than the disassembled form (Hwang et ai, 1994). Purification 
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or concentration of the disassembled CP by filtration for possible immunogenicity tests 
would be expensive and likely have limited success making it unviable. 
Much is still to be uncovered in relation to how best effect expression of epitopes as CP 
fusions. Several considerations may be useful for future investigators to make. Perhaps 
the most important is that an appropriate vector with high levels of CP accumulation 
should probably be used. TMGMV CP is useful in vectors expressing free proteins but 
may be a hinderence in epitope fusion expression. TMV VI CP has successfully been 
used to express a large number of different epitopes. Alternatively, a variety of other CP 
genes might be used in expression of epitopes. The flexibility of AIMV and potexviruses 
make them worthwhile options to explore as epitope display systems. Secondly, 
constrained epitope structures may be problematic to express as terminal CP fusions. 
Loosely structured sequences might be used with greater success. Heath et al (2002) 
successfully used the same vector to express a 24 amino acid muitiepitope sequence 
constructed by joining end to end 3 short loosely structured epitope sequences. In cases 
where there is a need to express a particular highly structured epitope, one of two 
strategies might be successfully amployed. By using a leaky stop codon it is possible to 
express the construct so that only a proportion of the CP subunits are decorated with the 
epitope (Awram et al 2002). An alternative site of insertion of epitopes such as the 60s 
loop of the TMV CP may be used. Both methods seem to successfully overcome the 
problems of expression and solubility associated with decoration of the CP subunit with 
large epitopes. 
The recent results on immunogenicity studies of chimeric virus particles produced in 
plants suggest that this is going to be a significant source of cheap and effective antigens 
and vaccine reagents in the near future. Epitope vaccines have not yet escaped the general 
problem facing subunit vaccines where B cells are stimulated without a corresponding T 
cell response (Awram et ai, 2002, Heath et aI2002). This problem can be overcome by 
insertion of the appropriate T-cell antigenic peptides or by use of an adjuvant to stimulate 
the immune system (A wram et ai, 2002). This is encouraging news for a continent reeling 
from the effects of the worst pandemic of the 21 5t century. 
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CHAPTERS 
CONCLUSION 
The seriousness of the health challenge that HIV I AIDS presents is unprecedented. 
However, given the advent of recombinant technologies and the resulting possibilities for 
the use of subunit vaccines, there is hope that rising to the HIV/AIDS challenge is not 
beyond us. For developing countries, the increase in popularity of plants as a bioreactor 
of choice for the production of vaccines and other protein products is timely. The need 
for cheap vaccines and the advantages plants can offer in this and other respects are 
reviewed in chapter 1 in relation to HIV I AIDS. This need is not limited to HIV I AIDS, 
however, as although effective vaccines exist for diphtheria, measles, pertussis 
(whooping cough), polio, tetanus and tuberculosis, these diseases still result in the death 
of more than 2 million children annually (Awram et al., 2002). 
Much progress has been made in the development of vaccines for HIV/AIDS. As work 
continues on the development of a completely protective neutralizing antibody response 
in the face of significant difficulties, the development of non-sterilizing and therapeutic 
immune protective measures is also going forward. The HIV -1 nef is an accessory gene 
that is likely to feature prominently in this regard due to its pivotal pathogenic functions 
and richness in epitopes of an kinds. 
The field of plant-derived vaccines is still in its formative stages, but a great deal is 
already known about what is likely to give the optimal results. The most successful plant-
derived vaccines appear to be those where the greatest yield has been achieved. As a 
consequence, the importance of achieving high levels of protein expression cannot be 
overstated. Detailed investigations of the expression of HIV-l proteins in plants are 
therefore necessary initial steps in the process of the development of plant-based HIV 
vaccines. The two methods known to produce the highest yield are the chloroplast 
transformation and virus-based expression systems. The prokaryotic nature of 
chloroplasts means virus-based expression systems, which use eukaryotic plant cellular 
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apparatus, may offer a superior product in terms of post-translational modification of 
proteins. High protein yields have been generated using TMV-based vectors expressing 
heterologous genes as free proteins and as fusions. 
There is an ever-increasing amount of reagents available for research into HN. 
Unfortunately, a disproportionately large number of these reagents are specific to HN-l 
subtypes Band E that are more prevalent in developed countries where the epidemic is 
more under control. This was underscored by the lack of a commercially available 
antiserum raised against HN-l SUbtype C Nef. The E. coli-based pProEX-HT expression 
system provided a rapid means of developing an immunoassay that would rely on cross 
reactivity of Nef-specific antibodies between the various subtypes. The production of 
His(6)-Nefalso made available a reagent that could be used to generate a HN-l subtype 
C Nef-specific antiserum in the event that such a reagent is required for future use. Most 
interestingly, in a study run concurrently to mine, Finzi et ai., (2003) further refined the 
methods of expressing Nefin E. coli by developing a two-step purification process based 
on the heparin binding ability of Nef and IMAC. This process produces the purified 
protein in its native configuration. Bacterial expression is likely to remain the most 
efficient way of rapidly producing heterologous protein reagents on a sman scale. 
A qualitative indirect ELISA assay was successfully developed for the detection ofNefin 
Nicotiana benthamiana using His(6)-Nef. The best ELISA-based quantitative method 
would probably have been a sandwich ELISA, which is known for its precision and 
reproducibility. This method, however, appears to be unpopular probably in part due to 
its requirement for labeling of antisera specific for each antigen. Western blotting and dot 
blots, are by far the most popular means of quantitation of heterologous proteins in 
plants. The relatively low amounts of antiserum required, its reasonable accuracy and in 
particular the ability to resolve proteins prior to detection made western blotting the ideal 
method for this study. 
Expression of Nef in Nicotiana benthamiana as a free protein produced modest results in 
terms of protein yield (Chapter 3). The levels of Nef expressed in benthamiana using 
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pBSG 1 057 were even lower than those seen in transgenic plants, although to be fair, I 
was unable to find an example of a transgenic plant expressing HN -1 N ef. Nonetheless, 
accumulation of protein to levels of less than 0.007% of total soluble protein is far from 
economically viable and would certainly present problems in purification. While filter 
concentrating the plant extract enabled visual detection of the protein by SDS-PAGE and 
western blot, the membrane filter devices used are expensive and would not be a viable 
option on a scaled-up process. A pBSG 1057 derivative vector containing a histidine tag 
has been developed in the laboratory and may be a useful option in the case of persistent 
low yields. 
Expression of Nef as a free protein enabled me to asses the importance of codon 
optimization in plant protein expression. This aspect of protein expression has been the 
subject of an ever-increasing number of studies. The nef gene was re-synthesized to 
reflect a plant codon bias based on the codon usage of Nicotiana benthamiana and 
inserted into the TMV vector. Although expression levels remained low, comparisons of 
levels of protein accumulation in plants expressing the codon optimized gene against that 
of plants expressing the wild type gene showed that codon optimization resulted in at 
least a two-fold increase in expression. While the exact mechanisms by which this is 
achieved are yet to be elucidated, there is a definite case for using codon optimized genes 
for expression of proteins using TMV. An additional point of interest would be to 
examine the expression of the gene optimized for TMV codon usage. The ability ofTMV 
to generate significant amounts of some viral products with genes that have a unique and 
TMV specific codon usage indeed suggests that this is an option well worth exploring. 
The recent application of molecular biology to characterize the antigenic determinants of 
pathogens has resulted in rapid progress in the development of new vaccines using 
epitope presentation systems. The coat protein of TMV was among the first plant viruses 
proteins to be used as a carrier molecule for antigenic epitopes. The abundance of well 
characterized CTL epitopes in N ef means that in all likelihood, successful vaccine 
candidates for HN -1 that use this approach will carry some N ef epitopes if they aim to 
raise a CTL response. Epitope decorated TMV particles have the advantage of being 
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large particulate antigens which may alleviate the need for an adjuvant. This has usually 
meant that the responses generated from such particles have been largely B-cell responses 
even where CTL epitopes have been used. For this reason we can be hopeful that some 
sort of protective immunity can be generated using antigens from the V3-100p of Env and 
that when the appropriate response is generated using CTL epitopes it will be a 
comprehensive and broad immune response. The epitope display system is particularly 
useful in that several antigenic determinants, even from different pathogens, can be 
presented on a single construct. The fact that I was unable to produce a chimeric CP that 
assembled into a decorated virus like particle points to some important considerations 
that need to be made for the successful use of this system, which have been pointed out 
already. Most importantly though, the large numbers of different products that have been 
produced and tested using this approach suggest that vaccines produced this way will 
soon become a marketable product with clear competitive advantages over currently used 
vaccines. 
While there have been some successful results from studies carried out already, the need 
for optimization of protein production levels stiB persists. There is still much scope for 
improvement of expression levels of free proteins and translational fusions. As pointed 
out earlier, codon usage is just one of the factors that will influence the expression of free 
proteins in plants. Other improvements in levels of foreign protein expression, genetic 
stability and infection phenotypes have been made through the inclusion of extra 
promoter elements to drive foreign gene expression and the creation of hybrid 
tobamovirus genomes. In particular, the use of the AIMV coat protein as an epitope 
carrier molecule is full of possibilities. The very exciting advances that have been made 
in the development of the PCR based technique of DNA shuffling means that attempts to 
improve vector efficiency are no longer limited by their reliance on available genetic 
diversity in virus isolates. Through this process researchers can now seek to evolve 
optimal viral components and compensate for deficiencies present in the expression 
vectors. The convergence of transgenic and virus based technologies is particularly useful 
as it addresses the most expensive aspect of production using virus based methods. The 
need for generating RNA transcripts is eliminated and costs are further reduced. 
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There is little doubt that the development of cheap plant based vaccine candidates ready 
to go into clinical trials is imminent. 
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STANDARD METHODS 
1. BACTERIAL MEDIA, ANTIBIOTICS AND BACTERIAL STRAINS 
All bacterial cultures were grown in Luria-Bertani (LB) medium ( Sg bacto-tryptone, 5g 
yeast extract, 109 NaCl, 9SOmI H20, pH 7.4 adjusted with NaOH, made up to IL and 
autoclaved) or Luria agar (LA) plates (Luria Bertani medium with lSg agar). Ampicillin 
was used at SOjlg/ml in LB and 100jlg/ml in LA. 
Unless otherwise stated all DNA was transformed into and isolated from E. coli strain 
DHSa. 
2. DNA ISOLATION PROCEDURES 
Mini-prep DNA was isolated from Sml cultures grown overnight at 37 C with shaking. 
Mini-preps were processed by the alkaline hydrolysis method of Sambrooke et al., (1998) 
using reagents and materials from the Roche® Hydrobond™ plasmid DNA extraction 
kit. 
Maxi-prep DNA was isolated from SOmI cultures grown overnight at 37 C with shaking. 
Maxi-prep DNA was processed by the alkaline hydrolysis method of Sambrooke et al., 
(1998) using reagents and materials from the Qiagen Midi plasmid DNA extraction kit. 
3. PCR 
PCR amplification reactions contained 1 pmol of each primer and 8.2ng of template DNA 
in a total reaction volume of SOjl!. MgCh was added to a final concentration of 1.2SmM 
and dNTPs were added to a final concentration of 2SmM. Roche® PCR buffer and a total 
of 5 units of Roche® Supertherm DNA polymerase were used. 
Reaction mixtures were subjected to an initial denaturatuon step of 94°C for 5 minutes. 
The reaction mixtres were then subjected to 25 cycles of amplification with a 
denaturation step of 94°C for 30 seconds, an annealing step of 55°C for 30 seconds and 
120 
Un
ive
rsi
ty 
of 
 C
ap
e T
ow
n
Appendix A: Standard Methods 
an elongation step of 72°C for 30 seconds. DNA amplifications were controlled by a 
GeneAmp®PCR System 9700 thermocycler. After amplification, samples were analysed 
by agarose gel electrophoresis. 
4. RESTRICTION ENZYME ANALYSIS OF DNA 
DNA was routinely digested by the required enzyme under the conditions stated by the 
supplier (Roche). Two units of enzyme was used per Jlg of DNA digested for 1.S hours at 
37 C 
5. GEL ELECTROPHORESIS OF RNA AND DNA 
Gel electrophoresis of RNA and DNA was carried out on 0.8% agarose gels in lxTBE 
and 0.5Jlglml ethidium bromide as indicated in Sambrook et aI. (1989). For all RNA gels 
all reagents were prepared RNase free. DNA and RNA were sized against A.-DNA 
digested with Pst 1 to give 29 fragments ranging from ISbp to 11497bp. 
6. GEL PURIFICATION OF DNA 
DNA from a PCR reaction mixture or endonuclease digest was loaded onto a 0.8% TBE 
agarose gel with O.SJlglml ethidium bromide for electrophoresis. The band of interest was 
visualised on a UV light box and excised using an ethanol-cleaned scalpel. The excised 
agarose gel piece was placed in a sterile 1.Sml microcentrifuge tube. The DNA was 
extracted from the agarose gel using reagents from and the protocol outlined in the 
Roche® High-Pure™ PCR Cleanup kit. 
7. LIGATION 
Ligations were routinely performed in lOJlI with 2 units T4 DNA ligase (Roche) at 4 C 
overnight. Unless otherwise stated, the vector:insert ratio for small inserts of less than 
500 base pairs was 1:8 with the DNA concentration not exceeding 800ng. For larger 
inserts a higher ratio was used. Ligation of the PCR product with pGEM®-T Easy was 
performed using reagents provided by the Promega® pGEM®-T Easy kit and following 
the protocol recommended by the manufacturer. A total of 3111 of the PCR product was 
used in the standard ligation reaction as per the manufacturer's recommendation. 
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8. TRANSFORMATION 
E. coli cells were made competent for transformation and transformation was carried out 
using the method of Chung and Miller (1988). Transformations using 5J11 of the ligation 
reactions were conducted using DH5a high efficiency competent cells. Ligation mix and 
competent cells were mixed in a microfuge tube and chilled on ice for 20 minutes. The 
cells were then heat shocked by incubating at 42 C for 30 seconds. Thereafter, 600JlI of 
LB was added and the transformation mix was incubated at 37 C for 1 hour with shaking. 
The transformation mix was plated and selection of transformed cells was done on LB 
plates with ampicillin. The plasmid pUC19 was used as a standard to check the 
transformation efficiency of the competent cells used. 
9. SEQUENCING 
Miniprep DNA was used for sequencing reactions. Purified plasmid DNA was sequenced 
at the Department of Molecular and Cell Biology's Sequencing Service by a modification 
of the dideoxy chain termination method of sanger et at. (1977) for dsDNA templates. 
Cycle sequencing reactions, with universal -80 forward (5'-
CGCCAGGGTTITCCCAGTCACGAC-3'; Pharmacia Biotech) and -80 reverse (5'-
GAGCGGATAACAATTTCACACAGG-3'; MWG Biotech) fluorescent-labelled CyS-
Far Red primers was done using the Thermosequence™ cycle sequencing kit (Arnersharn 
Life Science) and run on an ALF-Express™ DNA Sequencer version AMV2.0 
(Pharmacia Biotech). Labelling and termination reactions were carried out in the presence 
of 7-Deaza dGTP. Analysis of generated sequences was done using DNAMAN for 
Windows version 2.6 (Lynon Biosoft, ©1994-1996) 
10. RNA EXTRACTION 
100rng of leaf material from an inoculated plant was homogenised in liquid. Whilst the 
leaves were still frozen, Iml TRIZOL (Biorad) was added to the leaves and incubated for 
5 minutes at room temperature. The leaf suspension was centrifuged at 12000g in a 
microcentrifuge for 10 minutes at 4°C and the supernatant fraction removed and placed in 
a new tube. 200JlI of chloroform was added to the supernatant and shaken for 3 minutes 
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at room temperature. The tubes were then centrifuged at 12000g for 15 minutes at 4°C. 
The supernatant was removed and added to 0.5ml of isopropanol and left for 10 minutes 
at room temperature. The tubes were centrifuged at 12000g for 10 minutes at 4°C and the 
supernatant discarded. The pellet was washed with Iml 75% ethanol and centrifuged at 
7500g for 5 minutes at 4°C. The ethanol was discarded and the RNA pellet was re-
dissolved in 50JlI DEPC treated water 
11. REVERSE TRANSCRIPTION AND PCR AMPLIFICATION OF eDNA 
PCR amplification reactions contained Ipmol of each primer and IJlI of template RNA in 
a total reaction volume of 50JlI and dNTPs were added to a final concentration of 25mM. 
Primers were added to a final concentration of 0.3JlM. DMSO and DTT solutions were 
added to final concentrations of 7% and 5rnM respectively. 20 units of Rnase inhibitor 
were also added to every reaction tube. Finally RT-PCR buffer and the C. thermo 
Polymerase buffer mixture were added. The reaction mixture was equilibrated at 60°C 
and incubated for 30 minutes to allow the reverse transcription reaction. Amplification 
began with a 2 minute denaturation at 94°C. This was followed by 10 steps of30 seconds 
at 94°C, 30 seconds at 65°C and 1 minute at noc. The final amplification step consists 
of 25 cycles of 30 seconds at 94°C, 30 seconds at 65°C and 1 minute at 72°C with a 5 
second elongation for each cycle. The results were analysed by gel electrophoresis 
12. SDS-PAGE 
SDS-PAGE was performed essentially as described by Laemmli (1970). Gel slabs 
(1.5mm thick) comprising a 15% resolving gel and a 4% stacking gel were poured in a 
Hoefer SE-600 vertical slab gel apparatus (Hoefer Scientific Instruments). Samples to be 
electrophoresed were disrupted by mixing them with an equal volume of protein loading 
buffer (10% [w/v] SDS, 15% 2-mercaptoethanol, 15% glycerol, 0.01% bromophenol 
blue, 0.125M Tris-HCI pH6.8) and heated to 100 C for 10 minutes. Electrophoresis was 
carried out with a constant current of 30rnA until the tracking dye front reached the gel 
base. Gels were stained with 0.2% (w/v) PAGE blue 83 (BDH chemicals) dissolved in a 
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45:45:10% (v/v) mixture of methanol, water and glacial acetic acid and de-stained with 
repeated changes of the same mixture without the PAGE blue 83. 
13. BRADFORD ASSAY 
5111 of total protein extract was added to 95111 water and then added to 900111 of Bradford 
reagent (Biorad). The solution was gently mixed to avoid bubble fonnation and the 
absorbance of the sample was read at 595nm. The measurements were done between 5 
and 45 minutes after the addition of the Bradford reagent to the sample. The protein 
concentration was calculated by comparing the absorbance of the sample with a 
calibration curve created using BSA samples ranging in concentration from 10-1 OOIlg/ml 
14. WESTERN BLOT 
Protein from SDS-P AGE gels was transferred onto nitrocellulose by a semi-dry blotting 
method using an electroblotter (Bio-RadTM). Blotting was done at lOV for 3Omin. The 
membranes were then blocked for 30min at room temperature in blocking buffer and 
incubated in sheep polyclonal anti-HlY nef antibody (provided by Clive Gray of the 
National Institute of Virology) diluted 5000 times in blocking buffer overnight at 4°C 
with shaking. The blots were then washed 4 x 15-2Omin in blocking buffer with shaking. 
The blots were then incubated in alkaline phosphatase conjugated, mouse ant sheep/goat 
IgG (Sigma), diluted in blocking buffer (1:50000) at room temperature with shaking. 
They were then washed 4 x 15-2Omin in blocking buffer without the milk. Detection was 
via colorimetric methods using lOOIlg/ml NBT and 50Ilg/ml BCIP, diluted in substrate 
buffer. Rinsing the blot in dH20 stopped the reaction. 
15. INDIRECT ELISA 
Dilutions of plant protein extract and controls were made in PBS. These samples were 
placed in the bottom wens on a Polysorb multi-well ELISA plate and incubated at 4°C 
overnight. The ELISA plate was given four short washes with PBS with 500ul Tween 20 
per litre. Blocking was carried out by adding 200j.Ll of blocking buffer (1% milk powder 
in PBS with tween) to the wells and incubating at room temperature for an hour. The 
wens were washed four times with PBS with Tween 20. 100111 sheep polyclonal anti 
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HN-l Nef antiserum diluted in blocking buffer was added and incubated at room 
temperature for 2hrs. This was followed by 4 washes with 300111 per well of PBS with 
Tween. 100Jll of mouse anti goat/sheep IgG diluted in blocking buffer and incubated at 
37°C for an hour. Wens were washed four times with 300lli of PBS with tween. 100111 
PNNP was added to each wen and the plate was left in the dark for 30 minutes at room 
temperature. The reaction was stopped with SOlll of 0.5 M H2S04. The absorbances were 
read at 405nm and printed out for processing. 
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